Conditions: Diabetic Gastroparesis Idiopathic Gastroparesis
Keywords: Drug Therapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 242
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.

Detailed description:
The drug being tested in this study is called TAK-906. TAK-906 is being tested to treat people who have symptomatic idiopathic or diabetic gastroparesis.

The study will enroll approximately 205 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups (in 1:1:1:1 ratio) which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

* TAK-906 Maleate 5 mg (After implementation of Amendment 8, participants will not be further randomized to this arm)
* TAK-906 Maleate 25 mg
* TAK-906 Maleate 50 mg Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient

Prior to Amendment 8, participants were randomized to receive TAK-906 5 mg. After implementation of Amendment 8, participants will not be further randomized to this dose arm. All participants will be asked to take one capsule twice daily, at approximately the same time each day throughout the study.

This multi-center trial will be conducted worldwide. The overall study duration is approximately 17 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 30 days after receiving their last dose of study drug for a follow-up assessment.

Arms:
arm 1: TAK-906 maleate placebo-matching capsules, orally, twice daily (BID) for up to 12 weeks. arm 2: TAK-906 maleate 5 mg, capsules, orally, BID for up to 12 weeks. arm 3: TAK-906 maleate 25 mg, capsules, orally, BID for up to 12 weeks. arm 4: TAK-906 maleate 50 mg, capsules, orally, BID for up to 12 weeks.

Interventions: intervention 1: TAK-906 Maleate intervention 2: Placebo
Intervention descriptions: intervention 1: TAK-906 maleate capsules. intervention 2: TAK-906 maleate placebo-matching capsules.

Protocol document:
Prot_000.pdf: 



Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b 
Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally 
Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects 
with Symptomatic Idiopathic or Diabetic Gastroparesis
NCT Number: NCT03544229
Protocol Approve Date: 13 July 2020
Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal information, or 
to otherwise protect the integrity of the clinical study.


1.0 TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study 
to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting 
Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With 
Symptomatic Idiopathic or Diabetic Gastroparesis
Short Title
TAK-906, Parallel-Group, Phase 2b Dose Response, Efficacy and Safety Study in Adult 
Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis
Sponsor:
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of 
Takeda Pharmaceutical Company Limited 
40 Landsdowne Street
Cambridge, MA 02139
Please note: Millennium Pharmaceuticals, Inc, a wholly owned 
subsidiary of Takeda Pharmaceutical Company Limited, may be 
referred to in this protocol as “Millennium,” “Sponsor,” or “Takeda”.
Study Number:
TAK-906-2002
IND Number:
125296
EudraCT Number:
2018-001275-21
Compound:
TAK-906
Date:
13 July 2020
Version/Amendment 
Number:
8
Amendment History:
Date
Amendment Number
Amendment Type (for regional 
Europe purposes only)
Region
13 July 2020
Amendment 8
Substantial
Global
27 August 2019
Amendment 7
Nonsubstantial
Japan
08 August 2019
Amendment 6
Substantial
Global
23 May 2019
Amendment 5
Nonsubstantial
Belgium
15 November 2018
Amendment 4
Nonsubstantial
Japan
26 September 2018
Amendment 3
Nonsubstantial
Japan
06 August 2018
Amendment 2
Substantial
Global
16 July 2018
Amendment 1
Substantial
Global
23 March 2018
Initial protocol
Not applicable
Global
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 2 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
ADMINISTRATIVE INFORMATION
1.0
1.1
Contacts 
A separate contact information list will be provided to each site.
Takeda Development Center sponsored investigators per individual country requirements will be 
provided with emergency medical contact information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section 3.1 and relevant guidelines 
provided to the site.
Contact Type/Role
North America (US) Contact
European Contact
Serious adverse event and pregnancy 
reporting
Medical Monitor 
(medical advice on protocol and 
compound)
US: United States.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
ts will b
ts will 
bject.
bject
ssigned 
signe
nt guide
t guid
ean Con
ean Co
A
al Use Only and Subject to th


TAK-906
Study No. TAK-906-2002
Page 3 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
1.2
Approval 
REPRESENTATIVES OF TAKEDA 
This study will be conducted with the highest respect for the individual participants in 
accordance with the requirements of this study protocol and in accordance with the following:
!
The ethical principles that have their origin in the Declaration of Helsinki.
!
International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!
All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer and other signatories, as applicable can 
be found on the signature page.
Electronic signatures are provided on the last page of this document.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
wing:
wing:
olidated
lidate
a privac
priva
her si
er sign
his docu
s doc
and
Non-Commercial Use Only an


TAK-906
Study No. TAK-906-2002
Page 4 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, and 
any other product information provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and to protect the rights, safety, privacy, and 
well-being of study subjects in accordance with the following:

The ethical principles that have their origin in the Declaration of Helsinki.

International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated 
Guideline.

All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.

Regulatory requirements for reporting serious adverse events defined in Section 10.2 of this 
protocol.

Terms outlined in the Clinical Study Site Agreement.

Responsibilities of the Investigator (Appendix F).
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in (Appendix H) of this protocol.
Signature of Investigator
Date
Investigator Name (print or type)
Investigator’s Title
Location of Facility (City, State/Province)
Location of Facility (Country)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 5 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
1.3
Protocol Amendment 8 Summary and Rationale
This document describes the changes from the protocol incorporating Amendment No. 8. Results 
from a recently completed drug-drug interaction study with organic anion transporting 
polypeptide (OATP) 1B1 and 1B3 inhibitor, rifampin showed a potential risk of high exposure of 
TAK-906 necessitating the exclusion of the concomitant use of OATP1B1/1B3 inhibitors with 
TAK-906.
The lower range of body mass index (BMI) will be changed from ≥19 to ≥18 to allow inclusion 
of subjects in different regions where the general gastroparesis population tend to have lower 
BMI ranges.
Changes in Amendment 8:
Updated the signatories in Section 1.2.
1.
Updated number of study sites.
2.
Updated period of evaluation from 17 to 22 weeks from screening to follow-up.
3.
Updated and revised Section 4.2 with new nonclinical data.
4.
Added information about Study TAK-906-1004 and TAK-906-1009 to Section 4.3.1 Clinical 
5.
Pharmacology.
Revised Section 9.1.18.1 to remove Gastric Emptying Breath Test (GEBT) at Visit 5 
6.
(Week 4) and Visit 7 (Week 12).
Allow historical documented delayed gastric emptying (GEBT or scintigraphy or wireless 
7.
motility capsule) as inclusion criteria.
Discontinued randomization into the 5 mg dose arm.
8.
Removed the minimum number of diabetic gastroparesis (DG) and idiopathic gastroparesis 
9.
(IG) subjects in each dose arm.
Shorten safety visit follow up phone call from 40 to 30 days in schedule of assessments.
10.
Revised Section 7.1 Inclusion Criteria – Revising the lower end of the BMI range in 
11.
inclusion Criterion No. 8 from ≥19 to ≥18 kg/m2.
Revised Section 7.2 Exclusion Criteria – Exclusion Criteria Nos. 32, 33, and 35 were 
12.
combined under 1 inclusive liver disease Criterion (No. 32).
Revised Section 7.2 Exclusion Criteria – Added exclusion Criterion #41 for any subject with 
13.
suspected or known coronavirus disease-2019 (COVID-19) infection.
Revised Section 7.3 Excluded Medications – added OATP1B1/1B3 inhibitors and Otilonium 
14.
bromide/Spasmomen to excluded medications.
Revised Section 7.5 Criteria for Discontinuation or Withdrawal of a Subject – added criteria 
15.
for any subject with identified COVID-19 infection during the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 6 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Revised Section 9.1.6 Vital Signs Procedure – revised wording to read “When vital signs are 
16.
scheduled at the same time as blood sampling, vital signs will take priority and vital signs 
will be obtained within 0.5 hour before the scheduled blood draw.”
Revised Section 9.1.13 ECG Procedure to add PR interval and standardize when assessments 
17.
were to be taken.
Revised Section 9.1.14, Table 9.b by removing biomarker sample collection times.
18.
Revised Section 9.1.18.2 Patient Outcomes Measures with Food and Drug Administration 
19.
(FDA) recommended changes.
Added Section 9.5 to address possible changes to study procedures necessitated by the 
20.
COVID-19 pandemic.
Added COVID-19-related disease and COVID-19 pneumonia to Table 10.a Takeda 
21.
Medically Significant AEs. 
Revised Section 13.1.3.1 Primary Efficacy Analysis for clarity and completeness.
22.
Revised Section 13.2 to address removal of interim efficacy analysis.
23.
Revised Section 13.3 Determination of Sample Size to address reduction in number of 
24.
subjects to be enrolled and revised wording of sample size justification and power estimate.
Revised language for collection of prolactin samples for clarification.
25.
Revised Appendix A Schedule of Study Procedures and footnotes.
26.
Revised pharmacokinetic (PK) sampling scheme in Appendix A Schedule of Study 
27.
Procedures to reduce patient burden.
In this amendment, minor grammatical, editorial, formatting, and administrative changes not 
affecting the conduct of the study are included for clarification and administrative purposes only.
Protocol Amendment 8
Summary of Changes Since the Last Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description 
Rationale 
Section 1.2 Approval
Updated signatories.
A new global clinical lead has been 
assigned to the study.
Section 2.0 Study Summary
Updated number of study sites.
Updated the number of study sites
Section 2.0 Study Summary
Updated period of evaluation from 
17 to 22 weeks.
The period of evaluation from first 
screening visit to safety follow-up 
phone call is 22 weeks.
Section 4.2 Nonclinical 
Information
Revised Section 4.2 with new 
nonclinical data provided in the
Investigator’s Brochure (IB)
update.
To align with IB Edition 04 update.
Section 4.3.1 Clinical 
Pharmacology
Added results from Studies TAK-
906-1004 and TAK-906-1009.
Updates on the TAK-906-1004 and 
TAK-906-1009 study results.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 7 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Protocol Amendment 8
Summary of Changes Since the Last Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description 
Rationale 
Section 5.1.3 Additional Objectives
Section 5.2.4 Additional Endpoints
Section 6.1 Study Design
Section 6.2.1 Rationale for Study 
Design
Section 9.1.18.1 GEBT
Section 2.0 Study summary
Appendix A Schedule of Study 
Procedures
Removed GEBT) at Visit 5 
(Week 4) and Visit 7 (Week 12).
To reduce patient burden.
Section 6.1 Study Design
Section 7.1 Inclusion Criteria
Section 9.1.18.1 GEBT
Section 2.0 Study Summary
Appendix A Schedule of Study 
Procedures
Allow historical documented 
delayed gastric emptying GEBT or 
scintigraphy or wireless motility 
capsule as inclusion criteria (in lieu 
of requiring GEBT at screening –
GEBT required if no previously 
documented test demonstrating 
gastric emptying).
To reduce subject burden for patients 
who already have a diagnostic test 
demonstrating delayed gastric 
emptying documented in the medical 
record.
Section 6.1 Study Design
Figure 6.a Schematic of Study 
Design
Section 6.2.1 Rationale for Study 
Design
Section 8.1.1 Dosage Form, 
Manufacturing, Packaging, and 
Labeling
Section 8.4 Study Drug Blind 
Maintenance
Section 13.3 Determination of 
Sample Size
Section 2.0 Study Summary
Discontinued randomization into 
the 5 mg dose arm.
Randomization into the 5 mg dose arm 
is being discontinued to improve 
operational feasibility in the setting of 
the COVID-19 pandemic and to reduce 
the number of subjects being exposed 
to a potentially minimally efficacious 
dose that likely approaches the lower 
end of the dose response curve.
Section 6.2.1 Rationale for Study 
Design
Section 2.0 Study Summary
Removed the minimum number of 
DG and IG subjects in each dose 
arm.
To mitigate the impact of the COVID-
19 pandemic on enrollment rates.
Section 7.2 Exclusion Criteria
Updated exclusion criteria to adapt 
for removal of GEBT at Visits 5 
and 7.
Updated chronic smoker exclusion 
criteria to adapt for removal of GEBT 
at Visits 5 and 7.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 8 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Protocol Amendment 8
Summary of Changes Since the Last Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description 
Rationale 
Section 6.1 Study Design
Section 10.2.1 Collection and 
Reporting of AEs
Section 2.0 Study Summary
Appendix A Schedule of Study 
Procedures
Revised safety visit follow up 
phone call from 40 to 30 days.
To shorten safety visit follow-up to 
standard timeframe of 30 days
Section 7.2 Exclusion Criteria
Section 2.0 Study Summary
Revision of the accepted BMI 
range.
In order to reflect the lower BMI seen 
in the gastroparesis population.
Section 7.2 Exclusion Criteria
Section 2.0 Study Summary
Summarized and combined 
exclusion Criteria Nos. 32, 33, and 
35 under Criterion No. 32.
To create one inclusive liver disease 
exclusion criterion.
Section 7.2 Exclusion Criteria
Section 2.0 Study Summary
Added exclusion criterion for any 
subjects with suspected or known 
COVID-19 infection. 
To include this exclusion, related to 
the COVID-19 pandemic situation.
Section 7.3 Excluded Medications
Added OATP1B1/1B3 inhibitors 
and otilonium bromide/Spasmomen 
to excluded medications.
A recently completed OATP (drug-
drug interaction (DDI) study (Study 
TAK-906-1009) suggested that 
coadministration of TAK-906 with a 
single dose of rifampin (OATP1B1 
and 1B3 inhibitor) resulted in high 
exposure of TAK-906,which may 
potentially increase the safety risk (eg, 
adverse events [AEs], toxicities). Thus, 
the concomitant use of OATP1B1/1B3 
inhibitors will be excluded.
Added otilonium bromide/Spasmomen 
to the list of excluded medications due 
to its anticholinergic and 
antispasmodic effects.
Section 7.5 Criteria for 
Discontinuation or Withdrawal of a 
Subject
Revised Section 7.5 Criteria for 
Discontinuation or Withdrawal of a 
Subject.
Added criteria for any subject with 
identified COVID-19 infection during 
the study.
Section 9.1.6 Vital Signs Procedure
Revised wording to standardize 
timing of vital signs procedures.
To standardize vital signs collection in 
relation to blood draws.
Section 9.1.13 ECG Procedure
Appendix A Schedule of Study 
Procedures
Revised wording of 
electrocardiogram (ECG)
procedures. 
To clarify that PR interval should be 
part of ECG assessment and to 
standardize time of assessments.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 9 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Protocol Amendment 8
Summary of Changes Since the Last Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description 
Rationale 
Section 9.1.14 PGx and PK Sample 
Collection
Section 6.1 Study Design
Appendix A Schedule of Study 
Procedures
Removal of biomarker samples 
collection.
To reduce the number of blood 
collections and streamline at home 
study procedures.
Section 9.1.18.2 Patient Outcome 
Measures
Appendix E Patient Global 
Impression Scales
Revised wording to acknowledge 
the use of an updated Patient 
Global Impression of Severity 
(PGI-S) scale and the use of PGI-
Change (C) scale instead of the 
PGI- Improvement (I) scale and 
added an appendix.
To comply with FDA recommended 
changes
Section 9.5 Possible Changes to the 
Procedures to Address Interruptions 
Due to Pandemic Outbreak
Added Section 9.5
To implement any changes needed to 
study procedures, related to the impact 
of the COVID-19 pandemic.
Section 10.1.4 SAEs
Added COVID-19-related disease 
and COVID-19 pneumonia to 
Table 10.a.
To follow the general company's 
guidance, the preferred terms COVID-
19-related disease and COVID-19 
pneumonia are added into the list of 
Takeda medically significant AEs.
Section 13.1.3.1 Primary Efficacy 
Analysis
Section 2.0 Study Summary
Revised language in Section 
13.1.3.1 Primary Efficacy Analysis
Updates made for clarity and 
completeness.
Section 13.2 Interim Analysis
Revised Section 13.2 interim 
analysis.
To address removal of interim efficacy 
analysis.
Section 13.3 Determination of 
Sample Size
Section 2.0 Study Summary
Updated number of subjects and 
revised wording of sample size 
justification and power estimate.
Sample size is adjusted in order to 
manage the likelihood of statistical, 
clinical and operational success of this 
study in the setting of the COVID-19 
pandemic. Specifically, to manage the 
risk associated with statistical 
decision-making and operational 
delays, the statistical testing is revised 
from 2-sided (with a significance level 
of 5%) to 1-sided (with a significance 
level of 5%). In addition, the planned 
sample size is reduced by 10 subjects 
per arm and randomization into the 5 
mg dose arm will be discontinued. As 
a result, the study power is re-
estimated and remains approximately 
80%.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 10 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Protocol Amendment 8
Summary of Changes Since the Last Version of the Approved Protocol
Sections Affected by Change
Description of Each Change and Rationale
Location
Description 
Rationale 
Appendix A Schedule of Study 
Procedures
Revised language for collection of 
prolactin samples.
To clarify that Visits 2 and 3 prolactin 
samples are not mandatory.
Appendix A Schedule of Study 
Procedures
Aligned wording in footnotes of 
Schedule of Study Procedures with 
changes in the text.
To align footnotes with changes in the 
text regarding clarification of 
assessments and timing of 
assessments.
Appendix A Schedule of Study 
Procedures
Revised the PK sampling scheme 
of Schedule of Study Procedures.
To reduce the patient burden by 
reducing the number of blood PK
collections
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 11 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
TABLE OF CONTENTS
ADMINISTRATIVE INFORMATION ...........................................................................2
1.0
1.1
Contacts.....................................................................................................................2
1.2
Approval....................................................................................................................3
1.3
Protocol Amendment 8 Summary and Rationale ........................................................5
STUDY SUMMARY ....................................................................................................16
2.0
STUDY REFERENCE INFORMATION ......................................................................21
3.0
3.1
Study-Related Responsibilities.................................................................................21
3.2
Coordinating Investigator.........................................................................................21
3.3
List of Abbreviations ...............................................................................................22
3.4
Corporate Identification ...........................................................................................24
INTRODUCTION.........................................................................................................24
4.0
4.1
Background .............................................................................................................24
4.2
Nonclinical Information...........................................................................................25
4.2.1
Nonclinical Pharmacology .................................................................................25
4.2.2
Safety Pharmacology .........................................................................................25
4.2.3
Pharmacokinetics and Product Metabolism ........................................................26
4.2.4
Toxicology.........................................................................................................27
4.3
Human Experience...................................................................................................28
4.3.1
Clinical Pharmacology.......................................................................................28
4.4
Rationale for the Proposed Study.............................................................................29
4.5
Benefit/Risk Profile .................................................................................................30
STUDY OBJECTIVES AND ENDPOINTS..................................................................31
5.0
5.1
Objectives................................................................................................................31
5.1.1
Primary Objective ..............................................................................................31
5.1.2
Secondary Objective ..........................................................................................31
5.1.3
Additional Objectives.........................................................................................31
5.2
Endpoints.................................................................................................................31
5.2.1
Primary Endpoint...............................................................................................31
5.2.2
Secondary Endpoints..........................................................................................31
5.2.3
Safety and Tolerability Endpoints ......................................................................32
5.2.4
Additional Endpoints .........................................................................................32
STUDY DESIGN AND DESCRIPTION.......................................................................33
6.0
6.1
Study Design ...........................................................................................................33
6.2
Justification for Study Design, Dose, and Endpoints ................................................35
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 12 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
6.2.1
Rationale for Study Design ................................................................................35
6.2.2
Rationale for Dose .............................................................................................36
6.2.3
Rationale for Placebo .........................................................................................36
6.2.4
Rationale for Endpoints......................................................................................37
6.3
Premature Termination or Suspension of Study or Study Site...................................38
6.3.1
Criteria for Premature Termination or Suspension of the Study ..........................38
6.3.2
Criteria for Premature Termination or Suspension of Study Sites .......................39
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)..............................................................................39
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS ..............39
7.0
7.1
Inclusion Criteria .....................................................................................................39
7.2
Exclusion Criteria ....................................................................................................40
7.3
Excluded Medications..............................................................................................43
7.4
Diet, Fluid, Activity Control ....................................................................................45
7.5
Criteria for Discontinuation or Withdrawal of a Subject ...........................................45
7.6
Procedures for Discontinuation or Withdrawal of a Subject......................................46
CLINICAL STUDY MATERIAL MANAGEMENT.....................................................47
8.0
8.1
Study Drug and Materials ........................................................................................47
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling.....................................47
8.1.2
Storage...............................................................................................................48
8.1.3
Dose and Regimen .............................................................................................48
8.1.4
Overdose............................................................................................................48
8.2
Study Drug Assignment and Dispensing Procedures ................................................48
8.3
Randomization Code Creation and Storage ..............................................................49
8.4
Study Drug Blind Maintenance ................................................................................49
8.5
Unblinding Procedure..............................................................................................49
8.6
Accountability and Destruction of Sponsor-Supplied Drugs.....................................50
STUDY PLAN ..............................................................................................................51
9.0
9.1
Study Procedures .....................................................................................................51
9.1.1
Informed Consent Procedure..............................................................................51
9.1.1.1 PGx Informed Consent Procedure ................................................................51
9.1.2
Demographics, Medical History, and Medication History Procedure ..................51
9.1.3
Physical Examination Procedure ........................................................................52
9.1.4
Assessment of the Extrapyramidal System .........................................................52
9.1.5
Weight, Height, and BMI ...................................................................................52
9.1.6
Vital Signs Procedure.........................................................................................52
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 13 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
9.1.7
Primary Efficacy Measurement ..........................................................................53
9.1.8
Documentation of Concomitant Medications......................................................53
9.1.9
Documentation of Concurrent Medical Conditions .............................................53
9.1.10 Procedures for Clinical Laboratory Samples.......................................................53
9.1.11 Contraception and Pregnancy Avoidance Procedure...........................................55
9.1.11.1
Male Subjects and Their Female Partners ...............................................55
9.1.11.2
Female Subjects and Their Male Partners ...............................................55
9.1.11.3
Definitions and Procedures for Contraception and Pregnancy 
Avoidance....................................................................................................56
9.1.12 Pregnancy ..........................................................................................................58
9.1.13 ECG Procedure ..................................................................................................58
9.1.14 PGx and PK Sample Collection..........................................................................59
9.1.14.1
PGx Measurements.................................................................................59
9.1.15 PK Sample Collection and Analysis ...................................................................59
9.1.16 Documentation of Screen Failure .......................................................................59
9.1.17 Documentation of Randomization ......................................................................60
9.1.18 Other Procedures................................................................................................60
9.1.18.1
GEBT.....................................................................................................60
9.1.18.2
Patient Outcome Measures .....................................................................61
9.2
Monitoring Subject Treatment Compliance..............................................................61
9.3
Schedule of Observations and Procedures ................................................................61
9.3.1
Poststudy Care ...................................................................................................62
9.4
Biological Sample Retention and Destruction ..........................................................62
9.5
Possible Changes to the Procedures to Address Interruptions Due to Pandemic 
Outbreak..................................................................................................................62
PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................63
10.0
10.1
Definitions...............................................................................................................63
10.1.1 Pretreatment SAEs.............................................................................................63
10.1.2 AEs....................................................................................................................63
10.1.3 Additional Points to Consider for AEs................................................................63
10.1.4 SAEs..................................................................................................................65
10.1.5 AEs of Special Interest.......................................................................................66
10.1.6 Severity of AEs..................................................................................................68
10.1.7 Causality of AEs ................................................................................................69
10.1.8 Relationship to Study Procedures .......................................................................69
10.1.9 Start Date...........................................................................................................69
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 14 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
10.1.10
Stop Date .....................................................................................................69
10.1.11
Frequency ....................................................................................................69
10.1.12
Action Concerning Study Drug ....................................................................70
10.1.13
Outcome.......................................................................................................70
10.2
Procedures...............................................................................................................70
10.2.1 Collection and Reporting of AEs........................................................................70
10.2.1.1
AE Collection Period..............................................................................70
10.2.1.2
AE Reporting .........................................................................................71
10.2.2 Collection and Reporting of SAEs/AESI ............................................................72
10.2.3 Reporting of Abnormal LFTs .............................................................................72
10.3
Follow-up of SAEs ..................................................................................................72
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities .....73
STUDY-SPECIFIC COMMITTEES .............................................................................73
11.0
11.1
IDMC ......................................................................................................................73
DATA HANDLING AND RECORDKEEPING............................................................73
12.0
12.1
eCRFs......................................................................................................................73
12.2
Record Retention .....................................................................................................74
STATISTICAL METHODS ..........................................................................................75
13.0
13.1
Statistical and Analytical Plans ................................................................................75
13.1.1 Analysis Sets......................................................................................................75
13.1.2 Analysis of Demographics and Other Baseline Characteristics ...........................75
13.1.3 Efficacy Analysis...............................................................................................76
13.1.3.1
Primary Efficacy Analysis ......................................................................76
13.1.3.2
Secondary Efficacy Analyses..................................................................76
13.1.4 PK Analysis .......................................................................................................77
13.1.5 Other Analyses...................................................................................................77
13.1.6 Safety Analysis ..................................................................................................77
13.1.6.1
AEs ........................................................................................................77
13.1.6.2
Other Safety Evaluations ........................................................................77
13.2
Interim Analysis ......................................................................................................77
13.3
Determination of Sample Size..................................................................................78
QUALITY CONTROL AND QUALITY ASSURANCE...............................................78
14.0
14.1
Study-Site Monitoring Visits ...................................................................................78
14.2
Protocol Deviations..................................................................................................78
14.3
Quality Assurance Audits and Regulatory Agency Inspections ................................79
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 15 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
ETHICAL ASPECTS OF THE STUDY........................................................................79
15.0
15.1
IRB and/or IEC Approval ........................................................................................79
15.2
Subject Information, Informed Consent, and Subject Authorization .........................80
15.3
Subject Confidentiality ............................................................................................81
15.4
Publication, Disclosure, and Clinical Trial Registration Policy.................................81
15.4.1 Publication and Disclosure.................................................................................81
15.4.2 Clinical Trial Registration..................................................................................82
15.4.3 Clinical Trial Results Disclosure ........................................................................82
15.5
Insurance and Compensation for Injury....................................................................82
REFERENCES..............................................................................................................83
16.0
LIST OF IN-TEXT TABLES
Table 9.a
Clinical Laboratory Tests ...................................................................................54
Table 9.b
Primary Specimen Collections ...........................................................................59
Table 10.a
Takeda Medically Significant AE List................................................................66
LIST OF IN-TEXT FIGURES
Figure 6.a
Schematic of Study Design ................................................................................34
LIST OF APPENDICES
Appendix A
Schedule of Study Procedures ............................................................................86
Appendix B
Hepatic Function Categories Based on Child-Pugh Score...................................90
Appendix C
Guidance for Assessment of the Extrapyramidal System ....................................91
Appendix D
Schedule of Questionnaire Assessments.............................................................92
Appendix E
Patient Global Impression Scales .......................................................................93
Appendix F
Responsibilities of the Investigator.....................................................................94
Appendix G
Elements of the Subject Informed Consent .........................................................96
Appendix H
Investigator Consent to Use of Personal Information ..........................................99
Appendix I
ANMS GCSI-DD.............................................................................................100
Appendix J
Bloating Severity Scale ....................................................................................101
Appendix K
Protocol History...............................................................................................102
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 16 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
STUDY SUMMARY
2.0
Name of Sponsor(s):
Millennium Pharmaceuticals, Inc., a wholly owned 
subsidiary of Takeda Pharmaceutical Company
Limited
Compound:
TAK-906
Title of Protocol: 
A Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Parallel-Group, Phase 2b Study to Evaluate the 
Efficacy and Safety of Twice-Daily Oral Administration of 
a Peripherally Acting Dopamine Receptor D2/D3
Antagonist, TAK-906 for the Treatment of Adult Subjects 
With Symptomatic Idiopathic or Diabetic Gastroparesis
IND No.: 125296
EudraCT No.: 
2018-001275-21
Study Number: TAK-906-2002
Phase: 2b
Study Design: This is a global multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2b 
study to evaluate the efficacy and safety of twice daily (BID) oral (PO) capsule administration of a peripherally 
acting dopamine (DA) receptor D2/D3 antagonist, TAK-906, in adult male and female subjects aged 18 to 85 years, 
inclusive, with symptomatic idiopathic or diabetic gastroparesis ([IG and DG], respectively). Gastroparesis is a 
disorder of the stomach characterized by delayed gastric emptying, in the absence of mechanical obstruction.
Subjects will attend the study site for a screening/consent visit (Visit 1, Day -35), when their consent will be 
obtained, and general eligibility to participate in the study will be reviewed. After signing the informed consent 
form, subjects will have a blood sample taken to assess their laboratory values. Subjects will discontinue all 
excluded medications and return to the site 3 to 17 days later to perform a 4-hour 13C-Spirulina Gastric Emptying 
Breath Test (GEBT) (Visit 2, Day -21). Subjects with confirmed delayed gastric emptying by an accepted diagnostic 
method that is documented in the subject’s medical records prior to screening do not have to undergo the Visit 2 
GEBT and may skip Visit 2. Subjects who are not taking any medications at the screening visit that require washout 
may attend the clinic for Visit 2 earlier than 2 weeks and only after laboratory results have been reviewed by the 
investigator. An 8-hour fast is required before the GEBT. Subjects who required the Visit 2 GEBT will then 
complete Visit 3 (Day -14) within 7 days after the GEBT visit to confirm their eligibility based on the gastric 
emptying criteria. Once the subject is confirmed to have delayed gastric emptying, subjects will be instructed on the 
use of an electronic patient reported outcomes tool (ePRO) for collecting the daily symptoms of gastroparesis, daily 
dosing and meal time recordings, and capture of rescue medication use. The instrument used to capture symptom 
data will be the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-
Daily Diary (ANMS GCSI-DD) along with a bloating severity scale. Subjects will record their symptoms once daily 
(in the evening) and will return to the clinic approximately 2 weeks later to assess their gastroparesis symptom 
eligibility based on the ANMS GCSI-DD (Visit 4, randomization). Subjects need to be compliant with completing 
the Daily Symptom Diary, defined as ≥80% diary completions, during the 2-week symptom assessment period. 
Subjects will be randomized 1:1:1 into 1 of 3 treatment groups: TAK-906 maleate (TAK-906M) 25, and 50 mg 
capsule BID or matching placebo BID, stratified by IG and DG. Medication should be taken 1 dose in the morning 
approximately 1 hour before the first meal of the day and another dose in the evening approximately 1 hour before 
the main last meal of the day, at a regular dose interval. Subjects will take their first dose of study medication at the 
randomization visit (Day 1) and will take their morning dose in clinic at Visits 5, 6, and 7. Subjects will complete 
the Daily Symptom Diary daily for 12 weeks and complete visits at Weeks 4 (Visit 5), 8 (Visit 6), and 12 (Visit 7). 
At Day 1 and Weeks 4, 8, and 12/early termination, pharmacokinetic (PK) samples will be taken both predose and 
postdose. A safety follow-up phone call will be made approximately 30 days after last dose of study medication.
Subjects who withdraw prematurely will be followed up by the physician for an early termination visit as soon as 
possible and will continue completing the Daily Symptom Diary until this termination visit using the ePRO device. 
Subjects will be contacted for a follow-up safety call approximately 30 days after the last dose of study medication 
to check if any adverse events occurred during this follow-up period.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 17 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Primary Objective:
To assess the efficacy of treatment with 2 dose levels of TAK-906 in adult subjects with gastroparesis compared 
with placebo during 12 weeks of treatment.
Secondary Objectives:
To evaluate the safety and tolerability of TAK-906 doses compared with placebo during 12 weeks of treatment.
Additional Objectives:

To evaluate the PK of TAK-906 in subjects with gastroparesis.

To evaluate the effect of TAK-906 on quality of life compared with placebo.
Subject Population: Men and women with DG and IG aged ≥18 to 85 years, inclusive.
Number of Subjects:
Approximately 205 subjects
TAK 906M 5 mg capsule BID: approximately 25 subjects 
prior to discontinuation of randomization into this dose 
arm
TAK-906M 25 mg capsule BID: n=60
TAK-906M 50 mg capsule BID: n=60
Placebo capsule BID: n=60
Number of Sites: 
Estimated total: Up to 120 sites in North America, 
Europe, and Japan
Dose Level(s):
TAK 906M 5 mg capsule BID: approximately 25 subjects 
prior to discontinuation of randomization into this dose 
arm
TAK-906M 25 mg capsule BID
TAK-906M 50 mg capsule BID
Placebo capsule BID
Route of Administration:
PO
Duration of Treatment:
12 weeks 
Period of Evaluation:
Approximately 22 weeks from screening through 
safety follow-up.
Main Criteria for Inclusion: 
Subject eligibility is determined according to the following criteria before entry into the study:

Adult men and women aged 18 to 85 years, inclusive, and with body mass index (BMI) ≥18 to ≤40 kg/m2
inclusive.

Subjects should have symptoms of gastroparesis (eg, postprandial fullness, nausea, vomiting, upper abdominal 
pain, and early satiety) for at least 3 months before screening as assessed by a physician. 

Subjects must have an average composite ANMS GCSI-DD symptom score ≥2 during the 7 days before 
randomization. The predominant symptom experienced by subjects must not be abdominal pain.

Subjects must experience nausea: nausea subscale (of ANMS GCSI-DD) symptom score ≥2 at least 4 of 7 days 
or an average nausea subscale symptom score ≥2 during the 7 days before randomization. Nausea symptoms 
must not be attributable to a central disorder (eg, motion sickness, glaucoma, menstrual cycles, migraine 
headache).

Subjects must have confirmed delayed gastric emptying using an accepted diagnostic testing method that is 
documented in the subject’s medical records prior to screening, OR that is confirmed by the GEBT performed at 
Visit 2. Delayed gastric emptying is defined as time to gastric half emptying (t1/2) ≥79 minutes (80th percentile).

Absence of gastric outlet obstruction confirmed by upper gastrointestinal (GI), computed tomography, or 
endoscopy.
Special Inclusion for Subjects with Diabetes Mellitus

Subjects must have glycosylated hemoglobin (HbA1c) ≤11% before the randomization visit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 18 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Main Criteria for Exclusion: 
Any subject who meets any of the following criteria will not qualify for entry into the study: 

Known secondary causes of gastroparesis including but not limited to Parkinson disease, cancer, viral illness, or 
connective tissue diseases.

Predominant gastroparetic symptom is epigastric pain, diffuse abdominal pain, or pain associated with bowel 
movement.

Is taking medications that affect gastric emptying including opioids, glucagon-like peptide-1 analogs (eg,
exenatide, liraglutide), amylin analogs (eg, pramlintide), and cannabinoids.

Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding 
bariatric surgery pyloroplasty, vagotomy, or fundoplication, which has manipulated the natural anatomy of the 
stomach.

History of intrapyloric botulinum toxin injection within 3 months of screening or currently has a functioning 
implantable gastric electric stimulator.

Nasogastric, percutaneous endoscopic gastrostomy, or percutaneous endoscopic jejunostomy feeding tube or 
inpatient hospitalization for gastroparesis within 2 weeks before the screening visit.

Required parenteral nutrition for treatment of gastroparesis within 2 months before the screening visit.

Previous diagnosis of gastric bezoar (the presence of retained liquid, bile, or small amounts of poorly organized 
food residue is permitted).

Poor control of diabetes within 30 days before study entry, including diabetic ketoacidosis, hypoglycemia 
requiring medical intervention, admission for control of diabetes or diabetic complications.

Elevated serum prolactin (>upper limit of normal [ULN]) at screening. A high prolactin level at the screening 
visit that is considered to be due to stress of venipuncture, chest wall stimulation, or other physiological causes 
may be retested after a few days and if normal, the subjects may be enrolled in the study.

Medical history of hypogonadism, current clinically significant menstrual abnormalities, or other clinical 
features of hyperprolactinemia will be excluded.

The subject has acute or chronic liver disease meeting any of the criteria described below:
–
The subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total 
bilirubin >2.0 times the ULN.
–
The subject has pre-existing liver cirrhosis that meets Child-Pugh Class B (moderate; total score 7 to 
9 points) or C (severe; total score 10 to 15 points) (see Appendix B).
–
The subject has acute or chronic hepatitis B or C virus infection, manifesting as one of the following at 
screening:

Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). NOTE: if a 
subject tests negative for HBsAg, but positive for HBcAb, the subject would be eligible if the 
Investigator has documentation of other test results showing that the subject does not have active 
hepatitis B infection.

Subjects with positive hepatitis C antibody (HCV IgG) and quantitative HCV polymerase chain 
reaction (PCR). HCV PCR is performed only if HCV IgG is positive.

Any signs/symptoms or history of extrapyramidal system disease and other clinically relevant central nervous 
system or neuropsychiatric disease including but not limited to tardive dyskinesia, neuroleptic malignant 
syndrome, acute dystonia, parkinsonian like symptoms, severe depression, and history of suicide attempt.

The subject has known COVID-19 infection, or suspected COVID-19 infection (as assessed by the 
investigator).
Main Criteria for Evaluation and Analyses:
Primary Endpoints:

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD composite score (nausea, 
early satiety, upper abdominal pain, and postprandial fullness). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 19 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Secondary Endpoints: 

Proportion of subjects with at least 50% reduction from baseline in ANMS GCSI-DD composite score at 
Week 12. 

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD nausea symptom score.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD early satiety symptom score. 

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD postprandial fullness 
symptom score. 

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD upper abdominal pain 
symptom score. 

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD recorded vomiting 
frequency.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD overall severity of 
gastroparesis symptoms score.

Change from baseline to Week 12 of the treatment period in the bloating severity scale score.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD total score (nausea, early 
satiety, upper abdominal pain, postprandial fullness, bloating, and vomiting).

Proportion of symptomatic weeks (weeks with symptoms assessed as >mild [average ANMS GCSI-DD 
composite score ≥2]) during 12 weeks of treatment. 

Change from baseline to Week 12 of the treatment period in the Patient Assessment of Upper Gastrointestinal 
Disorders-Symptom Severity Index (PAGI-SYM) total score.
Safety and Tolerability Endpoints

Safety and tolerability will be evaluated using the following general assessments:
–
Treatment-emergent adverse events.
–
Vital signs.
–
12-lead electrocardiograms.
–
Clinical laboratory parameters (hematology, clinical chemistry, and urinalysis).
Additional Endpoints:

Percentage of symptomatic days (days with symptoms assessed as >mild (ANMS GCSI-DD score ≥2) using the 
ANMS GCSI-DD during 12 weeks of treatment.

Proportion of subjects with ≥20% reduction in ANMS GCSI-DD composite score from baseline in the last 
6 consecutive weeks of the study.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD core symptom score (nausea, 
early satiety, upper abdominal pain, postprandial fullness, and vomiting).

Change from baseline to Week 12 of the treatment period in Clinician Symptom Severity Rating form.

Change from baseline to Week 12 of the treatment period in Patient Assessment of Upper Gastrointestinal 
Disorders Quality-of-Life Index (PAGI-QOL) total score. 

Differences at Week 12 in Overall Treatment Effect (OTE) Scales. 

Change from baseline to Week 12 in Clinical Global Impression Scale–Severity of Illness scale (CGI-S).

Differences at Week 12 in Clinical Global Impression -Improvement scale (CGI-I).

Change from baseline to Week 12 in Patient Global Impression of Severity (PGI-S). 

Differences at Week 12 in Patient Global Impression of Change (PGI-C).

TAK-906 predose (trough) plasma concentration at Week 12.

Change from baseline to Week 12 of the treatment period in Short Form-12 (SF12) Health Survey subscale 
scores.

Use of rescue medication during the 12-week treatment period.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 20 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Statistical Considerations:
The full analysis set (FAS) will include all subjects who were randomized, received at least 1 dose of study drug, 
have baseline and at least 1 postbaseline value for assessment of efficacy. In the FAS efficacy summaries, subjects 
will be analyzed by the treatment to which they were randomized. 
The safety set will include all subjects who were randomized and received at least 1 dose of double-blind study 
medication. In safety summaries, subjects will be analyzed according to the treatment they received. If a subject 
receives more than 1 treatment, the actual treatment will be defined as the one that is used most frequently. If the 2 
most common treatments are used with equal frequency, then the randomized treatment will be used as the actual 
treatment.
Primary Efficacy Analysis: The primary endpoint is the change from baseline to Week 12 in weekly ANMS GCSI-
DD composite score. Analysis will be based on a mixed model for repeated measurements (MMRM) with treatment, 
center, week, subject disease population (DG and IG), and treatment-by-week interaction as fixed effects, baseline 
and baseline score-by-week interaction as covariates, with an unstructured covariance structure if applicable. The 
point-estimates, nominal p-values and confidence intervals (CIs) for the primary analysis will be based on the Week 
12 statistical comparisons between each of the 2 TAK-906 dose groups and placebo, with respect to the primary 
endpoint. The 2 statistical tests for the primary efficacy analysis are 1-sided and will be conducted using a 5% level 
of significance. Nominal p-values will be evaluated for statistical significance. In addition, point estimates and CIs 
along with descriptive statistics for change from baseline scores in ANMS GCSI-DD at earlier time points, will be 
presented. The MMRM-based analysis assumes that missing data follow a missing-at-random (MAR) assumption. 
Secondary Efficacy Analysis: The secondary endpoint of proportion of subjects with at least 50% reduction from 
baseline in ANMS GCSI-DD composite score will be analyzed at all time points by logistic regression adjusting for 
baseline score, subject disease population and treatment by the last observation carried forward method to handle 
missing data.
Sample Size Justification: 
In order to manage the likelihood of statistical, clinical, and operational success of this study in the setting of the 
COVID-19 pandemic, the sample-size considerations are revisited in Protocol Amendment 8. The statistical testing 
is revised from 2-sided (with a significance level of 5%) to 1-sided (with a significance level of 5%), the planned 
sample size is reduced by 10 subjects per arm and randomization into the 5 mg dose arm is to be discontinued. 
The sample-size rationale for the resultant reduced sample size and updated 1-sided statistical testing is as follows: 
Assuming a SD of 1.25 and a true difference of 0.625 between TAK-906M active dose and placebo in the change 
from baseline in the ANMS GCSI-DD composite score, and a 15% dropout rate, a total of 205 subjects is sufficient 
to achieve approximately 80% power to detect the treatment effect of 0.625 at a 1-sided 5% significance level. The 
total of 205 subjects consists of approximately 25 subjects who have already been randomized to receive 5 mg 
capsule BID prior to terminating randomization of subjects into the 5 mg dose arm, and 60 subjects per treatment 
groups of placebo, TAK-906M 25 mg, and TAK-906M 50 mg.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 21 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
STUDY REFERENCE INFORMATION
3.0
3.1
Study-Related Responsibilities
The sponsor will perform all study-related activities except for those identified in the Study-
Related Responsibilities template. The vendors identified in the template for specific 
study-related activities will perform these activities in full or in partnership with the sponsor.
3.2
Coordinating Investigator
Takeda will select a Signatory Coordinating Investigator from the investigators who participate 
in the study. Selection criteria for this investigator will include significant knowledge of the 
study protocol, the study drug, their expertise in the therapeutic area and the conduct of clinical 
research as well as study participation. The Signatory Coordinating Investigator will be required 
to review and sign the clinical study report and by doing so agrees that it accurately describes the 
results of the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 22 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
3.3
List of Abbreviations
ADL
activities of daily living
AE
adverse event
AESI
adverse event of special interest
ALT
alanine aminotransferase
ANMS GCSI-DD
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom 
Index-Daily Diary
ANOVA
analysis of variance
AST
aspartate aminotransferase
AUC
area under the concentration-time curve
AUC∞
area under the concentration-time curve from time 0 to infinity
BID
twice daily
BMI
body mass index
CFR
Code of Federal Regulations
CGI-I
Clinical Global Impression Scale–Global Improvement Scale
CGI-S
Clinical Global Impression Scale–Severity of Illness Scale
CI
confidence interval
CNS
central nervous system
Cmax
maximum observed concentration
COVID-19
coronavirus disease-2019
CRO
contract research organization
CTCAE
Common Terminology Criteria for Adverse Events
CYP
cytochrome P-450
DA
dopamine 
DG
diabetic gastroparesis 
DNA
deoxyribonucleic acid
ECG
electrocardiogram
eCRF
electronic case report form
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
ePRO
electronic patient reported outcomes
EPS
extrapyramidal symptoms
FAS
full analysis set
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
GCP
Good Clinical Practice
GEBT
Gastric Emptying Breath Test
GGT
γ-glutamyl transferase
GI
gastrointestinal
HbA1c
glycosylated hemoglobin
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 23 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
HBcAb
hepatitis B core antibody
HBV
hepatitis B virus
hERG
human ether-à-go-go–related gene
HBsAg
hepatitis B virus surface antigen
hCG
human chorionic gonadotropin
HCV
hepatitis C virus
IB
Investigator’s Brochure
ICH
International Conference on Harmonisation
ID
identification
IDMC
Independent Data Monitoring Committee
IEC
independent ethics committee
IG
idiopathic gastroparesis
INR
international normalized ratio
IRB
institutional review board
IRT
interactive response technology
IV
intravenous(ly)
LFT
liver function test
MAR
missing-at-random
MedDRA
Medical Dictionary for Regulatory Activities
MMRM
mixed model for repeated measurements
NOAEL
no-observed-adverse-event level
OATP
organic anion transporting polypeptide
OTE
overall treatment effect
PAGI-QOL
Patient Assessment of Upper Gastrointestinal Disorders Quality-of-Life Index
PAGI-SYM
Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index
PCR
polymerase chain reaction
PD
pharmacodynamic(s)
PGI-C
Patient Global Impression of Change
PGI-I
Patient Global Impression of Improvement
PGI-S
Patient Global Impression of Severity
Pgp
P-glycoprotein
PGx
pharmacogenomics
PI
principal investigator
PK
pharmacokinetic(s)
PO
oral
PPS
per-protocol set
QD
once daily
QTc
QT and corrected QT
QTcF
QT interval with Fridericia correction method
SAE
serious adverse event
SAP
statistical analysis plan
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 24 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
SF12
Short Form-12 Health Survey
SUSAR
suspected unexpected serious adverse reaction
t1/2
time to gastric half emptying
tmax
time of first occurrence of maximum observed concentration
TAK-906M
TAK-906 maleate
TEAE
treatment-emergent adverse event
ULN
upper limit of normal
US
United States
3.4
Corporate Identification 
MPI
Millennium Pharmaceuticals, Inc., a subsidiary of Takeda Pharmaceutical Company 
Limited
TDC Japan
Takeda Development Center Japan
TDC Europe
Takeda Development Centre Europe Ltd.
TDC Americas
Takeda Development Center Americas, Inc.
TDC
TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda
MPI, TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
INTRODUCTION
4.0
4.1
Background
TAK-906 is being developed as an oral (PO) therapy for moderate to severe, diabetic 
gastroparesis (DG) and idiopathic gastroparesis (IG). A significant unmet medical need for safe 
and effective chronic therapies remains for these patients. Gastroparesis is a disorder of the 
stomach characterized by delayed gastric emptying in the absence of mechanical obstruction. It 
is estimated that there is in the range of 5 to 10 million gastroparetics (approximately 3% of the 
total population) in the United States (US) [1], with idiopathic (36%), diabetic (29%), 
postsurgical (13%), and Parkinson (7%) etiologies comprising the majority of cases in the 
tertiary referral setting [2]. Symptoms consist of nausea, vomiting, early satiety, abdominal pain,
and postprandial fullness that are chronic with episodic symptom exacerbation [3]. Gastroparesis 
causes nutritional compromise, impaired glucose control, and a reduced quality of life, 
independent of other factors such as age, tobacco and alcohol use, or type of diabetes [3]. The 
impact of gastroparesis has a serious outcome on day-to-day functioning is well-documented 
both for the patient’s deteriorating quality of life, productivity, and on the direct and indirect 
economic burden placed on society [4].
Currently in the US, there exists a significant unmet medical need because there are no approved 
therapies for the chronic treatment of DG. Validated targets for gastroparesis are the dopamine 
(DA) receptors D2 and D3. The D2 receptor antagonist metoclopramide is indicated for the short-
term treatment of acute and recurrent DG and has been limited in dose and duration of treatment 
because of well-documented toxicities, the most notable of which are extrapyramidal symptoms 
(EPS) [5]. EPS are caused by the blockade of the D2 receptor in the dorsal striatum and thus are 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 25 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
potential side effects of all centrally-acting drugs that share this mechanism of action, including 
D2 receptor antagonists. Of greatest concern is tardive dyskinesia, a severe and often irreversible 
EPS. The risk of developing tardive dyskinesia increases with dose level and duration of 
treatment (total cumulative dose), and consequently, the US package insert for metoclopramide 
includes a black box warning regarding the chronic use of metoclopramide for longer than 
12 weeks [6].
Domperidone is a peripherally-acting DA receptor D2/D3 antagonist marketed for use as an 
antiemetic and prokinetic agent in a number of countries worldwide, although not in the US 
because of its cardiovascular safety profile, which includes a risk for drug-induced QT 
prolongation, torsades de pointes, and sudden cardiac death [7]. DA receptor antagonists are 
effective in the treatment of delayed gastric emptying and gastroparesis symptoms because of the 
role of DA receptors D2 and D3 in the upper gastrointestinal (GI) tract and in the area postrema, 
which controls vomiting [8-10]. Both of these areas are outside of the blood brain barrier. 
Therefore, a peripherally-selective D2/D3 antagonist could achieve the desired efficacy without 
the undesired central nervous system (CNS) effects such as EPS [11,12].
TAK-906 is a peripherally acting (ie, limited penetration of the blood brain barrier) DA receptor 
D2/D3 antagonist. 
4.2
Nonclinical Information
4.2.1
Nonclinical Pharmacology
In vitro studies of receptor binding affinity and activity and in vivo studies of pharmacodynamic 
effects on prolactin secretion in rats and apomorphine-induced emesis in dogs have demonstrated 
primary pharmacologic actions of TAK-906 consistent with D2/D3 antagonism. Overall, 
TAK906 is expected to be effective in the treatment of gastroparesis, based on nonclinical 
pharmacology data demonstrating D2/D3 antagonism with a potency comparable to or greater 
than domperidone and metoclopramide. 
4.2.2
Safety Pharmacology
A series of safety pharmacology studies evaluated TAK-906 as outlined in International 
Conference on Harmonisation (ICH) S7A, including assessments of cardiovascular safety, CNS 
safety, and respiratory safety. TAK-906 weakly blocked human ether-à-go-go–related gene
(hERG) potassium channel current (50% inhibitory concentration [IC50] = 15.6 μM). In a dog 
cardiovascular safety pharmacology study, small decreases in systolic and pulse pressure were 
observed at ≥10 mg/kg with a compensatory increase in heart rate with associated lower QT and 
PR interval electrocardiogram (ECG) parameters observed at 30 mg/kg. There were no changes 
in corrected QT interval (QTc). Changes in locomotor activity (rearing, basic, and fine 
movement) were observed at ≥100 mg/kg in the repeat-dose 28-day rat study, but TAK-906 was 
not associated with any other biologically significant changes in CNS or respiratory parameters.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
de
de
use as an
se as 
ot in the
ot in th
duce
uced Q
d Q
tor antag
or anta
sympto
symp
ct and in
and 
the blo
the b
ieve the 
eve th
EPS 
EPS [1
n of the 
of the
finit
nity an
y a
s and ap
and a
f TAK
TAK
f
effect
ffective
iv
strating
stratin
metoclop
etocl
Pharma
harm
fetyty pha
ph
y
on Har
on H
nd respi
nd resp
G) pota
pot
diovasc
ova
observe
bserv
PR i
PR 
ini


TAK-906
Study No. TAK-906-2002
Page 26 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
4.2.3
Pharmacokinetics and Product Metabolism
Absorption, distribution, metabolism, excretion, and pharmacokinetic (PK) properties of TAK-
906 and [14C]TAK-906 were evaluated using in vitro or in vivo assays. Using the maleate form 
intended for the clinic, studies in rats and dogs demonstrated that TAK-906 is absorbed 
following PO administration. The absolute bioavailability (BA) of TAK-906 was approximately 
19% in rats following PO gavage administration, and up to 18% in dogs following PO capsule 
administration. At pharmacologically relevant PO doses, time of first occurrence of maximum 
observed plasm concentration (tmax) was 20 to 30 minutes. TAK-906 administered PO shows a 
somewhat greater than proportional increase in TAK-906 exposure with dose across the wide 
range of doses studied; 3 to 1000 mg/kg in rats and 1 to 500 mg/kg in dogs. Exposure in female 
animals was generally greater than that in males but usually by less than 2-fold. Accumulation 
was not observed with repeated dosing. An in vitro permeability study of [14C]TAK-906 using 
human colonic adenocarcinoma (Caco-2) cells showed that TAK-906 has moderate permeability. 
[14C]TAK-906-derived radioactivity distributed widely into tissues, and almost completely 
eliminated from them by 72 hours after a single PO dose to albino rats; in pigmented rats, 
[14C]TAK-906-derived radioactivity had little affinity for melanin. Plasma protein binding of 
TAK-906 in mouse, rat, dog, and human plasma was ≥90% and mainly to human serum albumin 
(HSA). Penetration of TAK-906 into the brain is minimal as demonstrated by 
plasma-to-cerebrospinal fluid(CSF) level comparisons in rats and dogs using the PO route of 
administration, and by plasma to whole brain level comparisons in mice using the intraperitoneal 
(IP) route of administration.
In vitro, using hepatocytes from humans, rats, and dogs, TAK-906 is metabolized to a ketone 
reduction metabolite (M23) and unidentified metabolites. No unique human metabolites are 
observed. TAK-906 is mainly metabolized by a non-cytochrome P-450 (CYP) pathway and via 
CYP2C8 and CYP3A4/5. In vitro investigations demonstrated that formation of M23 occurred in 
human liver cytosol and not in CYP-expressing liver microsomes. Therefore, M23 is likely 
formed by a cytosolic nicotinamide adenine dinucleotide phosphate (NADPH)-dependent 
reductase like aldo-keto (AKR) and/or short-chain dehydrogenase (SDR) rather than by CYP. A 
metabolic stability study with TAK-906 in human liver S9 with or without a pan CYP inhibitor 
(ABT), indicated the relative contribution of CYP and non-CYP toward in vitro metabolism of 
TAK-906 was 43.3% and 56.7%, respectively. In vivo metabolic profiling of plasma and excreta 
from rats and dogs indicated the presence of TAK-906, M23, N-dealkylated metabolite (M28), 
and unidentified metabolites. TAK-906 was the major component in rat and dog plasma. In 
fasted rats, the excretion of radioactivity was largely via feces. Biliary excretion was the major 
excretory route for TAK-906 and related substances in bile duct-cannulated rats. Similarly, in 
fasted dogs, urinary and fecal excretion were 8.0% and 91.3%, respectively, over 96 hours.
TAK-906 showed little potential to inhibit or induce CYP. TAK-906 is a substrate of P-
glycoprotein (Pgp), OATP1B1 and OATP1B3, but not breast cancer resistance protein, organic 
anion transporter 1/3, organic cation transporter 2, multidrug and toxin extrusion transporter 1, 
and multidrug and toxin extrusion transporter 2-K. In vitro investigations using human 
hepatocytes and OATP1B1/1B3-expressing cells demonstrated that uptake of [14C]TAK-906 into 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 27 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
human hepatocytes is primarily mediated by OATP1B1. TAK-906 is unlikely to inhibit 
transporter proteins at clinically relevant concentrations.
4.2.4
Toxicology
The safety of TAK-906 was tested in range-finding and pivotal repeat-dose toxicity studies up to 
13 weeks in duration in rats and dogs with once daily oral administration. Rat and dog repeat 
dose studies with twice daily dosing (BID) up to 28-days were completed to be consistent with 
the BID clinical dose regimen and to guide dose selection for 6-month rat and 9-month dog BID 
studies. A full battery of genotoxicity assays (in vitro Ames and chromosome aberration and in 
vivo rat micronucleus assays), embryo-fetal development studies in rats and rabbits, a fertility 
and early embryonic development study in rats, and a phototoxicity study in rats were also 
conducted. Mouse repeat dose BID studies were conducted to guide dose selection for a 6-month 
transgenic mouse carcinogenicity study.
Dose-limiting toxicity was seen in the form of tremors and weight loss in dogs treated with 
TAK-906 at ≥250 mg/kg for up to 4 days. At lower repeated doses (<100 mg/kg/day), slight 
tremor and the presence of expected class-related pharmacological effects, including signs 
associated with mild sedation, were observed in dogs.
In the pivotal 13-week repeat-dose toxicity study in rats with TAK-906 administered once daily 
(QD) by PO gavage, the no-observed-adverse-event level (NOAEL) was 1000 mg/kg/day. Target 
organ effects in male and female mammary tissue, mucification in the cervix and vagina, and 
corpus luteum hypertrophy in the ovary were associated with hyperprolactinemia, which is a 
known indicator for target engagement for this drug class and may result in reproductive changes 
consistent with hyperprolactinemia (ie, amenorrhea, infertility in females, gynecomastia in 
males). 
In the pivotal 13-week repeat-dose toxicity study in dogs with TAK-906 administered QD PO by 
capsule, the NOAEL was 50 mg/kg/day, at which CNS-associated pharmacological effects 
typical of this pharmacologic class occurred at 50 mg/kg/day, including decreased activity, 
tremors, incoordination (ataxia), decreased muscle tone (drooping eye lids), partly closed eyes 
(squinting), and protruding nictitating membrane (periocular swelling). Based on the overall 
nonclinical safety profile, the dog is considered the more sensitive species.
In 28-day repeat dose toxicity studies with TAK-906 in both rats and dogs, NOAELs were lower 
with BID versus QD administration. The 28-day rat BID NOAEL was determined to be 
150 mg/kg BID (300 mg/kg/day), as doses of 500 mg/kg BID (1000 mg/kg/day) were not 
tolerated and adverse liver findings (hepatocellular vacuolation with occasional inflammation) 
were noted at 375 mg/kg BID (750 mg/kg/day). The 28-day female dog BID NOAEL was 
determined to be 10 mg/kg BID (20 mg/kg/day) due to adverse prolactin-related mammary gland 
inflammation and fibrosis at 30 mg/kg BID (60 mg/kg/day).
TAK-906 was nongenotoxic in in vitro mutagenicity and chromosomal aberration assays or in an 
in vivo micronucleus assay in rats at a limit dose of 1000 mg/kg BID (2000 mg/kg/day total 
dose) administered by PO gavage. TAK-906 was negative for cutaneous and ocular phototoxicity 
in pigmented rats at doses up to 500 mg/kg BID (1000 mg/kg/day).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 28 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
In the pivotal rat embryo-fetal development study at QD doses of 30, 100, and 300 mg/kg/day, 
TAK-906-related clinical observations of squinting eyes, clear ocular discharge, hypoactivity, 
and dilated vagina were observed at 300 mg/kg/day. TAK-906 did not cause fetal toxicity or 
developmental effects at any dose level. The maternal and fetal NOAELs were 100 mg/kg/day 
and 300 mg/kg/day, respectively. In the pivotal rabbit embryo-fetal development study at doses 
of 50, 150, and 500 mg/kg BID (100, 300, and 1000 mg/kg/day), TAK-906 did not result in 
maternal toxicity, fetal toxicity, or developmental effects at any dose level. Based on a lack of 
adverse effects, the rabbit maternal and fetal NOAEL was 500 mg/kg BID (1000 mg/kg/day). In 
the pivotal rat fertility and early embryonic development study at doses of 50, 150, and 
325 mg/kg BID (100, 300, and 650 mg/kg/day) in males and females, TAK-906 was associated 
with effects on gross necropsy findings and/or organ weights in the prostate, uterus, and ovary, 
reproductive performance, and intrauterine parameters at ≥100 mg/kg/day. The NOAEL for 
female reproductive toxicity and early embryonic toxicity could not be determined because all 
doses were considered adverse. The effects on reproduction performance in males were 
considered secondary to the effects noted for the females. The NOAELs for systemic toxicity 
were 300 mg/kg/day and 650 mg/kg/day for males and females, respectively.
4.3
Human Experience
4.3.1
Clinical Pharmacology
To date, 6 clinical studies with TAK-906 maleate (TAK-906M) capsule have been completed, 
and 1 clinical study is ongoing in subjects with DG and IG.
Study AT-01C consisted of 2 phases: a single ascending dose phase and a multiple ascending 
dose phase. In general, PO administration of single (5 to 300 mg) or multiple (50 or 100 mg BID 
over 5 days) doses of TAK-906M was safe and well tolerated in healthy male and female 
subjects.
TAK-906 showed a rapid absorption (median plasma TAK-906 tmax across both single and 
multiple PO doses of TAK-906M across all cohorts was approximately 1.1 hours) and a rapid 
elimination over 24 hours (mean plasma TAK-906 terminal disposition phase half-life was 
approximately 4.0 hours across all cohorts in the single ascending dose phase and was 11.0 and 
6.2 hours at the 50 and 100 mg BID doses, respectively, on Day 5 in the multiple ascending dose 
phase). Food significantly reduced exposure to TAK-906M 25 mg; maximum observed 
concentration (Cmax) and area under the concentration-time curve (AUC) in fed subjects were 
approximately 40% lower compared with the same subjects when fasting. With single PO doses 
of TAK-906M between 5 and 300 mg, TAK-906 exposure increased in a manner proportional to 
dose increment. With BID dosing of 50 and 100 mg TAK-906M for 5 days, accumulation was 
minor. Additionally, TAK-906 PK profiles were generally similar between Japanese men 
(TAK-906-1004) and non-Japanese healthy men and women (Study AT-01C).
M23, the major and pharmacologically inactive metabolite identified in rat and dog plasma, 
represented approximately 11% of the TAK-906 (parent) AUC. Following PO administration of
TAK-906, approximately 1.5% of the administered dose was excreted as unchanged TAK-906 in 
the urine of humans. Based on preliminary population PK analysis (utilizing data from first in 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 29 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
human AT-01C and TAK-906-1002), estimated glomerular filtration rate (eGFR) had no 
significant effect on exposure of TAK-906 in healthy subjects or DG and IG subjects.
Coadministration of itraconazole (potent inhibitor of CYP3A4 and Pgp) with TAK-906 increased 
geometric mean Cmax by approximately 1.98-fold and area under the concentration-time curve 
from time 0 to infinity of TAK-906 by approximately 1.28-fold (TAK-906-1003). AUC∞and 
Cmax of TAK-906 decreased approximately 12% to 13% when coadministered with 40 mg 
esomeprazole compared to 25 mg TAK-906 administration alone in healthy subjects 
(TAK-906-1006).
Coadministration of a single intravenous (IV) infusion of 600 mg rifampin (a prototypic inhibitor 
of OATP1B1 and OATP1B3) with a single oral dose of 25 mg TAK-906 increased the mean area 
under the concentration-time curve from time 0 to infinity (AUC∞), and Cmax by approximately 
5.2 and 6.2-fold (TAK-906-1009). 
The prolactin increase following PO administration of single doses of TAK-906M, which was 
substantial compared with placebo, was rapid and short-lived. Serum prolactin concentration did 
not increase in a dose-proportional manner. There was little if any accumulation in serum 
prolactin concentration with BID dosing for 5 days.
The concentration QT interval with Fridericia correction method (QTcF) analysis of data from 
Study AT-01C was performed using linear mixed effects modeling methods. The analysis 
demonstrated that TAK-906M in single doses from 5 to 300 mg, which resulted in plasma 
concentrations of up to 171 ng/mL, did not have a clinically meaningful effect (<10 msec) on the 
placebo-adjusted change from baseline in QTcF (at relevant concentration range <200 ng/mL).
In summary, given the efficacy associated with D2 antagonist drugs and the nonclinical and 
phase 1 clinical observations, TAK-906 may be a promising new therapeutic for the treatment of 
gastroparesis.
Please refer to the TAK-906 Investigator’s Brochure (IB) for complete information on the 
investigational product.
4.4
Rationale for the Proposed Study
The prevalence of gastroparesis in the US is 24.2 per 100,000 [1]. The most common causes of 
gastroparesis in these countries are idiopathic (~36%) and diabetes (~29%). Domperidone and 
metoclopramide are D2 antagonists, which have been shown to reduce symptoms associated with 
gastroparesis but are associated with serious cardiovascular (domperidone) and CNS 
(metoclopramide) side effects. There is, therefore, a significant unmet need for a safe and 
efficacious chronic treatment of gastroparesis in patients. TAK-906 is a peripherally acting 
D2/D3 antagonist with minimal known CNS penetration and cardiac effects, likely attributable to 
structural difference or chemotype difference from metoclopramide and domperidone. In phase 1 
studies in healthy volunteers, TAK-906 demonstrated suitable PK and pharmacodynamic (PD) 
properties without the CNS liabilities of metoclopramide or cardiac liabilities associated with 
domperidone. Given the positive on-target effects and good tolerability, TAK-906 is being 
developed for use in patients with gastroparesis.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 30 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
TAK-906-2002 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 
phase 2b study to evaluate the efficacy and safety of BID PO administration of TAK-906M 
capsules in adult male and female subjects aged 18 to 85 years inclusive, with symptomatic IG or 
DG. 
Pharmacogenomic (PGx) analysis may be conducted to evaluate the contribution of genetic 
variance and/or gene expression on drug response, for example, its efficacy and safety. 
Participation of study subjects in PGx sample collection is optional.
As PGx is an evolving science, currently many genes and their function are not yet fully 
understood. Future data may suggest a role of some of these genes in drug response or disease, 
which may lead to additional hypothesis-generating exploratory research on stored samples.
4.5
Benefit/Risk Profile 
Gastroparesis causes nutritional compromise, impaired glucose control, and a reduced quality of 
life, independent of other factors such as age, tobacco and alcohol use, or type of diabetes [4]. 
The serious negative impact of gastroparesis on day-to-day functioning is well-documented both 
for the patient’s deteriorating quality of life, productivity and on the direct and indirect economic 
burden placed on society.
DA receptors D2 and D3 have been shown to be validated targets for gastroparesis since D2
receptors are known to be involved in the control of nausea and vomiting, and D3 receptors play 
a role in gastric motility [8-10]. Blocking D2 receptors is associated with a reduction in nausea 
and vomiting and blocking D3 receptors is associated with an increase in gastric motility [8-10].
However, DA receptor D2/D3 antagonist domperidone’s safety profile includes a risk for 
drug-induced QT prolongation, cardiac arrhythmia, and death [7], and DA receptor D2 antagonist 
metoclopramide’s neurological safety profile includes increased risk of adverse events (AEs) 
related to EPS and the potential for tardive dyskinesia. In addition, DA receptor D2/D3
antagonists elevate serum prolactin levels, which may lead to AEs related to reproductive 
endocrinology such as infertility, galactorrhea, amenorrhea, gynecomastia, and impotence in 
some subjects.
Consequently, there currently exists a significant unmet medical need because there are no 
approved therapies for the chronic treatment of DG or IG.
TAK-906 is a peripherally acting DA receptor D2/D3 antagonist with a high safety margin 
between in vitro hERG channel inhibition and projected efficacious clinical exposures; no effects 
in dog ECG parameters in nonclinical safety studies, no clinically significant cardiovascular AEs 
in the phase 1 healthy subject study or in the drug-drug interaction studies were observed. 
Therefore, treatment with TAK-906 is not expected to result in the adverse effects associated 
with cardiotoxicity especially the QT prolongation observed with domperidone. EPS side effects 
such as tardive dyskinesia, acute dystonia and Parkinson-like symptoms have been reported with 
the use of metoclopramide. However, TAK-906 is a peripherally acting DA receptor D2/D3
antagonist with limited CNS penetration expected. As such, the risk of CNS and extrapyramidal 
system effects are anticipated to be low. Hyperprolactinemia and prolactin related symptoms are 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 31 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
expected of all D2 receptor antagonists such as domperidone, metoclopramide and neuroleptics. 
However, given the relatively short (12 weeks) duration of the study, this risk is considered 
manageable and risk mitigation measures have been included in this study to ensure safety of 
subjects who may develop hyperprolactinemia or prolactin related symptoms.
Therefore, given the significant unmet medical need and the expected reduced cardiovascular 
and CNS safety risk and manageability of risk of hyperprolactinemia/prolactin related symptoms
compared with other drugs in the class, the benefit-risk profile is thought to be favorable for the 
use of clinically effective doses of TAK-906 in DG/IG subjects.
STUDY OBJECTIVES AND ENDPOINTS
5.0
5.1
Objectives
5.1.1
Primary Objective 
To assess the efficacy of treatment with 2 dose levels of TAK-906 in adult subjects with 
gastroparesis compared with placebo during 12 weeks of treatment.
5.1.2
Secondary Objective 
To evaluate the safety and tolerability of TAK-906 doses compared with placebo during 
12 weeks of treatment.
5.1.3
Additional Objectives 

To evaluate the PK of TAK-906 in subjects with gastroparesis. 

To evaluate the effect of TAK-906 on quality of life compared with placebo.
5.2
Endpoints 
5.2.1
Primary Endpoint 

Change from baseline to Week 12 of the treatment period in the American 
Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily 
Diary (ANMS GCSI-DD) composite score (nausea, early satiety, upper abdominal pain, and 
postprandial fullness). 
5.2.2
Secondary Endpoints 

Proportion of subjects with at least 50% reduction from baseline in ANMS GCSI-DD 
composite score at Week 12.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD nausea 
symptom score.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD early 
satiety symptom score. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 32 of 105
Protocol Incorporating Amendment No. 8
13 July 2020

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD 
postprandial fullness symptom score. 

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD upper 
abdominal pain symptom score. 

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD recorded 
vomiting frequency.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD overall 
severity of gastroparesis symptoms score.

Change from baseline to Week 12 of the treatment period in the bloating severity scale score.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD total score 
(nausea, early satiety, upper abdominal pain, postprandial fullness, bloating, and vomiting).

Proportion of symptomatic weeks (weeks with average composite symptom score assessed as 
>mild [ANMS GCSI-DD score ≥2]) during 12 weeks of treatment.

Change from baseline to Week 12 of the treatment period in the Patient Assessment of Upper 
Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) total score. 
5.2.3
Safety and Tolerability Endpoints

Safety and tolerability will be evaluated using the following general assessments:
–
Treatment-emergent AEs.
–
Vital signs.
–
12-lead ECGs. 
–
Clinical laboratory parameters (hematology, clinical chemistry, and urinalysis).
5.2.4
Additional Endpoints

Percentage of symptomatic days (days with symptoms assessed as >mild [ANMS GCSI-DD 
Score ≥2]) using the ANMS GCSI-DD during 12 weeks of treatment.

Proportion of subjects with ≥20% reduction in ANMS GCSI-DD composite score from 
baseline in the last 6 consecutive weeks of the study.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD core 
symptom score (nausea, early satiety, upper abdominal pain, postprandial fullness, and 
vomiting).

Change from baseline to Week 12 of the treatment period in Clinician Symptom Severity 
Rating form.

Change from baseline to Week 12 of the treatment period in Patient Assessment of Upper 
Gastrointestinal Disorders Quality-of-Life Index (PAGI-QOL) total score. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 33 of 105
Protocol Incorporating Amendment No. 8
13 July 2020

Differences at Week 12 in Overall Treatment Effect (OTE) Scales. 

Change from baseline to Week 12 in Clinical Global Impression Scale–Severity of Illness 
Scale (CGI-S).

Differences at Week 12 in Clinical Global Impression Scale–Global Improvement Scale
(CGI-I).

Change from baseline to Week 12 in Patient Global Impression of Severity (PGI-S). 

Differences at Week 12 in Patient Global Impression of Change (PGI-C).

TAK-906 predose (trough) plasma concentration at Week 12.

Change from baseline to Week 12 of the treatment period in Short Form-12 (SF12) Health 
Survey subscale scores.

Use of rescue medication during the 12-week treatment period.
STUDY DESIGN AND DESCRIPTION
6.0
6.1
Study Design
This is a global multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 
2b study to evaluate the efficacy and safety of BID PO capsule administration of a peripherally 
acting DA receptor D2/D3 antagonist, TAK-906, in adult male and female subjects aged 18 to 
85 years, inclusive, with symptomatic IG or DG. Gastroparesis is a disorder of the stomach 
characterized by delayed gastric emptying, in the absence of mechanical obstruction.
The study is designed to characterize the dose-response relationship to support dose selection for 
evaluation of subjects to be enrolled in the planned phase 3 studies. 
Subjects will attend the study site for a screening/consent visit (Visit 1, Day -35), when their 
consent will be obtained, and general eligibility to participate in the study will be reviewed. After 
signing the informed consent form, subjects will have a blood sample taken to assess their 
laboratory values. Subjects will discontinue all excluded medications and return to the site 3 to 
17 days later to perform a 4-hour 13C-Spirulina GEBT (Visit 2, Day -21). Subjects who have 
confirmation of delayed gastric emptying confirmed by an accepted diagnostic testing method 
(ie, scintigraphy, GEBT, or wireless motility capsule) that is documented in the subject’s medical 
records prior to screening, are not required to undergo the Visit 2 GEBT, and may proceed 
directly to Visit 3 for instruction on use of the electronic patient reported outcomes tool. Subjects 
who are not taking any medications at the screening visit that require washout may attend the 
clinic for Visit 2 earlier than 2 weeks and only after laboratory results have been reviewed by the 
investigator. An 8-hour fast is required before the GEBT. Subjects will then complete Visit 3 
(Day -14) within 7 days after the GEBT visit to confirm their eligibility based on the gastric 
emptying criteria. At Visit 3, subjects confirmed to have delayed gastric emptying will be 
instructed on the use of an electronic patient reported outcomes tool (ePRO) for collecting the 
daily symptoms of gastroparesis, daily dosing and meal time recordings, and capture of rescue 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 34 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
medication use. The instrument used to capture symptom data will be the ANMS GCSI-DD 
along with a bloating severity scale. Subjects will record their symptoms once daily (in the 
evening) and will return to the clinic approximately 2 weeks later to assess their gastroparesis
symptom eligibility based on the ANMS GCSI-DD (Visit 4, randomization). Subjects need to be 
compliant with completing the Daily Symptom Diary, defined as ≥80% diary completions, 
during the 2-week symptom assessment period.
Subjects will be randomized 1:1:1 into 1 of 3 treatment groups: TAK-906 maleate (TAK-906M) 
25, and 50 mg capsule BID or matching placebo BID, stratified by IG and DG. Medication 
should be taken 1 dose in the morning approximately 1 hour before the first meal of the day and 
another dose in the evening approximately 1 hour before the main last meal of the day, at a 
regular dose interval. Subjects will take their first dose of study medication at the randomization 
visit (Day 1) and will take their morning dose in clinic at Visits 5, 6, and 7. Subjects will 
complete the Daily Symptom Diary daily for 12 weeks and attend the clinic at Weeks 4 (Visit 5), 
8 (Visit 6), and 12 (Visit 7). At Day 1 and Weeks 4, 8, and 12/early termination, PK samples will 
be taken both predose and postdose. A safety follow-up phone call will be made approximately 
30 days after last dose of study medication.
Subjects who withdraw prematurely will be seen by the physician for an early termination visit 
as soon as possible and will continue completing the Daily Symptom Diary until this termination 
visit using the ePRO device. They will then be contacted for a follow-up safety call 
approximately 30 days after the last dose of study medication to check if any AEs occurred 
during this follow-up period.
A schematic of the study design is included as Figure 6.a. A schedule of assessments is listed in 
Appendix A.
Figure 6.a
Schematic of Study Design
Screening Period
Double-Blind Treatment Period
Safety Follow-
up Period
TAK-906 25 mg
TAK-906 50 mg
Placebo
Visit 1   Visit 2
Visit 3 Randomization
Visit 4
    Week 12
      Visit 7
Follow-up Call
*Provides view of updated schematic following discontinuation of randomization into the 5 mg treatment arm
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 35 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
6.2
Justification for Study Design, Dose, and Endpoints
6.2.1
Rationale for Study Design
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 
2b study to evaluate the efficacy and safety of BID PO administration of a peripherally acting 
DA receptor D2/D3 antagonist, TAK-906 in adult male and female subjects aged 18 to 85 years 
inclusive, with symptomatic IG or DG. Subjects will be eligible for enrollment if they have a 
body mass index (BMI) ≥18 to ≤40 kg/m2 and a minimum of 3-month history of symptoms 
consistent with gastroparesis as assessed by a physician (eg, postprandial fullness, nausea, 
vomiting, upper abdominal pain, and early satiety [at least intermittently]). Subjects need to be 
compliant with completing the Daily Symptom Diary, defined as ≥80% diary completions during 
the 2-week symptom assessment period (+3-day window). Subjects without previous 
confirmation of delayed gastric emptying prior to screening will undergo a GEBT after they have 
stopped taking prohibited medications. 
Subjects who have a history of gastroparesis symptoms and confirmed slow gastric emptying 
meeting entry criteria will be instructed on the use of an ePRO tool to record their baseline 
symptoms. They must have an average composite ANMS GCSI-DD symptom score ≥2 during 
the last week of the screening period. The predominant symptom experienced by subjects must 
not be abdominal pain and subjects must also experience nausea: nausea subscale (of ANMS 
GCSI-DD) symptom score ≥2 at least 4 of 7 days or an average nausea subscale symptom score 
≥2 during the last week of the screening period. Nausea symptoms should not be attributable to a 
central disorder.
Subjects with diabetes must qualify by having diabetes mellitus with glycosylated hemoglobin 
(HbA1c) ≤11% at screening, before randomization.
The comprehensive inclusion criteria outlined with the focus on delayed gastric emptying, 
history of gastroparesis symptoms, and moderate-to-severe gastroparesis symptoms at baseline, 
before receiving study drug, will ensure the enrollment of an appropriate population of subjects 
with moderate-to-severe symptomatic gastroparesis most likely to respond to and benefit from 
treatment with TAK-906.
The study will be randomized, double-blind, placebo-controlled, parallel-group enrollment with 
3 treatment arms (2 active doses and placebo) to characterize the dose-response relationship for 
TAK-906. The use of randomization and blinding will remove bias on allocating subjects to 
treatment arms and on treatment outcomes. There will be a screening period of up to 5 weeks, 
during which gastric motility and gastroparesis symptoms will be assessed. The run-in period is 
of sufficient duration to allow subjects to stop taking their prescribed GI motility drugs before 
measuring their GI motility using the GEBT, where required. It will also allow subjects to 
become proficient at using the ePRO device and providing sufficient and accurate baseline 
symptom data to assess their suitability for randomization. Subjects will then be treated for 
12 weeks during which time their symptoms will be recorded daily. A 12-week treatment period 
has been selected for this study as this is a sufficient duration to allow for the drug to take effect 
and for the collection of symptom data to evaluate efficacy and for the collection of safety data. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 36 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
The study will also be used to perform final validation of the ePRO tool (Daily Symptom Diary) 
[13] for use in the phase 3 studies. 
Overall, the design of the study, including the use of randomization, blinding, size, duration, 
subject population, and endpoints will provide good quality efficacy and safety data in a safe 
study environment to show if there is a treatment effect of study drug.
6.2.2
Rationale for Dose
This study was originally designed with 3 active treatment doses that were chosen based on the 
data in healthy subjects from the phase 1 Study AT-01C. The TAK-906 5, 25, and 50 mg BID 
doses are expected to maximize therapeutic effect and minimize potential safety and tolerability 
concerns. Under Protocol Amendment 8, randomization into the 5 mg dose arm has been 
discontinued. Randomization into the 5 mg dose arm was halted to improve operational 
feasibility in the setting of the COVID-19 pandemic and to reduce the number of subjects being 
exposed to a potentially minimally efficacious dose that likely approaches the lower end of the 
dose response curve. This change was not necessitated by safety findings. Several drug-related 
parameters were evaluated for dose-selection including safety, tolerability, PK, and PD. In 
general, oral administration of single (5 to 300 mg) or multiple (50 or 100 mg BID over 5 days) 
doses of TAK-906 was well tolerated in healthy male and female subjects. Prolactin has been 
used as a measure of target engagement. At a TAK-906 plasma concentration of approximately 
20 ng/mL (~Cmax of 50 mg dose), the TAK-906–prolactin concentration relationship reached 
near maximum, and without clinically meaningful adverse effects. TAK-906 plasma 
concentration of approximately 2 ng/mL (~Cmax of 5 mg dose) is expected to be the minimum 
effective concentration. The 25 mg dose is between the estimated minimum and maximum effect 
concentration and is expected to be a safe and efficacious dose. The 10-fold window in PK 
exposure (2 ng/mL to 20 ng/mL) will permit adequate characterization of the exposure/response 
relationships for TAK-906. 
6.2.3
Rationale for Placebo
Currently in the US, there are no approved therapies for the chronic treatment of DG. 
Metoclopramide is indicated for the short-term treatment of acute and recurrent DG and has been 
limited in dose and duration of treatment by well-documented toxicities, the most notable of 
which are a category of movement disorders known as EPS, including tardive dyskinesia, a 
severe and often irreversible EPS [5]. The risk of developing tardive dyskinesia increases with 
dose level and duration of treatment and as such, the US package insert includes a black box 
warning regarding the chronic use of metoclopramide for longer than 12 weeks.
Domperidone is a DA receptor D2/D3 antagonist marketed for use as an antiemetic and prokinetic 
agent in a number of countries worldwide, although not in the US because of its cardiovascular 
safety profile, which includes a risk for drug-induced long QT syndrome, torsades de pointes, 
and sudden cardiac death [7].
Erythromycin is a macrolide antibiotic with prokinetic properties. In addition to the risk of 
developing antimicrobial resistances, tachyphylaxis develops in patients receiving chronic 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 37 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
erythromycin therapy, due to down-regulation of motilin receptors, which can develop as early 
as a few days of initiating therapy [14].
Therefore, because of safety concerns associated with the above treatments and the fact that this 
will be a global study including the US, there is no suitable active comparator that can be used in 
a clinical study of 12 weeks duration. 
There is often a significant treatment response to placebo in patients with functional GI disease 
including gastroparesis and this has been observed in clinical trials using experimental GI 
motility compounds such as relamorelin [15]. It is therefore important to take this potential for a 
placebo effect into account by having a placebo treatment arm when designing the study to show 
that there is a positive treatment effect over placebo and not just from baseline to the end of the 
study.
The study is therefore placebo-controlled as the choice of competitors is severely limited by 
potential side effects (metoclopramide, domperidone) or tachyphylaxis (erythromycin) and to 
observe any potential for a placebo response in the study population.
During screening, there will be no restrictions on the use of rescue medication until Visit 3 
(Day -14). After Visit 3, the use of rescue medication will be limited to 2 doses per day for up to 
3 days per week only when subjects experience nausea and/or vomiting (oral intake decreased 
without significant weight loss, dehydration or malnutrition) of Common Terminology Criteria 
for Adverse Events (CTCAE) grade 2 or greater. Note that during the randomized treatment 
period, rescue medication use will be limited to BID for up to 3 days per week. If the subject 
uses rescue medication BID for 3 days per week for 2 consecutive weeks, the subject will be 
discontinued from the study due to lack of efficacy. All types and doses of 
antinausea/antivomiting rescue medication will be documented and the rescue medication will be 
provided by the subject’s treating physician. 
Antinausea/antivomiting rescue medication is recommended for use as nausea and vomiting are 
likely to be the most debilitating and commonly reported symptoms in the gastroparesis 
population [2,16,17]. The preferred rescue medication is ondansetron 4 mg given orally. 
Alternatively, antiemetics such as diphenhydramine, dimenhydrinate, promethazine, or others 
may be provided based on local guidelines and principal investigator (PI) and subject preference. 
All types and doses of antinausea/antivomiting rescue medication prescription will be 
documented and the rescue medication will be provided by the subject’s study investigator.
6.2.4
Rationale for Endpoints
Gastroparesis is a disorder of the stomach characterized by delayed gastric emptying in the 
absence of mechanical obstruction and is associated with symptoms consisting of nausea, 
vomiting, early satiety, abdominal pain, and postprandial fullness that are chronic with episodic 
symptom exacerbation [14]. The core signs and symptoms of gastroparesis, reported by 
incidence, are nausea (92% to 96%), vomiting (68% to 88%), postprandial fullness (54% to 
77%), early satiety (42% to 86%), and upper abdominal pain (36% to 85%) [2,16,17]. Given that 
gastroparesis is a symptomatic disease, it is important to assess improvement in symptoms as a 
clinical outcome. Symptom data will be used for the primary endpoint in the study which is 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 38 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD Composite 
Score (nausea, early satiety, upper abdominal pain, and postprandial fullness). Symptom data 
will be captured each evening using the Daily Symptom Diary on an ePRO device.
As part of the Daily Symptom Diary, the ANMS GCSI-DD has been selected for use in this 
study as it is currently under development to measure symptoms to evaluate potential new 
treatments in DG and IG clinical trials. The ANMS GCSI-DD was based on the original 
Gastroparesis Cardinal Symptom Index (GCSI) [18,19], which is the most frequently used 
symptom severity measure in gastroparesis clinical trials and other clinical studies [16,20-27], 
including the National Institutes of Health Gastroparesis Clinical Research Consortium 
Gastroparesis Registry study [28,29]. 
Efficacy will be based on a significant difference between group means. The primary endpoint 
will be between group differences on the ANMS CGSI-DD composite score of nausea, upper 
abdominal pain, early satiety, and postprandial fullness. Furthermore, item level responses will 
be evaluated as secondary endpoints to determine which symptom item(s) are driving changes in 
the overall composite score, and to evaluate if any symptoms within the composite score are 
worsening. Of note, bloating will also be recorded using the electronic diary along with the other 
symptoms routinely captured in the ANMS GCSI-DD (nausea, early satiety, upper abdominal 
pain, postprandial fullness, vomiting episodes, and overall symptom severity) for ease of patient 
use. Bloating is being captured as an additional endpoint using the electronic diary and is 
currently not part of the ANMS GCSI-DD. 
6.3
Premature Termination or Suspension of Study or Study Site
6.3.1
Criteria for Premature Termination or Suspension of the Study
The study will be completed as planned unless 1 or more of the following criteria are satisfied 
that require temporary suspension or early termination of the study:

New information or other evaluation regarding the safety or efficacy of the study drug that 
indicates a change in the known benefit-risk profile for TAK-906 such that the benefit-risk is 
no longer favorable for subjects participating in the study. This may include (but not limited 
to):
–
Extrapyramidal symptoms and other clinically relevant CNS or neuropsychiatric disease 
including tardive dyskinesia, neuroleptic malignant syndrome, acute dystonia, 
parkinsonian-like symptoms, convulsive seizure, severe mental depression, and 
hallucinations.
–
Evidence of other serious clinical problems that would put subjects exposed to TAK-906 
at risk. 
–
Significant violation of Good Clinical Practice (GCP) that compromises the ability to 
achieve the primary study objectives or compromises subject safety.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 39 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
The Independent Data Monitoring Committee (IDMC) will assess the incidence and nature of 
safety events and will make appropriate recommendations, which could include continue, 
modify, temporarily suspend, or terminate the study.
6.3.2
Criteria for Premature Termination or Suspension of Study Sites
A study site may be terminated prematurely or suspended if the site (including the investigator) 
is found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study, or as otherwise permitted by the contractual agreement.
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)
If the sponsor, an institutional review board (IRB)/independent ethics committee (IEC), or 
regulatory authority elects to terminate or suspend the study or the participation of a study site, a 
study-specific procedure for early termination or suspension will be provided by the sponsor; the 
procedure will be followed by applicable study sites during termination or study suspension.
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.0
All entry criteria, including test results, need to be confirmed before randomization.
7.1
Inclusion Criteria 
Subject eligibility is determined according to the following criteria before entry into the study: 
In the opinion of the investigator, the subject is capable of understanding and complying with 
1.
protocol requirements.
The subject or, when applicable, the subject’s legally acceptable representative signs and 
2.
dates a written, informed consent form and any required privacy authorization before the 
initiation of any study procedures. 
The subject should have symptoms of gastroparesis (eg, postprandial fullness, nausea, 
3.
vomiting, upper abdominal pain, and early satiety) for at least 3 months before screening as 
assessed by a physician. 
The subject must have confirmed delayed gastric emptying by meeting 1 of the following 
4.
criteria:
a) Confirmed by an accepted diagnostic testing method (GEBT, scintigraphy, or wireless 
motility capsule) that is documented in the subject's medical records prior to screening; 
OR 
b) Subjects without previous confirmation of delayed gastric emptying prior to screening 
will undergo a GEBT after they have stopped taking prohibited medications.
The subject must have an average composite ANMS GCSI-DD symptom score ≥2 during the 
5.
7 days before randomization. The predominant symptom experienced by subjects must not be 
abdominal pain.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 40 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
The subject must experience nausea: nausea subscale (of ANMS GCSI-DD) symptom score 
6.
≥2 at least 4 of 7 days or an average nausea subscale symptom score ≥2 during the 7 days
before randomization. Nausea symptoms must not be attributable to a central disorder (eg, 
motion sickness, glaucoma, menstrual cycles, migraine headache).
The subject is an adult man or woman aged 18 to 85 years, inclusive, at the first screening 
7.
visit. 
The subject has a BMI of ≥18 to ≤40 kg/m2 inclusive.
8.
Absence of gastric outlet obstruction confirmed by upper GI, computed tomography or 
9.
endoscopy.
A male subject who is nonsterilized* and sexually active with a female partner of 
10.
childbearing potential* agrees to use barrier method of contraception (eg, condom with or 
without spermicide)* from signing of informed consent throughout the duration of the study 
and for 95 days after last dose. The female partner of childbearing potential of the male 
subject should also use a highly effective method of contraception* during this period. 
A female subject of childbearing potential* who is sexually active with a nonsterilized* male 
11.
partner agrees to use a highly effective method of contraception* from signing of informed 
consent throughout the duration of the study and for 35 days after the last dose. 
*Definitions and highly effective methods of contraception are defined in 
Section 9.1.11 and reporting responsibilities are defined in Section 9.1.12.
Special Inclusion for Subjects With Diabetes Mellitus
A subject with diabetes mellitus must have HbA1c ≤11% before the randomization visit. 
12.
During Screening Period
The subject has shown compliance with the completion of the Daily Symptom Diary, defined
13.
as ≥80% diary completions for a minimum of 14 days during the symptom assessment 
period.
7.2
Exclusion Criteria 
Any subject who meets any of the following criteria will not qualify for entry into the study: 
The subject has received any investigational compound within 30 days or 5 half-lives, 
1.
whichever is longer, before screening.
The subject’s predominant symptom is epigastric pain, diffuse abdominal pain, or pain 
2.
associated with bowel movement.
The subject has received TAK-906 in a previous clinical study or as a therapeutic agent.
3.
The subject is an immediate family member, study site employee, or is in a dependent 
4.
relationship with a study site employee who is involved in conduct of this study (eg, spouse, 
parent, child, sibling) or may consent under duress.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 41 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
The subject has, in the judgment of the investigator, clinically significant abnormal 
5.
hematological parameters of hemoglobin, hematocrit, or erythrocytes at screening.
The subject takes or is required to take excluded medications (see Section 7.3).
6.
If female, the subject is pregnant, lactating, breastfeeding, or has breastfed within 6 months 
7.
or is intending to become pregnant before participating in this study, during the study, and 
within 35 days after last dose of the study drug; or intending to donate ova during such time 
period.
If male, the subject intends to donate sperm during the course of this study or for 95 days 
8.
thereafter. 
The subject has known secondary causes of gastroparesis including but not limited to 
9.
Parkinson disease, cancer, viral illness, or connective tissue diseases.
The subject has a history of gastric surgery, including but not limited to gastrectomy, gastric 
10.
bypass, gastric banding, bariatric surgery, pyloroplasty, vagotomy, or fundoplication, which 
has manipulated the natural anatomy of the stomach.
The subject has a presence of thyroid dysfunction not controlled by treatment.
11.
The subject has a known or history of inflammatory bowel disease.
12.
The subject has current chronic diarrhea (defined as >3 loose bowel movements daily for at 
13.
least 2 weeks).
The subject has a history of intrapyloric botulinum toxin injection within 3 months of 
14.
screening or currently has functioning implantable gastric electric stimulator.
The subject has had a nasogastric, percutaneous endoscopic gastrostomy, or percutaneous 
15.
endoscopic jejunostomy feeding tube or inpatient hospitalization for gastroparesis within 
2 weeks before the screening visit.
The subject has had required parenteral nutrition for treatment of gastroparesis within 
16.
2 months before the screening visit.
The subject has a previous diagnosis of gastric bezoar (the presence of retained liquid, bile, 
17.
or small amounts of poorly organized food residue is permitted).
The subject has a clinically significant known disorder of small intestinal absorption (eg, 
18.
refractory celiac disease), exocrine pancreatic function (eg, chronic pancreatitis), and 
pulmonary function (eg, severe chronic obstructive pulmonary disease or O2 requirements).
The subject has a history of alcohol or drug abuse or dependence within the last year before 
19.
screening or a positive drug test result at screening.
The subject is a chronic smoker who is unable or unwilling to abstain from smoking during 
20.
the performed GEBT at Visit 2.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 42 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
The subject has experienced poor control of diabetes within 30 days prior to randomization, 
21.
including diabetic ketoacidosis, hypoglycemia requiring medical intervention, admission for 
control of diabetes, or diabetic complications.
The subject has a history of anorexia nervosa, binge eating or bulimia within 5 years of 
22.
screening. 
The subject has a history of acute myocardial infarction or unstable angina within 12 months 
23.
before study entry.
The subject has a severe cardiovascular autonomic neuropathy. 
24.
The subject has any clinically important abnormalities in rate, rhythm, conduction, or 
25.
morphology of resting ECG. 
The subject has prolonged QTcF interval (≥450 msec) or risk factors of QT interval 
26.
prolongation, for example, clinically relevant electrolyte imbalance and family history of QT 
interval prolongation.
The subject uses a cardiac medical device such as pacemakers and defibrillators (bladder 
27.
stimulators, spinal stimulators, medication infusion devices, insulin pumps, continuous 
glucose monitors are permitted).
The subject has a lifestyle in which drowsiness may risk personal or public safety. 
28.
The subject has an elevated serum prolactin (>upper limit of normal [ULN]) at screening. A 
29.
high prolactin level at the screening visit that is considered to be due to stress of 
venipuncture, chest wall stimulation, or other physiological causes may be retested after a 
few days and if normal, the subject may be enrolled in the study.
The subject has concurrent hypogonadism, current clinically significant menstrual 
30.
abnormalities such as amenorrhea or oligomenorrhea related to hyperprolactinemia, or other 
clinical features of hyperprolactinemia such as galactorrhea or gynecomastia.
The subject has any signs/symptoms or history of extrapyramidal system disease and other 
31.
clinically relevant CNS or neuropsychiatric disease including but not limited to tardive 
dyskinesia, neuroleptic malignant syndrome, acute dystonia, parkinsonian like symptoms, 
severe mental depression, and history of suicide attempt.
The subject has acute or chronic liver disease meeting any of the criteria described below:
32.

The subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or 
total bilirubin >2.0 times the ULN.

The subject has pre-existing liver cirrhosis that meets Child-Pugh Class B (moderate; 
total score 7 to 9 points) or C (severe; total score 10 to 15 points) (see Appendix B).

The subject has acute or chronic hepatitis B or C virus infection, manifesting as one of 
the following at screening:

Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). 
NOTE: if a subject tests negative for HBsAg, but positive for HBcAb, the subject 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 43 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
would be eligible if the Investigator has documentation of other test results showing 
that the subject does not have active hepatitis B infection.

Subjects with positive hepatitis C antibody (HCV IgG) and quantitative HCV 
polymerase chain reaction (PCR). HCV PCR is performed only if HCV IgG is 
positive.
The subject has a history of any psychiatric disorder or cognitive impairment that would 
33.
interfere with participation in the study.
The subject has any identified congenital or acquired immunodeficiency (eg, common 
34.
variable immunodeficiency, HIV infection, organ transplantation).
The subject has renal impairment, defined as a lower limit of (eGFR) <30 mL/min at 
35.
screening visit. 
The subject has active neoplastic disease or history of neoplastic disease within 5 years of 
36.
screening visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ 
of the uterine cervix that has been definitively treated with standard of care approaches).
The subject has poor venous access or inability to tolerate venipuncture.
37.
The subject has hypersensitivity to Spirulina, egg, milk, or wheat allergens.
38.
The subject has a history of sensitivity to any of the study medications, or components 
39.
thereof or a history of drug or other allergy that, in the opinion of the investigator 
contraindicates their participation.
The subject has any other significant, uncontrolled organic or systemic medical condition or 
40.
social circumstance that, in the investigator’s opinion, would mean it was not appropriate for 
the subject to participate in this clinical study.
The subject has known COVID-19 infection, or suspected COVID-19 infection (as assessed 
41.
by the investigator).
7.3
Excluded Medications
The following medications are not permitted during the course of the study, starting from the 
screening visit, unless specified otherwise:

Use of OATP1B1 or OATP1B3 inhibitors as concomitant medication (these include but are 
not limited to clarithromycin, erythromycin, gemfibrozil, cyclosporine, lapatinib, 
eltrombopag, atazanavir, ritonavir, lopinavir and ritonavir, simeprevir, and rifampin).

Use of metoclopramide, erythromycin, domperidone, prucalopride, or other prokinetic GI 
motility agents for at least 2 weeks before GEBT assessment (Visit 2, Day -21) is not 
permitted, and subjects must be willing not to take these medications during the course of the 
clinical study. 

Opiates.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 44 of 105
Protocol Incorporating Amendment No. 8
13 July 2020

Anticholinergic agents (eg, dicyclomine, hyoscyamine, scopolamine, otilonium 
bromide/Spasmomen).

Dopamine agonists and antagonists. Promethazine can be used as part of protocol specific 
rescue medication.

Glucagon-like peptide-1 agonists (eg, exenatide, liraglutide) and amylin analogues (eg, 
pramlintide). Note that other medications for the treatment of diabetes are permitted.

Cannabinoid use. 

Medications that prolong QT/corrected QT interval or are at risk of causing Torsades de 
Pointes. Including but not limited to amiodarone, arsenic trioxide, astemizole, bepridil, 
chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, 
domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, 
mesoridazine, methadone, moxifloxacin, pentamidine, pimozide, probucol, procainamide, 
quinidine, sotalol, sparfloxacin, terfenadine, thioridazine, vandetanib. Note that the use of 
ondansetron at a maximal dose of 8 mg twice a day is allowed as part of protocol specific 
rescue medication. 

Medications that can cause EPS or persistently elevate serum prolactin.

Use of antinausea/antivomiting rescue medication is permitted for moderate nausea and/or 
vomiting CTCAE Grade 2 (for nausea, oral intake decreased without significant weight loss, 
dehydration or malnutrition; for vomiting; outpatient IV hydration required) or higher. 
Rescue medication use is limited to BID for up to 3 days per week. If the subject takes this 
dose regimen for 2 consecutive weeks, they will be discontinued from the study due to lack 
of efficacy. The prescription for rescue medication will be provided by study investigator. 
The preferred rescue medication is ondansetron 4 mg given orally. Alternatively, other 
antiemetics such as diphenhydramine, dimenhydrinate or promethazine may be provided 
based on local guidelines, PI and subject preference. Although there is a risk of dose-related 
prolonged QT with ondansetron and development of EPS symptoms with promethazine, this 
risk is considered low based on the minimal doses being given for a short period of time. 
Permitted concomitant medications
Permitted concomitant medications must be stable for at least 2 weeks leading up to the initial 
screening/consent visit (Visit 1, Day -35) and must be maintained at the same doses during the 
study (daily adjustments of insulin doses are permitted). Changes to permitted medications 
(eg, laxatives taken as needed) need to be documented.
Subjects must be instructed not to take any medications including over-the-counter or herbal 
products, without first consulting with the investigator. 
The following medications are permitted only in the following circumstances:

A stable dose of a single antidepressant for the treatment of depression. Note that an 
additional antidepressant can be allowed if used for another indication such as chronic pain 
or insomnia.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 45 of 105
Protocol Incorporating Amendment No. 8
13 July 2020

Antibiotic use should be recorded for acute or returning conditions but excluded for chronic 
use. Acute or chronic treatment with macrolides antibiotics such as erythromycin, 
azithromycin, and clarithromycin is not allowed as these might have prokinetic properties.
7.4
Diet, Fluid, Activity Control 
Subjects will be instructed to take medication 1 dose in the morning approximately 1 hour before 
the first meal of the day and another dose in the evening approximately 1 hour before the main 
last meal of the day, at a regular dose interval. An 8-hour fast is required before the GEBT 
procedure is to be performed. 
There should be no lifestyle changes during the study including no changes to the amount of 
alcohol, caffeine, and tobacco consumed. The subject must be willing to abstain from smoking 
during the visit when the GEBT is being performed. Consumption of alcohol, caffeine and 
tobacco should not be excessive, per investigator discretion, for the duration of the study.
Exercise should be moderate and be consistent for the duration of the study.
7.5
Criteria for Discontinuation or Withdrawal of a Subject
The primary reason for discontinuation or withdrawal of the subject from the study or study drug 
should be recorded in the electronic case report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.1.16.
Treatment discontinuation due to an AE. The subject has experienced an AE that requires 
1.
early termination because continued participation imposes an unacceptable risk to the 
subject’s health, or the subject is unwilling to continue because of the AE. Such events may 
include, but are not limited to:

Extrapyramidal symptoms and other clinically relevant CNS or neuropsychiatric disease 
including tardive dyskinesia, neuroleptic malignant syndrome, acute dystonia, 
parkinsonian-like symptoms, convulsive seizure, severe mental depression, and 
hallucinations (please refer to Section 10.1.5. Guidance to Investigators for Management 
of Extrapyramidal System Disorders).

Clinically relevant symptoms related to hyperprolactinemia (please refer to 
Section 10.1.5. Guidance to Investigators for Management of Elevated Serum Prolactin).

Subjects who develop an illness that in the opinion of investigator may expose them to 
undue risk or could interfere with his/her continued participation in the study.

Any subject identified with COVID-19 infection during the study.
Liver Function Test (LFT) Abnormalities
2.
Study drug should be discontinued immediately with appropriate clinical follow-up 
(including repeat laboratory tests, until a subject’s laboratory profile has returned to 
normal/baseline status, see Section 9.1.10), if the following circumstances occur at any time 
during study drug treatment:

ALT or AST >8×ULN, or
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 46 of 105
Protocol Incorporating Amendment No. 8
13 July 2020

ALT or AST >5×ULN and persists for more than 2 weeks, or

ALT or AST >3×ULN in conjunction with elevated total bilirubin >2×ULN or 
international normalized ratio (INR) >1.5, or

ALT or AST >3×ULN with appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%).
Important protocol deviation. The discovery postrandomization that the subject failed to meet 
3.
protocol entry criteria or did not adhere to protocol requirements, and continued participation 
poses an unacceptable risk to the subject’s health, following consultation with the sponsor or 
designee. 
Lost to follow-up. The subject did not return to the clinic and attempts to contact the subject 
4.
were unsuccessful. Attempts to contact the subject must be documented in the subject’s 
source documents. 
Voluntary withdrawal. The subject (or subject’s legally acceptable representative) wishes to 
5.
withdraw from the study. The reason for withdrawal, if provided, must be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal 
and, where possible, the primary underlying reason should be recorded (ie, withdrawal due to 
an AE should not be recorded in the “voluntary withdrawal” category. Similarly, lack of 
efficacy should not be recorded in the “voluntary withdrawal” category).
Study termination. The sponsor, IRB/IEC or regulatory agency terminates the study.
6.
Pregnancy. The subject is confirmed to be pregnant.
7.
Note: If the subject is confirmed to be pregnant, the subject must be withdrawn immediately. 
The procedure is described in Section 9.1.12.
Lack of efficacy. The investigator has determined that the subject has a significant worsening 
8.
of symptoms and is not benefiting from study treatment; and, continued participation would 
pose an unacceptable risk to the subject, or subjects who use antinausea/antivomit ing rescue 
medication (only after the subject has reported nausea or vomiting of moderate (CTCAE 
Grade 2) or greater severity for 3 days/week for 2 consecutive weeks. 
Other. 
9.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.6
Procedures for Discontinuation or Withdrawal of a Subject
The investigator may discontinue a subject from study drug or study participation at any time 
during the study when the subject meets the discontinuation or withdrawal criteria described in 
Section 7.5. In addition, a subject may discontinue his or her participation without giving a 
reason at any time during the study. Should a subject’s participation be discontinued, the primary 
criterion for discontinuation or termination must be recorded by the investigator. In addition, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 47 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
efforts should be made to perform all procedures scheduled for the early termination visit. 
Discontinued or withdrawn subjects will not be replaced.
CLINICAL STUDY MATERIAL MANAGEMENT
8.0
8.1
Study Drug and Materials
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling
In this protocol, the term study medication refers to all or any of the drugs defined below.

TAK-906M capsules in strengths of 5, 25, and 50 mg.

Matching placebo capsules.
The study drug is TAK-906 maleate salt in an immediate-release capsule formulation, which 
contains 5, 25, or 50 mg of TAK-906 calculated on the basis of the free base. The 3 strengths of 
capsules have an identical appearance in capsule size and color. Matching placebo capsules are 
also provided.
The study medication will be packaged in high-density polyethylene bottles. Each bottle contains 
65 TAK-906M capsules for 4-week dosing plus 9 extra capsules. Each subject will receive 
1 bottle at each visit. The study subjects will be instructed to take 1 capsule at each dosing time.
Randomization into the 5 mg dose arm was halted in Protocol Amendment 8 to improve 
operational feasibility in the setting of the COVID-19 pandemic and to reduce the number of 
subjects being exposed to a potentially minimally efficacious dose that likely approaches the 
lower end of the dose response curve. This change was not necessitated by safety findings.
Rescue Medication
During screening, there will be no restrictions on the use of rescue medication until Visit 3 
(Day -14). After Visit 3, the use of rescue medication will be limited to 2 doses per day for up to 
3 days per week only when subjects experience nausea and/or vomiting (oral intake decreased 
without significant weight loss, dehydration or malnutrition) of CTCAE Grade 2 or greater. Note 
that during the randomized treatment period, rescue medication use will be limited to BID for up 
to 3 days per week. If the subject uses rescue medication BID for 3 days per week for 2 
consecutive weeks, the subject will be discontinued from the study due to lack of efficacy. All 
types and doses of antinausea/antivomiting rescue medication will be documented and the rescue 
medication will be provided by the subject’s treating physician. The preferred rescue medication 
will be ondansetron 4 mg given orally. Other routes of administration of ondansetron are allowed 
if clinically indicated (eg, intravenous in case of vomiting). Alternatively, other antiemetics may 
be provided based on local guidelines and PI and subject preference if not prohibited per 
protocol. Examples of alternative allowed rescue medications include diphenhydramine, 
dimenhydrinate or promethazine.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 48 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
8.1.2
Storage
Study drug must be stored in a secure, limited-access location under the storage conditions 
specified on the label until dispensed or returned to the sponsor or designee for destruction. The 
capsules should remain in the original container until dispensed.
8.1.3
Dose and Regimen
Subjects will take their first dose of study medication at the randomization visit and their 
morning dose in clinic at Visits 5 (Week 4), 6 (Week 8), and 7 (Week 12). Subjects will be 
instructed to take medication 1 dose in the morning approximately 1 hour before the first meal of 
the day and another dose in the evening approximately 1 hour before the main last meal of the 
day, at a regular dose interval. If a subject missed any individual dose, they may take the dose 
within a 4-hour window from the normal expected dosage time. If not taken within a 4-hour 
window, they should not take that dose and proceed to take the normal dose at the next scheduled 
time point.
8.1.4
Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by 
a study subject, at a dose above that which is assigned to that individual subject according to the 
study protocol.
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, to capture this important safety information consistently in the database. Cases of 
overdose without manifested signs or symptoms are not considered AEs. AEs associated with an 
overdose will be documented on AE CRF(s) according to Section 10.0.
Serious adverse events (SAEs) associated with overdose should be reported according to the 
procedure outlined in Section 10.2.2.
To date, the effects of an overdose of TAK-906 have not been characterized. TAK-906 has been 
investigated in clinical studies up to a maximum single oral dose of TAK-906M 300 mg and 
100 mg BID for 9 days. Treatment-emergent adverse events (TEAEs) observed at various dose 
levels include mild facial swelling, constipation, headache, dizziness and fatigue. All TEAEs 
were mild to moderate in intensity. 
In the event of an overdose, discontinue the study drug and treat the subject symptomatically and 
provide supportive care as needed. In the event of drug overdose, the next scheduled dose should 
be withheld, and the subjects should be treated considering their clinical presentation per local 
guidelines. Regular dosing may resume after discussion with the medical monitor after the 
subject recovers from effects of overdose. 
8.2
Study Drug Assignment and Dispensing Procedures
The investigator or the investigator’s designee will access the interactive response technology
(IRT) at screening to obtain the subject study number. The investigator or the investigator’s 
designee will use the IRT to randomize the subject into the study at Visit 4 (Day 1) should they 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 49 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
qualify. Randomization into the 5 mg dose arm is discontinued in Protocol Amendment 8. 
Subjects will be assigned in a 1:1:1 ratio to 1 of the 3 treatment arms of TAK-906M 25 or 50 mg 
or placebo BID.
During this contact, the investigator or designee will provide the necessary subject-identifying 
information, including the subject number assigned at screening. The medication identification 
(ID) number of the study drug to be dispensed will then be provided by the IRT. If sponsor-
supplied drug is lost or damaged, the site can request a replacement from IRT. (Refer to IRT 
manual provided separately.) At subsequent drug-dispensing visits, the investigator or designee 
will again access IRT to request additional study drug (and other sponsor-supplied drug[s]) for a 
subject. The medication ID number of the study drug to be dispensed will be provided by the 
IRT and entered onto the appropriate drug accountability log.
8.3
Randomization Code Creation and Storage 
The Sponsor’s randomization personnel or designee will generate the randomization schedule for 
the study; an IRT will be used in a centralized fashion for subject randomization and study 
medication assignments. All randomization information will be stored in a secured area, 
accessible only by authorized personnel.
8.4
Study Drug Blind Maintenance 
The study medication blind will be maintained using the IRT. The principal investigator at each 
study site will receive instructions on obtaining the medication assignment through the IRT.
During regularly scheduled monitoring visits, a study monitor from the sponsor or a designee 
will perform accountability of study drug inventory. All assigned/unassigned treatment 
medication will be reconciled and returned to the sponsor or a designee or authorized for on-site 
destruction or return at study closure.
After removal of the 5 mg treatment arm in Protocol Amendment 8, the study team will remain 
blinded to subject’s treatment allocation.
8.5
Unblinding Procedure 
The study drug blind shall not be broken by the investigator unless information concerning the 
study drug is necessary for the medical treatment of the subject. All study assessments and 
causality assessments should be performed, if possible, before unblinding. In the event of a 
medical emergency, if possible, the medical monitor should be contacted before the study drug 
blind is broken to discuss the need for unblinding.
For unblinding a subject, the study drug blind can be obtained by the investigator through the 
IRT.
The sponsor must be notified as soon as possible if the study drug blind is broken. The date, 
time, and reason the blind is broken must be recorded in the source documents and eCRF/IRT.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 50 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
If any site personnel are unblinded, study drug must be stopped immediately, and the subject 
must be withdrawn from the study. 
8.6
Accountability and Destruction of Sponsor-Supplied Drugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee or authorized for destruction.
The investigator or designee must ensure that the sponsor-supplied drug is used in accordance 
with the protocol and is dispensed only to subjects enrolled in the study. To document 
appropriate use of sponsor-supplied drug, the investigator or designee must maintain records of 
all sponsor-supplied drug delivered to the site, site inventory, dispensation and use by each 
subject, and return to the sponsor or designee.
On receipt of sponsor-supplied drug, the investigator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantity is correct, and the 
medication is in good condition. If quantity and conditions are acceptable, investigator or 
designee should acknowledge the receipt of the shipment by recording in IRT. If there are any 
discrepancies between the packing list versus the actual product received, Takeda or designee 
must be contacted to resolve the issue. All packing lists should be filed in the investigator’s 
essential document or pharmacy file.
The investigator or designee must maintain 100% accountability for all sponsor-supplied drugs 
received and dispensed during his or her entire participation in the study. Proper drug 
accountability includes, but is not limited to:

Continuously monitoring expiration dates if (expiry date/retest date) is provided to the 
investigator or designee. 

Frequently verifying that actual inventory matches documented inventory.

Verifying that all containers used are documented accurately on the log.

Verifying that required fields are completed accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor or designee must be notified 
immediately.
The IRT will include all required information as a separate entry for each subject to whom 
sponsor-supplied drug is dispensed.
The investigator or designee must record the current inventory of all sponsor-supplied drugs on a 
sponsor-approved drug accountability log. The log should include all required information as a 
separate entry for each subject to whom sponsor-supplied drug is dispensed. All log entries must 
be timely and legible, and all must be accompanied by the initials, signature, or seal of the person 
completing the noted action. 
All study drug not returned to the site by a subject must be investigated by the site and 
appropriately documented on the drug accountability log.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 51 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Before site closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor-supplied drug accountability and reconciliation. In all cases, this will be 
performed before sponsor-supplied drugs are returned to the sponsor or its designee or before 
destruction. The investigator or designee will retain a copy of the documentation regarding 
sponsor-supplied drug accountability, return, and/or destruction, and a copy will be sent to the 
sponsor or designee.
The investigator will be notified of any expiry date or retest date extension of sponsor-supplied 
drug during the study conduct. On expiry date notification from the sponsor or designee, the site 
must complete all instructions outlined in the notification, including segregation of expired 
sponsor-supplied drug for return to the sponsor or its designee for destruction.
In the event of expiry date extension of sponsor-supplied drug already at the study site, 
sponsor-supplied drugs may be relabeled with the new expiry date at that site. In such cases, 
Takeda or its designee will prepare additional labels, certificates of analyses, and all necessary 
documentation for completion of the procedure at the sites.
STUDY PLAN
9.0
9.1
Study Procedures
The following sections describe the study procedures and data to be collected. For each 
procedure, subjects are to be assessed by the same investigator or site personnel whenever 
possible. The Schedule of Study Procedures is in Appendix A.
9.1.1
Informed Consent Procedure
The requirements of the informed consent are described in Section 15.2.
Informed consent must be obtained before the subject enters into the study and before any 
protocol-directed procedures are performed.
A unique subject ID number (subject number) will be assigned to each subject at the time that 
informed consent is obtained; this subject number will be used throughout the study.
9.1.1.1
PGx Informed Consent Procedure 
A separate informed consent form pertaining to collection, storage, and analysis of the sample 
must be obtained before collecting a blood sample for PGx research for this study. The provision 
of consent to collect and analyze the PGx sample is independent of consent to the other aspects 
of the study.
9.1.2
Demographics, Medical History, and Medication History Procedure
Demographic information to be obtained will include date of birth or age as dictated by local 
law, sex, Hispanic ethnicity, race described by the subject, height, weight, and smoking status of 
the subject at screening. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 52 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Medical history to be obtained will include determining whether the subject has any significant 
conditions or diseases relevant to the disease under study that resolved at or before signing of 
informed consent. Ongoing conditions are considered concurrent medical conditions (see 
Section 9.1.9).
Medication history information to be obtained includes any medication relevant to eligibility 
criteria (and efficacy/safety evaluation) stopped at or within 90 days before signing of informed 
consent.
9.1.3
Physical Examination Procedure
A baseline physical examination (defined as the assessment before first dose of study drug) will 
consist of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; 
(4) respiratory system; (5) GI system; (6) dermatologic system; (7) extremities; 
(8) musculoskeletal system; (9) nervous system; (10) lymph nodes; (11) other. All subsequent 
physical examinations should assess clinically significant changes from the assessment before 
first dose examination. Any clinically significant changes from the baseline examination will be 
recorded as an AE.
9.1.4
Assessment of the Extrapyramidal System 
A detailed assessment of the extrapyramidal system will be performed at study entry, Weeks 4, 
8, and 12 or study exit by a healthcare professional qualified to perform this assessment using the 
guidance provided by Takeda. Subjects with any neurologic abnormalities will be referred to a 
neurologist for appropriate medical evaluation and any AEs should be reported as per AE 
reporting procedures provided in Section 10.0 of this protocol. A copy of the Guidance for 
Assessment of the Extrapyramidal System is provided in Appendix C.
9.1.5
Weight, Height, and BMI
A subject should have weight and height measured while wearing indoor clothing and with shoes 
off. Height is recorded in centimeters without decimal places. Weight is collected in kilograms 
(kg) with 1 decimal place. BMI should be derived as:
Metric:
BMI = weight (kg)/height (m)²
The eCRF will perform the BMI calculation based on the height and weight values entered.
9.1.6
Vital Signs Procedure
Vital signs will include body temperature (oral, tympanic, or axillary measurement), respiratory 
rate (supine/semisupine), blood pressure (systolic and diastolic) and pulse (beats per minute). 
Vital signs can be performed in supine or semisupine position but should be performed after 
resting for 5 minutes and consistently for each subject.
Vital signs assessment should occur before the study drug is taken. When vital signs are 
scheduled at the same time as blood sampling, vital signs will take priority and vital signs will be 
obtained within 0.5 hour before the scheduled blood draw.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 53 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
9.1.7
Primary Efficacy Measurement 
The ANMS GCSI-DD will be used to capture gastroparesis symptoms, which will be used as the 
primary efficacy measurement (Appendix I). Subjects need to be compliant with providing 
symptom data defined as ≥80% daily diary completion, during the 2-week symptom assessment 
period (Day -14 to randomization; +3-day window). The electronic diary should be completed at 
approximately the same time each day (evening) during the 12 weeks of treatment. 
9.1.8
Documentation of Concomitant Medications
Concomitant medication is any drug given in addition to the study drug. These may be 
prescribed by a physician or obtained by the subject over the counter and is not provided by the 
sponsor. At each study visit, subjects will be asked whether they have taken any medication 
other than the study drug (used from signing of informed consent through the end of the study), 
and all medication including vitamin supplements, over-the-counter medications, and oral herbal 
preparations, must be recorded in the eCRF.
9.1.9
Documentation of Concurrent Medical Conditions
Concurrent medical conditions are those significant ongoing conditions or diseases that are 
present at signing of informed consent. This includes clinically significant laboratory, ECG, or 
physical examination abnormalities noted at the screening/baseline examination, according to the 
judgment of the investigator. The condition (ie, diagnosis) should be documented.
9.1.10
Procedures for Clinical Laboratory Samples
All samples will be collected in accordance with acceptable laboratory procedures and after 
screening all samples will be collected fasted. Early termination visits will be fasting if visit 
circumstances allow. Details of these procedures and required safety monitoring will be given in 
the laboratory manual. Timing of these procedures are detailed in Appendix A.
Table 9.a lists the tests that will be obtained for each laboratory specimen.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 54 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Table 9.a
Clinical Laboratory Tests
Hematology
Serum Chemistry
Urinalysis
Red blood cells
White blood cells 
including differential
Hemoglobin
Hematocrit
Platelets
HbA1c a
Mean corpuscular hemoglobin
PT/INR
ALT
Albumin
Alkaline phosphatase
AST
Total and direct bilirubin
Total protein
Creatinine
Blood urea nitrogen
Creatine kinase
GGT
Potassium
Prolactin b
Sodium
Calcium
Chloride
Magnesium
Phosphate
Total cholesterol
Low-density lipoprotein cholesterol
High-density lipoprotein cholesterol
Triglycerides
Uric acid
Glucose
Albumin
Protein 
Glucose 
pH
Leukocytes 
Blood 
Bilirubin
Urobilinogen
Ketone
Creatinine 
Serum
Urine
HIV test (confirmatory testing is allowed; most sensitive test 
should take precedence).
Hepatitis panel, including HBsAg, anti-HBcAb, and anti-HCV c.
Female subjects only: hCG (for pregnancy)
Drug Screen
Female subjects only:
Beta hCG (for pregnancy).
Female subjects of childbearing potential:
FSH if menopause is suspected
Thyroid Stimulating Hormone (TSH)
ALT; alanine aminotransferase; anti-HBcAb: antibody to hepatitis B core antibody; AST: aspartate 
aminotransferase; DG: diabetic gastroparesis; FSH: follicle-stimulating hormone; GGT: γ-glutamyl transferase; 
HbA1c: glycosylated hemoglobin; HBsAg: hepatitis B virus surface antigen; hCG: human chorionic gonadotropin; 
HCV: hepatitis C virus; HIV: human immunodeficiency; INR: international normalized ratio; PT: prothrombin time; 
RNA: ribonucleic acid.
a HbA1c to be measured only in subjects with DG.
b Prolactin to be evaluated as part of clinical laboratory tests in all the scheduled visits and any necessary 
unscheduled visit as needed to confirm eligibility. Investigators will be blinded to prolactin measurements beginning 
with Visit 4 (Day 1). A subset of samples maybe used for prolactin assay bridging studies as needed. 
c HCV RNA viral load will be tested only in the subjects who test positive for hepatitis C antibody.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 55 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
The results of laboratory tests will be returned to the PI, who is responsible for ensuring that 
these results are reviewed and filed by a qualified designee.
If subjects experience ALT or AST >3×ULN, follow-up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, γ-glutamyl transferase [GGT], and INR) should 
be performed within a maximum of 3 days and preferably within 24 to 48 hours after the 
abnormality was noted. (Refer to Section 7.5 and Section 10.2.3 for the appropriate guidance on 
reporting abnormal LFTs.)
If ALT or AST remains elevated >3×ULN on these 2 consecutive occasions the investigator 
must contact the medical monitor for consideration of additional testing, close monitoring, 
possible discontinuation of study drug, discussion of the relevant subject details and possible 
alternative etiologies. The abnormality should be recorded as an AE (please refer to 
Section 10.2.3).
9.1.11
Contraception and Pregnancy Avoidance Procedure
9.1.11.1
Male Subjects and Their Female Partners
From signing of informed consent, throughout the duration of the study, and for 95 days after last 
dose of study drug, nonsterilized** male subjects who are sexually active with a female partner 
of childbearing potential* must use barrier contraception (eg, condom with or without 
spermicidal cream or jelly). In addition, they must not donate sperm during this period. Women 
of childbearing potential* who are partners of male subjects must also use highly effective 
contraception during this period as shown in the list below.
9.1.11.2
Female Subjects and Their Male Partners
From signing of informed consent, throughout the duration of the study, and for 35 days after last 
dose of study drug, female subjects of childbearing potential* who are sexually active with a 
nonsterilized male partner** must use a highly effective method of contraception (from the list 
below). 
In addition, they must be advised not to donate ova during this period.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 56 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
9.1.11.3
Definitions and Procedures for Contraception and Pregnancy Avoidance
The following definitions apply for contraception and pregnancy avoidance procedures.
* A woman is considered a woman of childbearing potential, that is, fertile, following menarche 
and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods 
include hysterectomy, and bilateral oophorectomy. A postmenopausal state is defined as no 
menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone
(FSH) level in the postmenopausal range (FSH >40 IU/L) may be used to confirm a 
postmenopausal state in younger women (eg, those <45 years old) or women who are not using 
hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months 
of amenorrhea with an FSH >40 IU/L or at least 5 years since last regular menses, a single FSH 
measurement is insufficient.
** Sterilized men should be at least 1-year postbilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchiectomy.
The following procedures apply for contraception and pregnancy avoidance.
Highly effective methods of contraception are defined as those, alone or in combination, that 
1.
result in a low failure rate (ie, less than 1% failure rate per year when used consistently and 
correctly). In this study, where medications and devices containing hormones are included, 
the only acceptable methods of contraception are:

Nonhormonal methods: 
–
Intrauterine device. 
–
Bilateral tubal occlusion. 
–
Vasectomized partner (provided that partner is the sole sexual partner of the study 
participant) and that the vasectomized partner has received medical assessment of the 
surgical success. 

Hormonal methods:
–
Combined (estrogen and progestogen) hormonal contraception associated with 
inhibition of ovulation initiated at least 3 months before the first dose of study drug 
OR combined with a barrier method (male condom, female condom or diaphragm) if 
for shorter duration until she has been on contraceptive for 3 months:

Oral.

Intravaginal (eg, ring).

Transdermal.
–
Progestogen-only hormonal contraception associated with inhibition of ovulation 
initiated at least 3 months before the first dose of study drug OR combined with a 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 57 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
barrier method (male condom, female condom, or diaphragm) if shorter till she has 
been on contraceptive for 3 months.

Oral.

Injectable/implantable.
Unacceptable methods of contraception are:
2.

Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods).

Spermicides only.

Withdrawal.

No method at all.

Use of female and male condoms together.

Cap/diaphragm/sponge without spermicide and without condom.

Sexual abstinence is NOT an acceptable method of contraception.
Subjects will be provided with information on highly effective methods of contraception as 
3.
part of the subject informed consent process and will be asked to sign a consent form stating 
that they understand the requirements for avoidance of pregnancy, donation of ova and sperm 
donation during the study.
During the study, regular urine human chorionic gonadotropin (hCG) pregnancy tests will be 
4.
performed only for women of childbearing potential and all subjects (male and female) will 
receive continued guidance with respect to the avoidance of pregnancy and sperm donation 
as part of the study procedures. Such guidance should include a reminder of the following:

Contraceptive requirements of the study.

Reasons for use of barrier methods (ie, condom) in male subjects with pregnant partners.

Assessment of subject compliance through questions such as:
–
Have you used the contraception consistently and correctly since the last visit?
–
Have you forgotten to use contraception since the last visit?
–
Are your menses late (even in women with irregular or infrequent menstrual cycles a 
pregnancy test must be performed if the answer is “yes”).
–
Is there a chance you could be pregnant?
In addition to a negative serum hCG pregnancy test at screening, female subjects of 
5.
childbearing potential must also have a negative urine hCG pregnancy test before receiving 
any dose of study medication [as close as possible and before the first dose of study 
medication, preferably on the same day].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 58 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
In women of childbearing potential who present with amenorrhea or signs/symptoms 
suggestive of pregnancy or delayed/missed menstrual period by >5 days (whichever comes 
first), the study drug must be immediately discontinued, a serum pregnancy test must be 
perform and if negative, the subject may restart the study drug. In cases of positive 
pregnancy, the subjects must be managed as described in Section 9.1.12.
An onsite end of study pregnancy test should be performed for subjects with menstrual 
irregularities, variable menstrual cycle length by more than ±5 days or missed last menstrual 
period by more than 5 days at the time of the safety follow-up call. 
9.1.12
Pregnancy
If any subject is confirmed to be pregnant during the study, the subject should be withdrawn, and 
any sponsor-supplied drug should be immediately discontinued. In addition, any pregnancies in 
the partner of a male subject occurring during study conduct or within 95 days after the last dose, 
should also be recorded following authorization from the subject’s partner. 
If the pregnancy occurs during administration of active study drug, for example, after the 
randomization visit, the pregnancy should be reported immediately, using a pregnancy 
notification form, to the contact listed in Section 1.0.
Should the pregnancy occur during or after administration of blinded drug, the investigator must 
inform the subject of their right to receive treatment information. If the subject chooses to 
receive unblinded treatment information, the individual blind should be broken by the 
investigator. Subjects randomized to placebo need not be followed.
If the female subject and/or female partner of a male subject agrees to the primary care physician 
being informed, the investigator should notify the primary care physician that the female 
subject/female partner of the subject was participating in a clinical study at the time she became 
pregnant and provide details of the study drug the subject received (blinded or unblinded, as 
applicable).
All pregnancies, including female partners of male subjects, in subjects on active study drug will 
be followed up to final outcome using the pregnancy form. Pregnancies will remain blinded to 
the study team. The outcome, including any premature termination, must be reported to the 
sponsor. An evaluation after the birth of the child will also be conducted.
9.1.13
ECG Procedure 
A standard 12-lead ECG will be recorded. Subject should have rested in supine or semisupine 
position for at least 5 minutes before ECG. When the timing of these measurements coincides 
with a blood collection, the ECG should be obtained before the nominal time of the blood 
collection. Triplicate tracings of ECGs should be performed. ECG will be assessed at Visit 1 
(Day -35), and approximately 1 to 2 hours postdose at Visit 4 (Day 1), Visit 5 (Week 4), Visit 6 
(Week 8), and Visit 7 (Week 12) on those visit days requiring study dosing, and at early 
termination (as specified in Appendix A). The time that the ECG was performed will be 
recorded.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 59 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
The investigator (or a qualified observer at the study site) will interpret the ECG using 1 of the 
following categories: within normal limits, abnormal but not clinically significant, or abnormal 
and clinically significant. ECGs assessed as abnormal and clinically significant must be sent to 
the sponsor’s or designee’s medical monitor for assessment and to confirm if the subject should 
continue in the study. 
The following parameters will be recorded on the eCRF from the subject’s ECG trace: heart rate, 
PR, QT and QTc, and QRS intervals. 
QTc interval will be calculated using Fridericia’s formula: QTcF=QT/RR1/3.
9.1.14
PGx and PK Sample Collection
Table 9.b
Primary Specimen Collections
Specimen Name
Primary 
Specimen
Primary Specimen 
Derivative
Description of 
Primary Use
Sample 
Collection
Plasma sample for TAK-906 
PK
Plasma
PK measurements
Mandatory
PK: pharmacokinetics. 
9.1.14.1
PGx Measurements 
Blood samples for deoxyribonucleic acid (DNA) for PGx analysis will be collected as specified 
in the Schedule of Study Procedures (Appendix A). Details on the collection, storage, 
processing, handling, and shipping of the samples are provided in the Laboratory Manual.
9.1.15
PK Sample Collection and Analysis 
Samples for PK analysis will be collected as specified in the Schedule of Study Procedures 
(Appendix A). Please refer to the Laboratory Manual for information on the collection, 
processing, and shipment of samples to the central laboratory. Metabolites may be analyzed if 
deemed necessary.
The actual date and times of all PK blood draws should be recorded for each subject on the 
eCRF. The actual dates and times of the dose administration in the clinic should be recorded in 
addition to the 2 previous doses. Placebo samples will not be analyzed.
9.1.16
Documentation of Screen Failure
Investigators must account for all subjects who sign informed consent.
If the subject is withdrawn during screening, the investigator should complete the eCRF. The 
IRT should be contacted as a notification of screen failure.
The primary reason for screen failure is recorded in the eCRF using the following categories:

AE.

Did not meet inclusion criteria or did meet exclusion criteria (specify reason).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 60 of 105
Protocol Incorporating Amendment No. 8
13 July 2020

Significant protocol deviation.

Lost to follow-up.

Voluntary withdrawal (specify reason).

Study termination.

Other (specify reason).
Subject ID numbers assigned to subjects who fail screening should not be reused.
9.1.17
Documentation of Randomization
Only subjects who meet all of the inclusion criteria and none of the exclusion criteria are eligible 
for randomization into the treatment phase.
If the subject is found to be not eligible for randomization, the investigator should record the 
primary reason for failure on the applicable eCRF.
Please refer to the study manual provided.
9.1.18
Other Procedures
9.1.18.1
GEBT
For subjects who do not have documented delayed gastric emptying using an accepted diagnostic 
method (see Section 7.1), a 4-hour 13C-Spirulina GEBT will be performed at Visit 2 (up to 
approximately 14 days after consent). The GEBT is preceded by a test meal and an 8-hour fast is 
required before the GEBT test meal. 
The GEBT is simple to administer and the test meal is manufactured under highly-controlled 
drug manufacturing procedures and subject’s breath samples are analyzed using sophisticated 
gas isotope ratio mass spectrometry, a US Food and Drug Administration (FDA) approved, 
validated analytical system.
The test is conducted over a 4-hour evaluation period after an 8-hour fast and is designed to 
show how rapidly the stomach empties solids by measuring carbon dioxide in a patient’s breath. 
Premeal breath samples are collected at the start of the test. Subjects then eat a special test meal. 
After consuming the meal, additional breath samples are collected at specified times. To ensure 
that the samples are evaluable, subjects are required to consume the entire test meal (egg mixture 
and at least 4 of the meal crackers).
Delayed gastric emptying by GEBT is defined as t1/2 ≥79 minutes (80th percentile).
If GEBT falls between 67 to 79 minutes, then site must confirm the diagnostic detail of the prior 
history: 

If patient has had confirmed gastric emptying delay consistent with the diagnosis of 
gastroparesis or evidence of retained food in a previous upper endoscopy or other 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 61 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
imaging test (eg, ultrasound) and is clinically symptomatic, that subject can be retested 
with a second GEBT.
–
GEBT second test equal to or above 79 minutes – the subject proceeds with 
screening
–
GEBT second test – below 79 minutes – the subject is excluded from the trial.
Further details regarding the GEBT will be provided in the study manual.
9.1.18.2
Patient Outcome Measures
The following questionnaires will be used to support the primary efficacy measurement (ANMS 
GCSI-DD) and copies for reference will be provided in the study manual: 

Bloating Severity Scale (Appendix J).

PAGI-SYM.

Clinician Symptom Severity Rating Form.

PAGI-QOL.

OTE Scale (subject and physician).

CGI-S.

CGI-I.

An updated PGI-S Scale (updated version included in Appendix D) will replace existing 
PGI-S scale.

The PGI-C scale (updated changes scale included in Appendix D) will replace existing 
Patient Global Impression of Improvement (PGI-I) scale. 

SF12 Health Survey.
The Schedule of Questionnaire assessments is provided in Appendix D.
9.2
Monitoring Subject Treatment Compliance
Subjects will be required to bring study drug containers/unused study drugs to each site visit. 
Dosing date and time will be recorded daily. 
If a subject is persistently noncompliant with the study drug (eg, <80% compliant or ≥6 
consecutive missed doses since the last study visit), the subject will be re-educated about the 
importance of being consistent with their dosing as per the protocol. The authorized study 
personnel conducting the re-education must document the process in the subject source records.
9.3
Schedule of Observations and Procedures
The schedule for all study-related procedures is shown in Appendix A. Assessments should be 
completed at the designated visit/time point(s).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 62 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
9.3.1
Poststudy Care
Study drug will not be available on completion of the subject’s participation in the study. The 
subject should be returned to the care of a physician and standard therapies as required.
9.4
Biological Sample Retention and Destruction 
In this study, specimens for PGx will be retained for up to but not longer than 15 years or as 
required by applicable law. After that time, the samples will be destroyed.
9.5
Possible Changes to the Procedures to Address Interruptions Due to Pandemic 
Outbreak
The following is intended to give guidance about which changes to the procedures could be 
accepted in case any study participants or study sites are impacted by the COVID-19 pandemic 
outbreak. The guidance takes references from the FDA Guidance on Conduct of Clinical Trials 
of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and 
Institutional Review Boards, March 2020 and the update from 11 May 2020, and the EMA 
Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic, 
Version 3 (28/04/2020).
As the COVID-19 pandemic outbreak may peak in different regions at different times and 
restrictions implemented by local laws and recommendations may vary, any decision on 
procedural changes should be made on a case by case basis following consultation with the 
medical monitor, with patient safety as the priority.
In case there are restrictions to conduct procedures as originally planned in consequence to the 
COVID-19 pandemic:

Informed consent form procedure for investigational sites and study participants related to 
the COVID-19 pandemic situation: If necessary, informed consent from a potential or current 
trial participant may be obtained via electronic informed consent (eIC) capabilities, or an 
electronic face-to-face consent interview when these individuals are unable to travel to the 
site.

Sites will employ all efforts to see subjects as described in the clinical assessments. In 
unavoidable circumstances, such as the COVID-19 pandemic, exceptions may be granted for 
alternative methods for conducting subject visits with approval by the medical monitor 
and/or sponsor. Such instances will be documented in the study records. These data collected 
with alternative methods may be handled differently in the final data analysis, with this 
documented in the statistical analysis plan.

Procedures for clinical laboratory samples:
–
Allow blood draws or other diagnostic tests to be performed by the investigator or the 
study coordinator or by a qualified nurse who can enter the trial participant’s home.
–
Allow blood draws or other diagnostic tests to be conducted at a local laboratory (or 
relevant clinical or office facility) authorized/certified to perform such tests routinely. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 63 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Starting with Visit 4 (Day 1), if samples are collected and analyzed by local lab, prolactin 
will not be evaluated, in order to maintain investigator blinding.

Assessment of the Extrapyramidal System: Allow the assessment via video to observe 
whether typical EPS symptoms (eg, pseudoparkinsonism, acute dystonia, tardive dyskinesia, 
akathisia) are present.

ECG, weight, and vital sign procedures: In situations when an on-site visit is not possible,
ECGs, weight, and vital signs may be performed by a qualified health care professional, or at 
a local healthcare facility, which is authorized/certified to perform such tests routinely.

Allow the use of web-based back-up system on electronic devices.

Deviations from the protocol (eg, missing required bloodwork, visit performed outside of 
window) will be noted as a protocol deviation related to COVID-19.
PRETREATMENT EVENTS AND ADVERSE EVENTS
10.0
10.1
Definitions
10.1.1
Pretreatment SAEs 
Pretreatment SAEs are the only AEs to be collected from the time a subject signs informed 
consent until the subject is first administered study drug (Day 1) or until screen failure.
10.1.2
AEs
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a drug; it does not necessarily have to have a causal relationship with this 
treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant 
abnormal laboratory value), symptom, or disease temporally associated with the use of a drug 
whether or not it is considered related to the drug.
10.1.3
Additional Points to Consider for AEs
An untoward finding generally may:

Indicate a new diagnosis or unexpected worsening of a pre-existing condition. (Intermittent 
events for pre-existing conditions or underlying disease should not be considered AEs.)

Necessitate therapeutic intervention.

Require an invasive diagnostic procedure.

Require discontinuation or a change in dose of study drug or a concomitant medication.

Be considered unfavorable by the investigator for any reason.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 64 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Diagnoses vs signs and symptoms:

Each event should be recorded to represent a single diagnosis. Accompanying signs 
(including abnormal laboratory values or ECG findings) or symptoms should NOT be 
recorded as additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be 
recorded appropriately as an AE(s).
Laboratory values and ECG findings:

Changes in laboratory values or ECG findings are only considered to be AEs if they are 
judged to be clinically significant (ie, if some action or intervention is required or if the 
investigator judges the change to be beyond the range of normal physiologic fluctuation). A 
laboratory or ECG retest and/or continued monitoring of an abnormal value or finding is not 
considered an intervention. In addition, repeated or additional noninvasive testing for 
verification, evaluation or monitoring of an abnormality is not considered an intervention.

If abnormal laboratory values or ECG findings are the result of pathology for which there is 
an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately as an AE.
Pre-existing conditions:

Pre-existing conditions (present at the time of signing of informed consent) are considered 
concurrent medical conditions and should NOT be recorded as AEs. If the subject 
experiences a worsening or complication of such a concurrent medical condition, the 
worsening or complication should be recorded appropriately an AE (worsening or 
complication occurs after start of study drug). Investigators should ensure that the event term 
recorded captures the change in the condition (eg, “worsening of…”).

If a subject has a pre-existing episodic concurrent medical condition (eg, asthma, epilepsy) 
any occurrence of an episode should only be captured as an AE if the condition becomes 
more frequent, serious or severe in nature. Investigators should ensure that the AE term 
recorded captures the change in the condition from baseline (eg “worsening of…”).

If a subject has a degenerative concurrent medical condition (eg, cataracts, rheumatoid 
arthritis), worsening of the condition should only be recorded as an AE if occurring to a 
greater extent to that which would be expected. Investigators should ensure that the AE term 
recorded captures the change in the condition (eg, “worsening of…”).
Worsening of AEs:

If the subject experiences a worsening or complication of an AE after any change in study 
drug, the worsening or complication should be recorded as a new AE. Investigators should 
ensure that the AE term recorded captures the change in the condition (eg, “worsening 
of…”).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 65 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Changes in intensity of AEs:

If the subject experiences changes in severity of an AE, the event should be captured once 
with the maximum intensity recorded.
Preplanned procedures (surgeries or interventions):

Preplanned procedures (surgeries or therapies) that were scheduled before signing of 
informed consent are not considered AEs/SAEs. Complications resulting from any planned 
surgery should be reported as AEs.
Elective surgeries or procedures:

Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as AEs/SAEs but should be documented in the subject’s source 
documents. Complications resulting from an elective surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):

Insufficient clinical response, efficacy, or pharmacologic action should NOT be recorded as 
an AE. The investigator must make the distinction between exacerbation of pre-existing 
illness and lack of therapeutic efficacy.
Overdose:

Cases of overdose with any medication without manifested side effects are NOT considered 
AEs, but instead will be documented on an overdose page of the eCRF. Any manifested side 
effects will be considered as an AEs and will be recorded on the AE page of the eCRF. 
10.1.4
SAEs
An SAE is defined as any untoward medical occurrence that at any dose:
Results in DEATH.
1.
Is LIFE THREATENING.
2.

The term “life threatening” refers to an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event that hypothetically might have caused 
death if it were more severe.
Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
3.
Results in persistent or significant DISABILITY/INCAPACITY.
4.
Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
5.
Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:
6.

May require intervention to prevent items 1 through 5 above.

May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 66 of 105
Protocol Incorporating Amendment No. 8
13 July 2020

Includes any event or synonym described in the Takeda Medically Significant AE List
(Table 10.a).
Table 10.a
Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory distress 
syndrome
Hepatic necrosis
Torsade de pointes/ventricular fibrillation/ventricular 
tachycardia
Acute liver failure
Anaphylactic shock
Malignant hypertension
Acute renal failure
Convulsive seizure
Pulmonary hypertension
Agranulocytosis
Pulmonary fibrosis
Aplastic anemia
Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens-Johnson syndrome Confirmed or suspected transmission of infectious agent by 
a medicinal product
COVID-19-related disease
Neuroleptic malignant syndrome/malignant hyperthermia
COVID-19 pneumonia
Spontaneous abortion/stillbirth and fetal death
AE: adverse events; COVID-19: coronavirus disease 2019.
Terms identified on the Medically Significant AE List represent the broad medical concepts to be considered as 
“Important Medical Events” satisfying SAE reporting requirements.
10.1.5
AEs of Special Interest
An AE of special interest ([AESI]; serious or nonserious) is one of scientific and medical 
concern specific to the compound or program, for which ongoing monitoring and rapid 
communication by the investigator to Takeda may be appropriate. Such events may require 
further investigation to characterize and understand them and would be described in protocols 
and instructions provided for investigators as to how and when they should be reported to 
Takeda. The following events are AESI for this study:
Extrapyramidal symptoms and other clinically relevant CNS or neuropsychiatric disease 
1.
including tardive dyskinesia, neuroleptic malignant syndrome, acute dystonia, parkinsonian-
like symptoms, convulsive seizure, severe mental depression, and hallucinations.
Clinically relevant hyperprolactinemia (see below).
2.
Guidance to investigators for management of extrapyramidal symptoms and central
nervous system/neuropsychiatric AEs
Extrapyramidal symptoms including tardive dyskinesia, acute dystonic reactions, 
parkinsonian-like symptoms [30] and akathisia are considered to be mainly caused by the 
blockade of D2 receptor in the dorsal striatum in the brain. These side effects have been reported 
with all centrally acting DA receptor D2 antagonists such as metoclopramide and atypical 
neuroleptics. TAK-906 is considered as a peripherally selective DA receptor D2/D3 antagonist 
with limited penetration of the blood brain barrier, hence it is considered to have a low potential 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 67 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
for causing extrapyramidal symptoms compared with metoclopramide or atypical neuroleptics. 
However, as TAK-906 is in early development and its complete safety profile is not 
characterized at this time, Takeda is closely monitoring medical events that may potentially be 
extrapyramidal in nature.
Of greatest concern is tardive dyskinesia, a severe and often irreversible and disfiguring disorder 
characterized by involuntary movements of the face, tongue, mouth, or jaw, and trunk and/or 
extremities. Although the risk for developing tardive dyskinesia in the general population may be 
increased among the elderly, women, and individuals with diabetes, it is not possible to predict 
which patients will develop D2 receptor antagonist-induced tardive dyskinesia. 
There is no known effective treatment of established cases of tardive dyskinesia, although in 
some patients, tardive dyskinesia may remit, partially or completely, within several weeks to 
months after discontinuation of causative agent. 
In subjects with suspected EPS, study drug should be immediately interrupted, and subjects 
referred for appropriate neurological consultation. If, after neurological consultation, EPS is 
confirmed, study drug should be discontinued, and the subject withdrawn from the study. In the 
remaining cases restarting of the study drug should be evaluated individually after discussion 
with the medical monitor.
In subjects who develop suspected CTCAE Grade 1 CNS/neuropsychiatric AEs, the study drug 
may be continued at investigator’s discretion after discussion with the medical monitor. 
However, in subjects with CTCAE ≥ Grade 2 CNS/neuropsychiatric AEs, the study drug should 
be immediately interrupted, and subjects referred for appropriate neurological consultation. If 
after neurological consultation, a CNS/neuropsychiatric AE is confirmed and considered related 
to the study drug, the study drug should be discontinued, and the subject withdrawn from the 
study. In the remaining cases restarting of the study drug should be evaluated individually after 
discussion with the medical monitor. If the study drug is interrupted for more than 10 days, the 
subject should be discontinued form the study and procedures stated in Section 7.6 “Procedures 
for Discontinuation or Withdrawal of a Subject” should be followed.
Guidance to investigator for management of elevated serum prolactin
Several physiologic and pathologic conditions for example, pregnancy, breastfeeding, breast 
stimulation, prolactinomas, vascular disorders, autoimmune disorders, chronic renal failure, chest 
wall trauma, seizures, and stress can result in increased plasma prolactin levels [31].
TAK-906 is a D2 receptor antagonist, which increases prolactin release by inhibiting the negative 
control mechanism of DA on prolactin, a pharmacological class effect shared with other D2
receptor antagonists. It is anticipated that TAK-906 will also increase serum prolactin levels. 
The most frequent symptoms of chronic hyperprolactinemia include reproductive dysfunction 
(anovulation, menstrual irregularity, subfertility, decreased estrogen and testosterone 
production), sexual impairment (diminished libido, erectile dysfunction, retrograde or painful 
ejaculation, orgasmic dysfunction, impotence), breast pathology (galactorrhea and breast 
enlargement) [32].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 68 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Medication-induced hyperprolactinemia is usually associated with prolactin levels ranging from 
25 to 100 µg/L; however, TAK-906 in some cases may lead to serum prolactin levels exceeding 
200 µg/L.
In subjects with symptoms suggestive of hyperprolactinemia, the investigator should manage the 
subject as clinically indicated. In these subjects, the benefit-risk of continued participation in the 
study should be evaluated and documented in the eCRF.
Only prolactin related symptoms leading to discontinuation of a subject from the study should be 
reported as an AESI and recorded as an AE in the eCRF and reported as per Section 10.2.2
should they meet the criteria for SAE (Section 10.1.4).
Prolactin related symptoms not leading to discontinuation of a subject from the study should not 
be reported as an AESI but recorded as an AE in the eCRF and reported as per Section 10.2.2
should they meet the criteria for SAE (Section 10.1.4). 
Elevated serum prolactin without clinical manifestations (asymptomatic hyperprolactinemia) 
should not be reported as an AESI, AE, or SAE; however, serum prolactin levels >ULN will be 
summarized as per statistical analysis plan (SAP) of this study. 
Subjects will be withdrawn from the study if the investigator requires unblinding of the study 
treatment or serum prolactin level because of suspected hyperprolactinemia.
In woman of childbearing potential who present with postdosing amenorrhea or signs/symptoms 
suggestive of pregnancy or delayed/missed menstrual period by >5 days (whichever comes first), 
the study drug must be immediately discontinued, a serum pregnancy test must be performed and 
if negative, the subject may restart the study drug. In cases of positive pregnancy, the subjects 
must be managed as described in Section 9.1.12.
The AESI should be recorded in an AE of special interest named Form and reported to the 
clinical contract research organization (CRO)/Pharmacovigilance department within 24 hours. 
AEs of special interest must be recorded as AEs in the eCRF. An evaluation form along with all 
other required documentation must be submitted to the sponsor.
If an AESI also meets the criteria of SAE (Section 10.1.4), it should be reported using both the 
AESI named Form AND the SAE Form.
10.1.6
Severity of AEs
All AEs, including clinically significant treatment-emergent laboratory abnormalities, will be 
graded according to CTCAE Version 4.03 
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06 14_QuickReference_8.5x11.pdf).
AEs not listed by the NCI CTCAE will be graded as below:
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 69 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Grade 2: Moderate; minimal, local or non-invasive intervention indicated; limiting age 
appropriate instrumental activities of daily living (ADL) (Instrumental ADL refer to preparing 
meals, shopping for groceries or clothes, using the telephone, managing money, etc.).
Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self-care ADL.
Grade 4: Life-threatening consequences; urgent intervention indicated.
Grade 5: Fatal AE; an event that results in the death of the subject.
10.1.7
Causality of AEs
The relationship of each AE to study drug(s) will be assessed using the following categories:
Related:
An AE that follows a reasonable temporal sequence from administration of a 
drug (including the course after withdrawal of the drug), or for which possible 
involvement of the drug cannot be ruled out, although factors other than the 
drug, such as underlying diseases, complications, concomitant medications and 
concurrent treatments, may also be responsible.
Not Related:
An AE that does not follow a reasonable temporal sequence from 
administration of a drug and/or that can reasonably be explained by other 
factors, such as underlying diseases, complications, concomitant medications 
and concurrent treatments.
10.1.8
Relationship to Study Procedures
Relationship (causality) to study procedures should be determined for all AEs.
The relationship should be assessed as Related if the investigator considers that there is 
reasonable possibility that an event is due to a study procedure. Otherwise, the relationship 
should be assessed as Not Related. 
10.1.9
Start Date
The start date of the AE/SAE is the date that the first signs/symptoms were noted by the subject 
and/or investigator.
10.1.10
Stop Date 
The stop date of the AE/SAE is the date at which the subject recovered, the event resolved but 
with sequelae or the subject died.
10.1.11
Frequency 
Episodic AEs/SAE or those that occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 70 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
10.1.12
Action Concerning Study Drug 

Drug withdrawn: a study drug is stopped due to the particular AE.

Dose interrupted: the dose was interrupted due to the particular AE. 

Dose not changed: the particular AE did not require stopping a study drug.

Unknown: only to be used if it has not been possible to determine what action has been 
taken.

Not applicable: a study drug was stopped for a reason other than the particular AE, for 
example, the study has been terminated, the subject died, dosing with study drug was already 
stopped before the onset of the AE.
10.1.13
Outcome 

Recovered/resolved: subject returned to first assessment status with respect to the AE.

Recovering/resolving: the intensity is lowered by 1 or more stages: the diagnosed AE or 
signs/symptoms has almost disappeared; the abnormal laboratory value improved but has not 
returned to the reference range or to baseline; the subject died from a cause other than the 
particular AE with the condition remaining “recovering/resolving”.

Not recovered/not resolved: there is no change in the diagnosis, signs or symptoms; the 
intensity of the diagnosed AE, signs/ symptoms or laboratory value on the last day of the 
observed study period has got worse than when it started; is an irreversible congenital 
anomaly; the subject died from another cause with the particular AE state remaining “Not 
recovered/not resolved”.

Resolved with sequelae: the subject recovered from an acute AE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis.

Fatal: the AEs which are considered as the cause of death. 

Unknown: the course of the AE cannot be followed up due to hospital change or residence 
change at the end of the subject’s participation in the study.
10.2
Procedures
10.2.1
Collection and Reporting of AEs
10.2.1.1
AE Collection Period
After informed consent, but before initiation of study medications, only SAEs will be collected. 
Collection of all AEs (serious and nonserious) will commence from the time that the subject is 
first administered study drug (randomization visit). Routine collection of AEs will continue for 
each subject throughout the study until 30 days after the last dose of study drug is taken.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 71 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
If an AE is ongoing at the end of the study for a subject, follow-up should be provided until 
resolution/stable level of sequelae is achieved, or until the investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow-up is provided, the 
investigator must provide a justification. The follow-up will be continued for up to 8 weeks after 
the subject has discontinued his/her investigational medicinal product. Information on SAEs 
obtained after clinical database lock will be captured through the safety database without 
limitation of time.
10.2.1.2
AE Reporting
At each study visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing an 
SAE must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to baseline or there is a satisfactory explanation for the change. 
All subjects experiencing AEs (postdose), whether considered associated with the use of the 
study drug or not, must be monitored until the symptoms subside and any clinically relevant 
changes in laboratory values have returned to baseline or until there is a satisfactory explanation 
for the changes observed. All AEs will be documented in the AE page of the eCRF, whether or 
not the investigator concludes that the event is related to the drug treatment. The following 
information will be documented for each event:
Event term.
1.
Start and stop date and time.
2.
Frequency.
3.
Intensity.
4.
Investigator’s opinion of the causal relationship between the event and administration of 
5.
study drug(s) (related or not related).
Investigator’s opinion of the causal relationship to study procedure(s), including the details 
6.
of the suspected procedure.
Action concerning study drug
7.
Outcome of event.
8.
Seriousness.
9.
The Daily Symptom Diary will not be used as a primary means to collect AEs. However, should 
the investigator become aware of a potential AE through the information collected with this 
instrument, proper follow-up with the subject for medical evaluation should be undertaken. 
Through this follow-up if it is determined that an AE not previously reported has been identified, 
normal reporting requirements should be applied.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 72 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
10.2.2
Collection and Reporting of SAEs/AESI
When an SAE and/or AESI occurs through the AE collection period it should be reported 
according to the following procedure:
As soon as an SAE/AESI is entered into the electronic data capture system, an alert is sent to the 
attention of the contact listed in Section 1.1 and to the safety database.
The SAE/AESI eCRF should be transmitted within 24 hours of first onset or notification of the 
event. However, as a back-up, if required, the SAE form should be completed and reported to the 
attention of the contact listed in Section 1.1.
The information should be completed as fully as possible but contain, at a minimum:
A short description of the event and the reason why the event is categorized as serious.

Subject ID number.

Investigator’s name.

Name of the study drug(s).

Causality assessment.
Any SAE/AESI spontaneously reported to the investigator following the AE collection period 
should be reported to the sponsor if considered related to study participation.
10.2.3
Reporting of Abnormal LFTs 
If a subject is noted to have ALT or AST elevated >3×ULN on 2 consecutive occasions, the 
abnormality should be recorded as an AE. In addition, an LFT Increases eCRF must be 
completed providing additional information on relevant recent history, risk factors, clinical signs 
and symptoms and results of any additional diagnostic tests performed.
If a subject is noted to have ALT or AST >3×ULN and total bilirubin >2×ULN for which an 
alternative etiology has not been identified, the event should be recorded as an SAE and reported 
per Section 10.2.2. The investigator must contact the medical monitor for discussion of the 
relevant subject details and possible alternative etiologies, such as acute viral hepatitis A or B or 
other acute liver disease or medical history/concurrent medical conditions. Follow-up laboratory 
tests as described in Section 9.1.10 must also be performed. In addition, an LFT Increases eCRF 
must be completed and transmitted with the Takeda SAE form (per Section 10.2.2).
10.3
Follow-up of SAEs
If information not available at the time of the first report becomes available at a later date, the 
investigator should complete a follow-up SAE form or provide other written documentation and 
fax it immediately, within 24 hours of receipt. Copies of any relevant data from the hospital 
notes (eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the 
addressee, if requested.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 73 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
All SAEs should be followed up until resolution or permanent outcome of the event. The 
timelines and procedure for follow-up reports are the same as those for the initial report.
10.3.1
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor or designee will be responsible for reporting all suspected unexpected serious 
adverse reactions (SUSARs) and any other applicable SAEs to regulatory authorities, including 
the European Medicines Agency, investigators and IRBs or IECs, as applicable, in accordance 
with national regulations in the countries where the study is conducted. Relative to the first 
awareness of the event by/or further provision to the sponsor or sponsor’s designee, SUSARs 
will be submitted to the regulatory authorities as expedited report within 7 days for fatal and 
life-threatening events and 15 days for other serious events, unless otherwise required by 
national regulations. The sponsor will also prepare an expedited report for other safety issues 
where these might materially alter the current benefit-risk assessment of a study drug/sponsor 
supplied drug or that would be sufficient to consider changes in the study drug/sponsor supplied 
drug administration or in the overall conduct of the trial. The study site also will fo rward a copy 
of all expedited reports to his or her IRB or IEC in accordance with local regulations.
STUDY-SPECIFIC COMMITTEES
11.0
11.1
IDMC 
An IDMC will be used during this study to allow study team members to remain blinded to 
subject treatment during the study. The IDMC will perform the customary duties of safeguarding 
the interest of study participants, assessing the safety of the interventions during the study, and 
for monitoring the overall conduct of the clinical study. The IDMC will provide 
recommendations about stopping or continuing the study. To enhance the integrity of the study, 
the IDMC may also formulate recommendations relating to the selection/recruitment/retention of 
participants, management of the study participants, improving adherence to protocol-specific 
regimens, and the procedures for data management and quality control.
Details of the IDMC including meeting frequency will be captured in a charter before the start of 
the study.
DATA HANDLING AND RECORDKEEPING
12.0
The full details of procedures for data handling will be documented in the Data Management 
Plan. AEs, medical history, and concurrent medical conditions will be coded using the Medical 
Dictionary for Regulatory Activities (MedDRA). Drugs will be coded using the World Health 
Organization Drug Dictionary (WHO).
12.1
eCRFs
Completed eCRFs are required for each subject who signs an informed consent. The sponsor or 
its designee will supply study sites with access to eCRFs. These forms are used to transmit the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 74 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
information collected in the performance of this study to the sponsor and regulatory authorities. 
eCRFs must be completed in English. Data are transcribed directly onto eCRFs.
After completion of the entry process, computer logic checks will be run to identify items, such 
as inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
The principal investigator must review the eCRFs for completeness and accuracy and must e-
sign the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibility for the accuracy and authenticity of all data entered on the eCRFs.
eCRFs will be reviewed for completeness and acceptability at the study site during periodic visits 
by the sponsor or its designee. The sponsor or its designee will be permitted to review the 
subject’s medical and hospital records pertinent to the study to ensure accuracy of the eCRFs. 
The completed eCRFs are the sole property of the sponsor and should not be made available in 
any form to third parties, except for authorized representatives of appropriate governmental 
health or regulatory authorities, without written permission of the sponsor.
12.2
Record Retention
The investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms), 
electronic copy of eCRFs, including the audit trail, and detailed records of drug disposition to 
enable evaluations or audits from regulatory authorities, the sponsor or its designees. Any source 
documentation printed on degradable thermal sensitive paper should be photocopied by the site 
and filed with the original in the subject’s chart to ensure long term legibility. Furthermore, ICH 
E6 Section 4.9.5 requires the investigator to retain essential documents specified in ICH E6 
(Section 8) until at least 2 years after the last approval of a marketing application for a specified 
drug indication being investigated or, if an application is not approved, until at least 2 years after 
the investigation is discontinued and regulatory authorities are notified. In addition, ICH E6 
Section 4.9.5 states that the study records should be retained until an amount of time specified by 
applicable regulatory requirements or for a time specified in the study site agreement between 
the investigator and sponsor.
Refer to the study site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of 
any such documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 75 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
STATISTICAL METHODS
13.0
13.1
Statistical and Analytical Plans
A SAP will be prepared and finalized before unblinding of subject’s treatment assignment. This 
document will provide further details regarding the definition of analysis variables and analysis 
methodology to address all study objectives.
A blinded data review will be conducted before unblinding of subject’s treatment assignment. 
This review will assess the accuracy and completeness of the study database, subject 
evaluability, and appropriateness of the planned statistical methods.
13.1.1
Analysis Sets
The safety set will include all subjects who were randomized and received at least 1 dose of 
double-blind study medication. In safety summaries, subjects will be analyzed according to the 
treatment they received. If a subject receives more than 1 treatment, the actual treatment will be 
defined as the one that is used most frequently. If the 2 most common treatments are used with 
equal frequency, then the randomized treatment will be used for safety summaries.
The full analysis set (FAS) will include all subjects who were randomized, received at least 
1 dose of study drug, and have a baseline value and at least 1 valid postbaseline value for 
assessment of primary efficacy. In FAS efficacy summaries, subjects will be analyzed by the 
treatment to which they were randomized.
The per protocol set (PPS) will include all FAS subjects who had no major protocol violations. If 
more than 5% of the total subjects in the FAS have major protocol violations, analyses based on 
the PPS will be performed for the primary efficacy variable only.
13.1.2
Analysis of Demographics and Other Baseline Characteristics
Demographic and baseline characteristics including sex, age, race, height, weight, BMI, and 
subject disease population (DG and IG) will be listed and summarized for each treatment group 
and overall. The demographic and baseline characteristics summary will be based on all 
randomized subjects.
Baseline values for efficacy parameters (ANMS GCSI-DD, PAGI-SYM, and Clinician Symptom 
Severity Rating, etc.) will also be presented for each treatment group and overall based on all 
randomized subjects.
Height and weight values will be presented in metric units (cm and kg respectively). BMI is 
calculated as [weight (kg)/height (m)2], using the weight collected at the first screening visit. 
For continuous variables, number of nonmissing values and the mean, median, SD, minimum 
and maximum will be tabulated by treatment group and overall. For the categorical variables, the 
count and percentages of each possible value will be tabulated by treatment group and overall.
For continuous variables, comparability of treatment groups will be assessed using an analysis of 
variance (ANOVA) with treatment, subject disease population and center as fixed factors. For 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 76 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
discrete variables, comparability will be assessed using the Cochran-Mantel-Haenszel general 
association test, stratified by center and subject disease population. P-values will be displayed as 
descriptive statistics of comparability.
All individual demographic and baseline data will be listed by treatment, study center and 
subject number.
13.1.3
Efficacy Analysis
The efficacy analyses and summaries will be based on the FAS. 
13.1.3.1
Primary Efficacy Analysis 
Change from baseline to Week 12 in weekly ANMS GCSI-DD composite score (nausea, early 
satiety, upper abdominal pain, postprandial fullness) will be the primary endpoint. Analysis will 
be based on a mixed model for repeated measurements (MMRM) with treatment, center, week, 
subject disease population, and treatment-by-week interaction as fixed effects, baseline and 
baseline score-by-week interaction as covariates, with an unstructured covariance structure, if 
applicable. The point-estimates, nominal p-values and confidence intervals (CIs) for the primary 
analysis will be based on the Week 12 statistical comparisons between each of the 2 TAK-906 
dose groups and placebo, with respect to the primary endpoint. The 2 statistical tests for the 
primary efficacy analysis are 1-sided and will be conducted using a 5% level of significance. 
Nominal p-values will be evaluated for statistical significance. In addition, point estimates and 
CIs along with descriptive statistics for change from baseline scores in ANMS GCSI-DD at 
earlier time points, will be presented. The MMRM-based analysis assumes that missing data 
follow a missing-at-random (MAR) assumption. 
As a sensitivity analysis, a method for missing value imputation based on pattern mixture models 
will be implemented.
13.1.3.2
Secondary Efficacy Analyses
For change from baseline in the continuous secondary variables (ANMS GCSI-DD total score, 
ANMS GCSI-DD individual symptom score, ANMS GCSI-DD overall severity of gastroparesis 
symptoms score, bloating severity scale score, and PAGI-SYM total score), comparisons 
between different doses of TAK-906 and placebo will be based on the similar methodology 
described for the primary efficacy analysis. 
The proportion of subjects with at least 50% reduction from baseline in ANMS GCSI-DD 
composite score will be analyzed at all time points by logistic regression adjusting for baseline 
score, subject disease population, and treatment using the last observation carried forward 
method to handle missing data. 
Percentage of symptomatic weeks (weeks with symptoms assessed as >mild) using the ANMS 
GCSI-DD after 12 weeks of treatment will be analyzed using ANOVA with treatment, subject 
disease population and center as fixed factors.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 77 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
13.1.4
PK Analysis 
No formal noncompartmental PK analyses will be performed on concentration-time data. 
Individual concentration-time data will be included in listings only. Additional analyses may be 
conducted if deemed necessary for the interpretation of the data.
A more detailed description of these analyses will be given in a separate analysis plan. The 
results from these analyses will not be included in the clinical study report and will be a 
stand-alone report.
13.1.5
Other Analyses
The PGx samples will be stored and may be analyzed at a later date, if required. A separate PGx 
analysis plan will be created.
13.1.6
Safety Analysis
Safety summaries will be based on the safety set. 
13.1.6.1
AEs
AEs will be reported throughout the study.
The definition of treatment-emergent AEs will be provided in the SAP. AEs will be coded using 
MedDRA and will be summarized by system organ class and preferred term in the core treatment 
period and entire study.
AEs that were reported more than once by a subject during the same period will be counted only 
once for that subject and period at the maximum severity.
13.1.6.2
Other Safety Evaluations
Absolute values and changes from screening/baseline in clinical safety laboratory tests, vital 
signs, ECG parameters, and weight will be summarized for each treatment group using 
descriptive techniques. Values outside reference ranges and markedly abnormal values will be 
flagged and tabulated.
13.2
Interim Analysis 
No interim analysis of efficacy data will be conducted.
Periodic interim safety data reviews will be performed by IDMC. Frequency of IDMC safety 
review meetings and procedures to protect the study blinding will be documented fully in the 
IDMC charter.
In addition, blinded sample size re-estimation may be performed if the variance of the primary 
endpoint or study dropout rate is much larger than originally assumed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 78 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
13.3
Determination of Sample Size
In order to manage the likelihood of statistical, clinical, and operational success of this study in 
the setting of the COVID-19 pandemic, the sample-size considerations are revisited in Protocol 
Amendment 8. The statistical testing is revised from 2-sided (with a significance level of 5%) to 
1-sided (with a significance level of 5%), the planned sample size is reduced by 10 subjects per 
arm and randomization into the 5 mg dose arm is to be discontinued. 
The sample-size rationale for the resultant reduced sample size and updated 1-sided statistical 
testing is as follows: Assuming a SD of 1.25 and a true difference of 0.625 between TAK-906M 
active dose and placebo in the change from baseline in the ANMS GCSI-DD composite score, 
and a 15% dropout rate, a total of 205 subjects is sufficient to achieve approximately 80% power 
to detect the treatment effect of 0.625 at a 1-sided 5% significance level. The total of 
205 subjects consists of approximately 25 subjects who have already been randomized to receive 
5 mg capsule BID prior to terminating randomization of subjects into the 5 mg dose arm, and 
60 subjects per treatment groups of placebo, TAK-906M 25 mg, and TAK-906M 50 mg.
QUALITY CONTROL AND QUALITY ASSURANCE
14.0
14.1
Study-Site Monitoring Visits
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The investigator and the study site guarantee access to source documents by the sponsor or its 
designee (CRO) and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or 
sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
Investigator’s Binder, study drug, subject medical records, informed consent documentation and 
review of eCRFs and associated source documents. It is important that the investigator and other 
study personnel are available during the monitoring visits and that sufficient time is devoted to 
the process.
14.2
Protocol Deviations
The investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will 
require deviation from protocol-specified procedures, the investigator should consult with the 
sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of action. 
There will be no exemptions (a prospectively approved deviation) from the inclusion or 
exclusion criteria.
The site should document all protocol deviations in the subject’s source documents. In the event 
of an important deviation, the site should notify the sponsor or its designee (and IRB or IEC, as 
required). Important deviations include, but are not limited to, those that involve fraud or 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 79 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment.
14.3
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the sponsor or designees. In this 
circumstance, the sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by regulatory agencies, 
including those of foreign governments (eg, the FDA, European National Agencies). If the study 
site is contacted for an inspection by a regulatory body, the sponsor should be notified 
immediately. The investigator and study site guarantee access for quality assurance auditors to 
all study documents as described in Section 14.1.
ETHICAL ASPECTS OF THE STUDY
15.0
This study will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonised Tripartite Guideline for GCP. Each investigator will conduct 
the study according to applicable local or regional regulatory requirements and align his or her 
conduct in accordance with the “Responsibilities of the Investigator” that are listed in 
Appendix F. The principles of Helsinki are addressed through the protocol and through 
appendices containing requirements for informed consent and investigator responsibilities.
15.1
IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local 
requirements of each participating region. The sponsor or designee will require documentation 
noting all names and titles of members who make up the respective IRB or IEC. If any member 
of the IRB or IEC has direct participation in this study, written notification regarding his or her 
abstinence from voting must also be obtained. Those Americas sites unwilling to provide names 
and titles of all members due to privacy and conflict of interest concerns should instead provide a 
Federal Wide Assurance Number or comparable number assigned by the Department of Health 
and Human Services.
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy of the informed consent 
form, and, if applicable, subject recruitment materials and/or advertisements and other 
documents required by all applicable laws and regulations, must be submitted to a central or 
local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and subject 
informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study (ie, before shipment of the sponsor-supplied drug or study specific 
screening activity. The IRB or IEC approval must refer to the study by exact protocol title, 
number, and version date; identify versions of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will ship drug/notify site once the sponsor has
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 80 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
confirmed the adequacy of site regulatory documentation and, when applicable, the sponsor has 
received permission from competent authority to begin the study. Until the site receives 
drug/notification, no protocol activities, including screening may occur.
Study sites must adhere to all requirements stipulated by their respective IRB or IEC. This may 
include notification to the IRB or IEC regarding protocol amendments, updates to the informed 
consent form, recruitment materials intended for viewing by subjects, local safety reporting 
requirements, reports and updates regarding the ongoing review of the study at intervals 
specified by the respective IRB or IEC, and submission of the investigator’s final status report to 
IRB or IEC. All IRB and IEC approvals and relevant documentation for these items must be 
provided to the sponsor or its designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
15.2
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form describes the planned and permitted 
uses, transfers, and disclosures of the subject’s personal and personal health information for 
purposes of conducting the study. The informed consent form further explains the nature of the 
study, its objectives, and potential risks and benefits, as well as the date informed consent are 
given. The informed consent form will detail the requirements of the participant and the fact that 
he or she is free to withdraw at any time without giving a reason and without prejudice to his or 
her further medical care.
The investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and if applicable, the subject authorization form. The informed consent 
form must be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form must be written in a language fully comprehensible to the 
prospective subject. It is the responsibility of the investigator to explain the detailed elements of 
the informed consent form to the subject. Information should be given in both oral and written 
form whenever possible and in the manner deemed appropriate by the IRB or IEC. In the event 
the subject is not capable of rendering adequate written informed consent, then the subject’s 
legally acceptable representative may provide such consent for the subject in accordance with 
applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity 
to: (1) inquire about details of the study and (2) decide whether or not to participate in the study. 
If the subject, or the subject’s legally acceptable representative, determines he or she will 
participate in the study, then the informed consent form and subject authorization form (if 
applicable) must be signed and dated by the subject, or the subject’s legally acceptable 
representative, at the time of consent and prior to the subject entering into the study. The subject 
or the subject’s legally acceptable representative should be instructed to sign using their legal 
names, not nicknames, using blue or black ballpoint ink. The investigator must also sign and date 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 81 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
the informed consent form and subject authorization (if applicable) at the time of consent and 
prior to subject entering into the study; however, the sponsor may allow a designee of the 
investigator to sign to the extent permitted by applicable law.
Once signed, the original informed consent form will be stored in the investigator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a copy of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA analysis can withdraw their 
consent and request disposal of a stored sample at any time prior to analysis. Notify sponsor of 
consent withdrawal.
15.3
Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the sponsor’s clinical trial database or documentation via a subject ID number. As permitted by 
all applicable laws and regulations, limited subject attributes, such as sex, age, or date of birth 
and subject initials may be used to verify the subject and accuracy of the subject’s unique ID 
number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the 
sponsor requires the investigator to permit the monitor or the sponsor’s designee, representatives 
from any regulatory authority (eg, FDA, European National Agencies), the sponsor’s designated
auditors, and the appropriate IRBs and IECs to review the subject’s original medical records 
(source data or documents), including, but not limited to, laboratory test result reports, ECG 
reports, admission and discharge summaries for hospital admissions occurring during a subject’s 
study participation, and autopsy reports. Access to a subject’s original medical records requires 
the specific authorization of the subject as part of the informed consent process (see 
Section 15.2).
Copies of any subject source documents that are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s eCRF).
15.4
Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1
Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived 
by the investigator from the study. During and after the study, only the sponsor may make study 
information available to other study investigators or to regulatory agencies, except as required by 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 82 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
law or regulation. Except as otherwise allowable in the study site agreement, any public 
disclosure (including publicly accessible websites) related to the protocol or study results, other 
than study recruitment materials and/or advertisements, is the sole responsibility of the sponsor.
15.4.2
Clinical Trial Registration
To ensure that information on clinical trials reaches the public in a timely manner and to comply 
with applicable laws, regulations and guidance, Takeda will, at a minimum register all 
interventional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly accessible websites before start of study, as defined in Takeda Policy/Standard. Takeda 
contact information, along with investigator’s city, state (for American investigators), country, 
and recruiting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in locating study sites closest to their homes by 
providing the investigator name, address, and phone number to the callers requesting trial 
information. Once subjects receive investigator contact information, they may call the site 
requesting enrollment into the trial. The investigative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of trial enrollment, they should be referred to the sponsor.
Any investigator who objects to the sponsor providing this information to callers must provide 
the sponsor with a written notice requesting that their information not be listed on the registry 
site.
15.4.3
Clinical Trial Results Disclosure
Takeda will post the results of clinical trials on ClinicalTrials.gov and/or other publicly 
accessible websites, as required by Takeda Policy/Standard, applicable laws and/or regulations.
15.5
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the 
site where the subject is participating. If a local underwriter is required, then the sponsor or 
sponsor’s designee will obtain clinical study insurance against the risk of injury to study 
subjects. Refer to the study site agreement regarding the sponsor’s policy on subject 
compensation and treatment of injury. If the investigator has questions regarding this policy, he 
or she should contact the sponsor or sponsor’s designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 83 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
REFERENCES
16.0
1.
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of G. 
Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108(1):18-37; 
quiz 8.
2.
Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical 
characteristics, psychological and abuse profiles, treatment, and long-term follow-up of 
patients with gastroparesis. Dig Dis Sci 1998;43(11):2398-404.
3.
Choung RS, Locke GR, 3rd, Schleck CD, Zinsmeister AR, Melton LJ, 3rd, Talley NJ. 
Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am 
J Gastroenterol 2012;107(1):82-8.
4.
Parkman HP, Camilleri M, Farrugia G, McCallum RW, Bharucha AE, Mayer EA, et al. 
Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. 
Neurogastroenterol Motil 2010;22(2):113-33.
5.
Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med 
2013;64:393-406.
6.
Metoclopramide hydrochloride tablets. Full Prescribing Information. Parsippany, NJ: 
Actavis Pharma, Inc., Revised June 2015.
7.
Michaud V, Turgeon J. Domperidone and sudden cardiac death: How much longer 
should we wait? J Cardiovasc Pharmacol 2013;61(3):215-7.
8.
Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev 
Endocrinol Metab 2010;5(5):653-62.
9.
Darmani NA, Zhao W, Ahmad B. The role of D2 and D3 dopamine receptors in the 
mediation of emesis in Cryptotis parva (the least shrew). J Neural Transm (Vienna) 
1999;106(11-12):1045-61.
10.
Kashyap P, Micci MA, Pasricha S, Pasricha PJ. The D2/D3 agonist PD128907 (R-(+)-
trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin- 9-ol) 
inhibits stimulated pyloric relaxation and spontaneous gastric emptying. Dig Dis Sci 
2009;54(1):57-62.
11.
Yoshikawa T, Yoshida N, Hosoki K. Involvement of dopamine D3 receptors in the area 
postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol 
1996;301(1-3):143-9.
12.
Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The 
abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and 
plasticity. Can J Physiol Pharmacol 1990;68(2):325-45.
13.
Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating 
symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the 
Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol 
Motil 2012;24(5):456-63, e215-6.
14.
Parkman HP, Hasler WL, Fisher RS, American Gastroenterological A. American 
Gastroenterological Association technical review on the diagnosis and treatment of 
gastroparesis. Gastroenterology 2004;127(5):1592-622.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 84 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
15.
Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy
and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, 
placebo-controlled study. Gastroenterology 2017;153(5):1240-50 e2.
16.
Anaparthy R, Pehlivanov N, Grady J, Yimei H, Pasricha PJ. Gastroparesis and 
gastroparesis-like syndrome: response to therapy and its predictors. Dig Dis Sci 
2009;54(5):1003-10.
17.
Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom 
in gastroparesis. Am J Gastroenterol 1999;94(4):1029-33.
18.
Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, et al. 
Development and validation of a patient-assessed gastroparesis symptom severity 
measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 
2003;18(1):141-50.
19.
Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, et al. 
Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient 
reported assessment of severity of gastroparesis symptoms. Qual Life Res 
2004;13(4):833-44.
20.
Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, Verbeke K, et al. Clinical trial: a 
randomized-controlled crossover study of intrapyloric injection of botulinum toxin in 
gastroparesis. Aliment Pharmacol Ther 2007;26(9):1251-8.
21.
Cassilly DW, Wang YR, Friedenberg FK, Nelson DB, Maurer AH, Parkman HP. 
Symptoms of gastroparesis: use of the gastroparesis cardinal symptom index in 
symptomatic patients referred for gastric emptying scintigraphy. Digestion 2008;78(2-
3):144-51.
22.
Ejskjaer N, Dimcevski G, Wo J, Hellstrom PM, Gormsen LC, Sarosiek I, et al. Safety and 
efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic 
gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil 
2010;22(10):1069-e281.
23.
Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the 
treatment of delayed gastric emptying. Am J Gastroenterol 2008;103(2):416-23.
24.
Khayyam U, Sachdeva P, Gomez J, Ramzan Z, Smith MS, Maurer AH, et al. Assessment 
of symptoms during gastric emptying scintigraphy to correlate symptoms to delayed 
gastric emptying. Neurogastroenterol Motil 2010;22(5):539-45.
25.
Maranki JL, Lytes V, Meilahn JE, Harbison S, Friedenberg FK, Fisher RS, et al. 
Predictive factors for clinical improvement with Enterra gastric electric stimulation 
treatment for refractory gastroparesis. Dig Dis Sci 2008;53(8):2072-8.
26.
Shin A, Camilleri M, Busciglio I, Burton D, Smith SA, Vella A, et al. The ghrelin agonist 
RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with 
type 1 diabetes mellitus. Clin Gastroenterol Hepatol 2013;11(11):1453-9 e4.
27.
Tack J, Rotondo A, Meulemans A, Thielemans L, Cools M. Randomized clinical trial: a 
controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms 
suggestive of gastroparesis. Neurogastroenterol Motil 2016;28(4):487-97.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 85 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
28.
Parkman HP, Yates K, Hasler WL, Nguyen L, Pasricha PJ, Snape WJ, et al. Similarities 
and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 
2011;9(12):1056-64; quiz e133-4.
29.
Hasler WL, Wilson LA, Parkman HP, Koch KL, Abell TL, Nguyen L, et al. Factors 
related to abdominal pain in gastroparesis: contrast to patients with predominant nausea 
and vomiting. Neurogastroenterol Motil 2013;25(5):427-38, e300-1.
30.
Benker G, Jaspers C, Hausler G, Reinwein D. Control of prolactin secretion. Klin 
Wochenschr 1990;68(23):1157-67.
31.
Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk 
Manag 2007;3(5):929-51.
32.
Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, 
and burden of premenstrual dysphoric disorder (PMS/PMDD). 
Psychoneuroendocrinology 2003;28 Suppl 3:1-23.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 86 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
CONFIDENTIAL
Appendix A
Schedule of Study Procedures
Screening
Treatment
Visit 1
Day -35 a
Visit 2 
Day -21 b
Visit 3 Day 
-14 c
Visit 4 
Randomization 
Visit (Day 1) d
Visit 5 
Week 4
Visit 6
Week 8
Visit 7 Week 
12/ End of 
Treatment
Early 
Termination e
Safety Follow-
up f
(30 Days 
After Last 
Dose)
Visit Window
-11 to +3 
days
±3 days
+3 days
±3 days
±3 days
±3 days
±5 days
Informed consent g
X
Inclusion/exclusion criteria
X
X
X
X
Demographics and medical 
history
X
Medication history
X
Physical examination including 
assessment of the extrapyramidal 
system h
X
X
X
X
X
X
Vital signs i
X
X
X
X
X
X
Height, weight, and BMI j
X
X
X
X
X
X
Concomitant medications 
X
X
X
X
X
X
X
X
X
Concurrent medical conditions
X
12-lead ECG k
X
X
X
X
X
X
TSH
X
HbA1c (DG only)
X
X
X
Finger stick glucose (only for 
DG subjects undergoing GEBT)
X 
Clinical laboratory evaluations l
X
X
X
X
X
X
Urine drug and alcohol screen
X
Pregnancy test (hCG) m
X
X
X
X
X
X
X n
FSH o
X
HIV
X
HBsAg, anti-HBcAb, and anti-
HCV
X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 87 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
CONFIDENTIAL
Screening
Treatment
Visit 1
Day -35 a
Visit 2 
Day -21 b
Visit 3 Day 
-14 c
Visit 4 
Randomization 
Visit (Day 1) d
Visit 5 
Week 4
Visit 6
Week 8
Visit 7 Week 
12/ End of 
Treatment
Early 
Termination e
Safety Follow-
up f
(30 Days 
After Last 
Dose)
Visit Window
-11 to +3 
days
±3 days
+3 days
±3 days
±3 days
±3 days
±5 days
Study drug dispensed
X
X
X
Study drug dosing p
X
X
X
X
GEBT q
X
Daily Study Diary r
X
X
X
X
X
X
PAGI-SYM 
X
X
X
X
X
SF12 
X
X
X
Clinician Symptom Severity 
Rating 
X
X
X
OTE Scale: subject 
X
X
OTE Scale: clinician 
X
X
PAGI-QOL 
X
X
X
X
X
CGI-S
X
X
X
X
X
CGI-I
X
X
PGI-S
X
X
X
X
X
PGI-C
X
X
Blood sample for DNA PGx s
X
Plasma samples for TAK-906 
PK t
X
X
X
X
X
Serum samples for prolactin u
X
X (if 
required) 
X (if 
required)
X
X
X
X
X
AE assessment v
X
X
X
X
X
X
X
X
X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 88 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
CONFIDENTIAL
Screening
Treatment
Visit 1
Day -35 a
Visit 2 
Day -21 b
Visit 3 Day 
-14 c
Visit 4 
Randomization 
Visit (Day 1) d
Visit 5 
Week 4
Visit 6
Week 8
Visit 7 Week 
12/ End of 
Treatment
Early 
Termination e
Safety Follow-
up f
(30 Days 
After Last 
Dose)
Visit Window
-11 to +3 
days
±3 days
+3 days
±3 days
±3 days
±3 days
±5 days
AE: adverse event; ANMS GCSI-DD: American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary; BMI: body mass index; CGI-I: 
Clinical Global Impression Scale–Global Improvement Scale; CGI-S: Clinical Global Impression Scale–Severity of Illness Scale, DG: diabetic gastroparesis; DNA: 
deoxyribonucleic acid; ECG: electrocardiogram; ePRO: electronic patient reported outcomes; FSH: follicle-stimulating hormone; GEBT: Gastric Emptying Breath Test; GCI-I: 
Clinical Global Impression Scale-Global Improvement Scale; CGI-S: Clinical Global Impression Scale- Severity of Illness Scale; HBcAb: hepatitis B core antibody; HBsAg: 
hepatitis B virus surface antigen; hCG: human chorionic gonadotropin; HCV: hepatitis C virus; HIV: human immunodeficiency; PAGI-QOL: Patient Assessment of Upper 
Gastrointestinal Disorders Quality-of-Life Index; PAGI-SYM: Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index; PGI-C: Patient Global 
Impression of Change; PGI-S: Patient Global Impression of Severity; PGx: pharmacogenomics; PK: pharmacokinetics; OTE: overall treatment effect; SAE: serious adverse event; 
SF12:Short Form-12 Health Survey; TSH: thyrotropin.
a Subjects will discontinue all medications to treat gastroparesis or the symptoms of gastroparesis. Treatment naïve subjects or subjects who have not been treated with prokinetics 
in the previous 2 weeks may proceed with Visit 2 after all laboratory results from Visit 1 have been evaluated. Subjects taking medications for gastroparesis that require washout
should return for Visit 2, 14 to 17 days after Visit 1. 
b Subjects requiring a washout period of their current gastroparesis medication(s) will use the 14+3 day window between Visit 1 and Visit 2. Treatment naïve subjects or subjects 
who have not been treated with prokinetics in the previous 2 weeks may return after receipt and evaluation of all Visit 1 study procedures (approximately 3 days).
c Subjects will complete Visit 3 once their GEBT results have been received and evaluated by the site (7±3 days from Visit 2). Subjects begin ANMS GCSI-DD.
d Subjects must be 80% compliant with the ePRO device for a minimum of 14 days between Visits 3 and 4.
e Subjects who withdraw prematurely will be seen for an early termination visit as soon as possible and will then be contacted for a follow-up approximately 30 days (30±5 days) 
after the last dose of study medication. These subjects will continue entering the Daily Symptom Diary until the early termination visit. 
f A safety follow-up phone call will be made approximately 30 days after last dose of study medication.
g Informed consent must be signed before any study-specific procedures are performed.
h All physical examinations (including assessment of the extrapyramidal system) are to be performed by the investigator, subinvestigator, or a qualified healthcare professional. 
Assessment of the extrapyramidal system should be performed by a healthcare professional qualified to perform this assessment using the guidance provided by Takeda. Subjects 
with any abnormalities will be referred for appropriate medical consultation and AEs should be reported as per AE reporting procedures provided in Section 10.0 of this protocol.
i Vital signs (eg, oral/tympanic/axillary temperature, respiration, pulse, and blood pressure) will be assessed at Visit 1 (Day -35), and predose at Visit 4 (Day 1), and onward at 
Visit 5 (Week 4), Visit 6 (Week 8), and Visit 7 (Week 12) on those visit days requiring study dosing, and at early termination. Vital signs should be measured after 5 minutes 
resting in the supine or semi-supine position and consistently for each subject. When the timing of the vital signs coincides with a blood collection, vital signs should be obtained 
before the nominal time of the blood collection and before the study medication is taken.
j Height and weight are measured, and BMI is calculated at initial screening visit only. Weight only is measured at subsequent visits. 
k Subject should have rested in supine or semisupine position for at least 5 minutes before ECG. When the timing of these measurements coincides with a blood collection, the 
ECG should be obtained before the nominal time of the blood collection. Triplicate tracings of ECGs should be performed. ECG will be assessed at Visit 1 (Day -35), and 
approximately 1 to 2 hours postdose at Visit 4 (Day 1), Visit 5 (Week 4), Visit 6 (Week 8), and Visit 7 (Week 12) on those visit days requiring study dosing, and at early 
termination.
l Clinical laboratory tests (chemistry, hematology) will be assessed at Visit 1 (Day -35), and predose at Visit 4 (Day 1), and onward at Visit 5 (Week 4), Visit 6 (Week 8), and Visit 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 89 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
CONFIDENTIAL
Screening
Treatment
Visit 1
Day -35 a
Visit 2 
Day -21 b
Visit 3 Day 
-14 c
Visit 4 
Randomization 
Visit (Day 1) d
Visit 5 
Week 4
Visit 6
Week 8
Visit 7 Week 
12/ End of 
Treatment
Early 
Termination e
Safety Follow-
up f
(30 Days 
After Last 
Dose)
Visit Window
-11 to +3 
days
±3 days
+3 days
±3 days
±3 days
±3 days
±5 days
7 (Week 12) on those visit days requiring study dosing, and at early termination. Clinical laboratory tests (chemistry, hematology) to be collected under fasted conditions after 
screening. Early termination visits will be fasting if visit circumstances allow. Urinalysis to be performed at Visit 1 only. 
m For women of child-bearing potential. Must be confirmed negative by serum hCG at screening and by urine hCG before medication dispensing at randomization and study visits.
n Onsite end of study pregnancy test must be performed for subjects with menstrual irregularities, variable menstrual cycle length by more than ±5 days or missed last menstrual 
period by more than 5 days.
o FSH level will be obtained for female subjects at screening if they are postmenopausal by history (eg, defined as at least 1 year since last regular menses with an FSH >40 IU/mL 
or at least 5 years since last regular menses, confirmed before any study medication is implemented) and not surgically sterile. The FSH result must be >40 IU/mL for the subject 
to be permitted not to use adequate contraception.
p Subjects will take their first dose of study medication at the randomization visit. Subjects will take their morning dose in clinic at Visits 5, 6, and 7. Subjects will be instructed to 
take medication 1 dose in the morning approximately 1 hour before the first meal of the day and another dose in the evening approximately 1 hour before the main last meal of the 
day, at a regular dose interval. If a subject missed any individual dose, they may take the dose within a 4-hour window from the normal expected dosage time. If not taken within a 
4-hour window, they should not take that dose and proceed to take the normal dose at the next scheduled time point.
q A 4-hour 13C-Spirulina GEBT, which is preceded by test meal. An 8-hour fast is required prior to the GEBT test meal. GEBT is not required for subjects who have confirmed 
delayed gastric emptying by an accepted diagnostic method (scintigraphy, GEBT, or wireless motility capsule) that is documented in the subject’s medical records prior to 
screening. 
r The Daily Study Diary is inclusive of: Daily Symptom Diary (including ANMS-GCSI-DD plus bloating severity scale), daily dosing, and meal time recordings, and capture of 
rescue medication use. Compliance with the daily completion of the Daily Symptom Diary, defined ≥80% diary completions, from the 2-week symptom assessment period (Day -
14 to randomization; +3-day window). Diary should be completed daily at approximately the same time each day (evening) in e-format with the ePRO device. 
s The sample for PGx may be drawn before dosing on Day 1.
t PK: Subjects will be asked to take their morning dose of study medication at the clinic when PK samples are being collected. The blood samples for PK analysis will collected on 
Day 1, Weeks 4, 8, 12 at the following time-points: Day 1: predose sample, Week 4: predose and 1 postdose sample at 0.5-1 h window, Week 8: predose and 1 postdose sample at 
1-3 h window and Week 12: predose and 2 postdose samples at 0.5-1 h and 2-4 h window or immediately before leaving the clinic, respectively. One blood sample will be 
collected at early termination. The actual date and times of all PK blood draws will be recorded for each subject on the eCRFs. The actual dates and times of the dose 
administration in the clinic should be recorded. PK sampling may be performed during unscheduled visits.
u Samples for prolactin measurement to be collected and analyzed as part of clinical laboratory evaluations at Visit 1, at scheduled Visits 4 to 7, and any necessary unscheduled 
visit. A high screening prolactin level at screening visit 1, which is considered to be due to stress of venipuncture, chest wall stimulation, or other physiological causes, may be 
retested at Visits 2 or 3. Then, if prolactin levels are normal or falling within the allowable range, the subjects may be enrolled in the study. A subset of samples may be used for 
prolactin assay bridging studies as needed. As TAK-906 may increase serum prolactin levels, investigators will be blinded to prolactin measurements beginning with Visit 4. In 
cases where investigators request unblinding of the study treatment or serum prolactin level, the subject must be withdrawn from the study immediately.
v SAEs will be collected from the time the subject signs an informed consent form through the duration of the study up to 30 days post–end of treatment. All nonserious AEs, in 
addition to SAEs, are collected from the first dosing through 30 days post–end of treatment.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 90 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix B
Hepatic Function Categories Based on Child-Pugh Score
Classification of clinical severity:
Mild (Class A): total score 5-6 points.
Moderate (Class B): total score 7-9 points.
Severe (Class C): total score 10-15 points.
Assessment Parameters
Points Scored for Observed Findings
1 point
2 points
3 points
Encephalopathy grade a
none
1 or 2
3 or 4
Ascites
absence
slight
moderate
Serum bilirubin, mg/dL
<2
2 to 3
>3
Serum albumin, g/dL
>3.5
2.8 to 3.5
<2.8
INR
<1.7
1.7-2.3
>2.3
Source: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
INR: international normalized ratio.
a Grade 0: normal consciousness, personality, neurological examination, electroencephalogram.
Grade 1: Restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cycles per second (cps) waves.
Grade 2: Lethargic, time-disoriented, inappropriate, asterixis, ataxia, slow triphasic waves.
Grade 3: Somnolent, stuporous, place-disoriented, hyperactive reflexes, rigidity, slower waves.
Grade 4: Unarousable coma, no personality/behavior, decerebrate, slow 2-3 cps delta activity.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 91 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix C
Guidance for Assessment of the Extrapyramidal System 
Any clinically relevant findings in this assessment should be reported and managed as per protocol 
Section 10.0 of this protocol.
Posture 
For example, abnormalities in sitting, standing or walking posture 
Gait
For example, shuffling, festinating gait with reduced arm swing, difficulty starting, stopping, and turning.
Speech 
For example, monotonous, low volume, lacks normal rhythm, soft, quiet, and hesitant speech or 
hyperkinetic dysarthria
Face
For example, expressionless, unblinking face, drooling, titubation, blepharoclonus, positive glabellar tap 
reflex), puckering and smacking. 
Jaw 
For example, biting, clenching, chewing, mouth opening and lateral movement.
Tongue
For example, abnormalities in darting in and out of mouth and tongue thrusting.
Abnormal movements in upper and lower limbs 
Abnormal movements in neck, shoulders and hips 
For example, rocking, twisting, squirming and pelvic gyrations
Coordination in upper and lower limbs 
For example, abnormal coordination using rapid alternating movements or finger-nose test, abnormal 
coordination using foot tapping or heel–shin test
Tremor 
For example, pill-rolling flexion at the thumb and forefinger. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 92 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix D
Schedule of Questionnaire Assessments
Instrument
Administered a
Estimated Subject Burden 
(Average Time to Complete)
Daily Symptom Diary
Daily (evening)
1 minute
PAGI-SYM
At Visit 4 (predose) to capture baseline 
values and thereafter at each scheduled study 
visit
5 minutes
Clinician Symptom 
Severity Rating Form
At Visit 4 (predose) to capture baseline 
values and at Visit 7 or early termination visit
NA it is clinician reported
OTE rated by the 
subject
At Visit 7 or early termination visit
1 minute
OTE rated by clinician
At Visit 7 or early termination visit
NA it is clinician reported
SF12
At Visit 4 (predose) to capture baseline 
values and at Visit 7
4 minutes
PAGI QOL
At Visit 4 (predose) to capture baseline 
values and thereafter at each scheduled study 
visit
7 minutes
CGI-S
At Visit 4 (predose) to capture baseline 
values and thereafter at each scheduled study 
visit
NA
CGI-I
At Visit 7 or early termination visit
NA
PGI-S
At Visit 4 (predose) to capture baseline 
values and thereafter at each scheduled study 
visit
1 minute
PGI-C
At Visit 7 or early termination visit
1 minute
ANMS GCSI-DD: American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom 
Index-Daily Diary; CGI-I: Clinical Global Impression Scale–Global Improvement Scale; CGI-S: Clinical Global 
Impression Scale–Severity of Illness Scale, NA: not applicable; OTE: overall treatment effect; PAGI-QOL: 
Patient Assessment of Upper Gastrointestinal Disorders Quality-of-Life Index; PAGI-SYM: Patient Assessment 
of Upper Gastrointestinal Disorders-Symptom Severity Index; PGI-C: Patient Global Impression of Change; 
PGI-S: Patient Global Impression of Severity; SF12: Short Form-12 Health Survey.
a For subjects who withdraw prematurely, ANMS GCSI-DD will be completed daily until the early termination 
visit and all the other questionnaires will be completed at the early termination visit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 93 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix E
Patient Global Impression Scales
New PGI-S Scale replacing the existing PGI-S scale:
Please choose the response below that best describes the overall severity of your gastroparesis 
symptoms over the past 7 days:
□ None
□ Mild
□ Moderate
□ Severe
PGI-C scale replacing the existing PGI-I scale: 
Please choose the response below that best describes the overall change in your gastroparesis 
symptoms since you started taking the study medication:
□ Much better
□ A little better
□ No change
□ A little worse
□ Much worse
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 94 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix F
Responsibilities of the Investigator
Clinical research studies sponsored by the sponsor are subject to ICH GCP and all the applicable 
local laws and regulations. The responsibilities imposed on investigators by the FDA are 
summarized in the “Statement of Investigator” (Form FDA 1572), which must be completed and 
signed before the investigator may participate in this study.
The investigator agrees to assume the following responsibilities by signing a Form FDA 1572:
1. Conduct the study in accordance with the protocol.
2. Personally conduct or supervise the staff who will assist in the protocol.
3. Ensure that study related procedures, including study specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of 
written approval from relevant governing bodies/authorities.
4. Ensure that all colleagues and employees assisting in the conduct of the study are informed 
of these obligations.
5. Secure prior approval of the study and any changes by an appropriate IRB/IEC that conform 
to 21 Code of Federal Regulations (CFR) Part 56, ICH, and local regulatory requirements.
6. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and 
approval of the protocol. Promptly report to the IRB/IEC all changes in research activity and 
all anticipated risks to subjects. Make at least yearly reports on the progress of the study to 
the IRB/IEC and issue a final report within 3 months of study completion.
7. Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regulations, are met.
8. Obtain valid informed consent from each subject who participates in the study and document 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
version approved by the IRB/IEC. Each informed consent form should contain a subject 
authorization section that describes the uses and disclosures of a subject’s personal 
information (including personal health information) that will take place in connection with 
the study. If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
9. Prepare and maintain adequate case histories of all persons entered into the study, including 
eCRFs, hospital records, laboratory results, etc., and maintain these data for a minimum of 
2 years following notification by the sponsor that all investigations have been discontinued or 
that the regulatory authority has approved the marketing application. The investigator should 
contact and receive written approval from the sponsor before disposing of any such 
documents.
10. Allow possible inspection and copying by the regulatory authority of GCP-specified essential 
documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 95 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
11. Maintain current records of the receipt, administration, and disposition of sponsor-supplied 
drugs, and return all unused sponsor-supplied drugs to the sponsor. This responsibility lies on 
the appropriate individual, designated by the site in Japan.
12. Report adverse reactions to the sponsor promptly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 96 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix G
Elements of the Subject Informed Consent
In seeking informed consent, the following information shall be provided to each subject:
1. A statement that the study involves research.
2. An explanation of the purposes of the research.
3. The expected duration of the subject’s participation.
4. A description of the procedures to be followed, including invasive procedures.
5. The identification of any procedures that are experimental.
6. The estimated number of subjects involved in the study.
7. A description of the subject’s responsibilities.
8. A description of the conduct of the study.
9. A statement describing the treatment(s) and the probability for random assignment to each 
treatment.
10. A description of the possible side effects of the treatment that the subject may receive.
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
12. A description of any benefits to the subject or to others that reasonably may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might 
be advantageous to the subject and their important potential risks and benefits.
14. A statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), 
IRB/IEC, and the monitor may inspect the records. By signing a written informed consent 
form, the subject or the subject’s legally acceptable representative is authorizing such access.
15. For research involving more than minimal risk, an explanation as to whether any 
compensation and an explanation as to whether any medical treatments are available if injury 
occurs and, if so, what they consist of or where further information may be obtained.
16. The anticipated prorated payment(s), if any, to the subject for participating in the study.
17. The anticipated expenses, if any, to the subject for participating in the study.
18. An explanation of whom to contact for answers to pertinent questions about the research 
(investigator), subject’s rights, and IRB/IEC and whom to contact in the event of a research-
related injury to the subject.
19. A statement that participation is voluntary, that refusal to participate will involve no penalty 
or loss of benefits to which the subject otherwise is entitled, and that the subject or the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 97 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
subject’s legally acceptable representative may discontinue participation at any time without 
penalty or loss of benefits to which the subject is otherwise entitled.
20. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by the subject.
21. A statement that the subject or the subject’s legally acceptable representative will be 
informed in a timely manner if information becomes available that may be relevant to the 
subject’s willingness to continue participation in the study.
22. A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the sponsor to do so.
23. The foreseeable circumstances or reasons under which the subject’s participation in the study 
may be terminated.
24. A written subject authorization (either contained within the informed consent form or 
provided as a separate document) describing to the subject the contemplated and permissible 
uses and disclosures of the subject’s personal information (including personal health 
information) for purposes of conducting the study. The subject authorization must contain the 
following statements regarding the uses and disclosures of the subject’s personal 
information:
a) that personal information (including personal health information) may be processed by or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assisting Takeda, its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, Takeda will make every effort to keep your personal information confidential, 
and your name will not be disclosed outside the clinic unless required by law;
c) that personal information (including personal health information) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safety and effectiveness of the study drug(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) on withdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and
e) that the subject’s identity will remain confidential if study results are published.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 98 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
25. Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually active must use highly effective contraception (as defined in the informed 
consent) from screening throughout the duration of the study, and for 35 days after last dose. 
Regular pregnancy tests will be performed throughout the study for all female subjects of 
childbearing potential. If a subject is found to be pregnant during study, study drug will be 
discontinued, and the investigator will offer the subject the choice to receive unblinded 
treatment information.
26. Male subjects must use highly effective contraception (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study, and for 95 days after 
last dose. If the partner or wife of the subject is found to be pregnant during the study, the 
investigator will offer the subject the choice to receive unblinded treatment information.
27. A statement that clinical trial information from this trial will be publicly disclosed in a 
publicly accessible website, such as ClinicalTrials.gov.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 99 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix H
Investigator Consent to Use of Personal Information
Takeda will collect and retain personal information of investigator, including his or her name, 
address, and other personally identifiable information. In addition, investigator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, US, and Japan), including the following:

Takeda, its affiliates, and licensing partners.

Business partners assisting Takeda, its affiliates, and licensing partners.

Regulatory agencies and other health authorities.

IRBs and IECs.
Investigator’s personal information may be retained, processed, and transferred by Takeda and 
these other parties for research purposes including the following:

Assessment of the suitability of investigator for the study and/or other clinical studies.

Management, monitoring, inspection, and audit of the study.

Analysis, review, and verification of the study results.

Safety reporting and pharmacovigilance relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other medications used in other clinical studies that may 
contain the same chemical compound present in the study drug.

Inspections and investigations by regulatory authorities relating to the study.

Self-inspection and internal audit within Takeda, its affiliates, and licensing partners.

Archiving and audit of study records.

Posting investigator site contact information, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Investigator’s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in investigator’s 
own country.
Investigator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 100 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix I
ANMS GCSI-DD
This is to illustrate the contents of ANMS GCSI-DD question items and does not reflect the 
exact appearance (such as instructions) in the actual administration mode.
Participant Number: ____________________
Date: _______________
Time: _________
ANMS GASTROPARESIS CARDINAL SYMPTOM INDEX – DAILY DIARY
Instructions: These questions ask about symptoms you may have each day. Please complete the daily diary at about 
the same time every evening.
For each symptom listed below, please mark with an X the box that best describes the worst severity of each 
symptom during the past 24 hours. Please be sure to answer each question.
None
Mild
Moderate
Severe
Very
Severe
1.
Nausea (feeling sick to your stomach as 
if you were going to vomit or throw up)
□
□
□
□
□
2.
Not able to finish a normal-sized meal 
(for a healthy person)
□
□
□
□
□
3.
Feeling excessively full after meals
□
□
□
□
□
4.
Upper abdominal pain (above the navel)
□
□
□
□
□
The next question asks you to record the number of times vomiting occurred in the last 24 hours. 
Please record the number of vomits (throwing up with food or liquid coming out) that occurred in 
the last 24 hours. Record zero if you have not vomited during the past 24 hours. If you vomited, 
write down the number of all vomits. If you vomited once, record one. If you vomited 3 times 
during the day, record 3. If you vomited 3 times, whether it was during the same trip to the 
bathroom or 3 separate trips, record 3 as the number of episodes of vomiting.
5. During the past 24 hours, how many episodes of vomiting did you have? ____
None
Mild
Moderate
Severe
Very
Severe
6.
In thinking about your gastroparesis 
disorder, what was the overall severity of 
your gastroparesis symptoms today 
(during the past 24 hours)?
□
□
□
□
□
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 101 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix J
Bloating Severity Scale
This is to illustrate the contents of the Bloating Severity Scale and does not reflect the exact 
appearance (such as instructions) in the actual administration mode.
DAILY DIARY
Instructions: These questions ask about bloating severity you may have each day. Please complete the Bloating 
Severity Scale at about the same time every evening.
For the bloating symptom below, please mark with an X the box that best describes the worst severity of bloating 
during the past 24 hours. Please be sure to answer each question.
None
Mild
Moderate
Severe
Very
Severe
Bloating (feeling like you need to loosen 
your clothes)
□
□
□
□
□
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 102 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Appendix K
Protocol History
Date
Amendment Number
Amendment Type (for regional 
Europe purposes only)
Region
13 July 2020
Amendment 8
Substantial
Global
27 August 2019
Amendment 7
Nonsubstantial
Japan
08 August 2019
Amendment 6
Substantial
Global
23 May 2019
Amendment 5
Nonsubstantial
Belgium
15 November 2018
Amendment 4
Nonsubstantial
Japan
26 September 2018
Amendment 3
Nonsubstantial
Japan
06 August 2018
Amendment 2
Substantial
Global
16 July 2018
Amendment 1
Substantial
Global
23 March 2018
Initial protocol
Not applicable
Global
Protocol Amendment 7 was a local amendment and is not applicable to the global protocol.
Rationale for Amendment 6
This document describes the changes from the protocol incorporating Amendment No. 6. 
Through feedback from investigators, the Sponsor has determined the need to revise the list of 
prohibited medications, add a rationale for the use of ondansetron and promethazine as rescue 
medications, clarify rescue medication use, clarify the estimated glomerular filtration rate 
(eGFR) eligibility criteria, clarify Gastric Emptying Breath Test (GEBT) and eligibility for 
retesting, revise the interim analysis adding a futility analysis, and clarify the duties and 
responsibilities of the Independent Data Monitoring Committee (IDMC).
Minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of 
the study are included for clarification and administrative purposes only.
Changes in Amendment 6:
Updated the signatories in Section 1.2.
1.
Updated and revised Section 4.2.3 Pharmacokinetics and Product Metabolism with new 
2.
metabolism data.
Revised Section 4.3.1 Clinical Pharmacology to show effects of eGFR on exposure of 
3.
TAK-906 and the effects of coadministration of esomeprazole on the area under the 
concentration-time curve from time 0 to infinity (AUC∞) and maximum observed 
concentration (Cmax) of TAK-906.
Revised wording in Section 5.2.4 Additional Endpoints regarding change from baseline to 
4.
Week 12 of the treatment period in the American Neurogastroenterology and Motility 
Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 103 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Deleted the requirement for medication to be taken “on an empty stomach (at least 2 hours of 
5.
fasting except for water); Section 6.1 Study Design.
Revised the interim analysis by adding a futility analysis; Section 6.1 Study Design.
6.
Clarified the use of rescue medication (Section 6.2.3 Rationale for Placebo).
7.
Revised exclusion Criterion No. 26 to define prolonged QT interval with Fridericia 
8.
correction method (QTcF) as ≥450 msec and to exclude subjects with risk factors for QT 
interval prolongation.
Clarified the exclusion Criterion No. 30 for significant menstrual abnormalities such as 
9.
amenorrhea or oligomenorrhea.
Revised exclusion Criterion No. 31 to exclude subjects who have any signs/symptoms or 
10.
history of extrapyramidal system disease or history of suicide attempt.
Changed exclusion Criterion No. 37 to exclude subjects with renal impairment, defined as a 
11.
lower limit of eGFR <30 mL/min at screening visit and deleted the formulas for calculating 
eGFR in various subject populations.
Removed proton pump inhibitors and histamine H2 receptor antagonists, and CYP2C8 strong 
12.
inhibitors and inducers as excluded medication and clarified the remaining list of excluded 
medication (Section 7.3 Excluded Medications).
Clarified the conditions for use of certain permitted concomitant medications.
13.
Removed the stipulation that subjects who had taken <80% of study drug in the previous 
14.
4-week period would be withdrawn from the study because of noncompliance with study 
medication (Section 7.5 Criteria for Discontinuation or Withdrawal of a Subject).
Clarified the use of rescue medication and defined the preferred rescue medication. 
15.
(Section 8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling).
Remove the requirement for confirmed menses in the month before first dosing (no delayed 
16.
menses; Section 9.1.11.3 Definitions and Procedures for Contraception and Pregnancy 
Avoidance).
Clarified and defined gastric emptying by GEBT and clarified when retesting could be done 
17.
(Section 9.1.18.1 GEBT).
Revised Section 9.2 Monitoring Subject Treatment Compliance to add the criteria that
18.
subjects who are <80% compliant or who missed ≥6 consecutive doses since the last study 
visit will be re-educated about the importance of being consistent with their dosing as per the 
protocol.
Clarified duties of IDMC (Section 11.1 IDMC).
19.
Clarified that concomitant medication information would be collected during the safety 
20.
follow-up period (Appendix A Schedule of Study Procedures).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 104 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Rationale for Amendment 5
This document describes the changes from the protocol incorporating Amendment No. 2. The 
primary reason for this Amendment 5 for Belgium is to update the exclusion criteria for 
clarification, in response to the Belgian Ethics Committee’s (ECʼs) recommendations.
Minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of 
the study are included for clarification and administrative purposes only.
Changes in Amendment 5
Updated exclusion Criterion No. 31 in response to the Belgian ECʼs recommendations.
1.
Protocol Amendment 4 was a local amendment and is not applicable to the global protocol.
Protocol Amendment 3 was a local amendment and is not applicable to the global protocol.
Rationale for Amendment 2
This document describes the changes in reference to the protocol incorporating Amendment 
No. 1. The primary reason for this amendment is. 
Minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of 
the study are included for clarification and administrative purposes only.
Changes in Amendment 2:
Updated the secondary endpoints.
1.
Updated the biomarkers to be analyzed.
2.
Updated and clarified the Schedule of Study Procedures, including timing and procedures 
3.
performed.
Clarified the clinical laboratory tests performed.
4.
Clarified the timing, collection, and reporting of adverse events, serious adverse events, and 
5.
adverse events of interest.
Clarified the inclusion criterion.
6.
Rationale for Amendment 1
This document describes the changes in reference to the protocol incorporating Amendment 
No. 1. The primary reason for this amendment is. 
Minor grammatical, editorial, formatting, and administrative changes not affecting the conduct of 
the study are included for clarification and administrative purposes only.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906
Study No. TAK-906-2002
Page 105 of 105
Protocol Incorporating Amendment No. 8
13 July 2020
Changes in Amendment 1:
Update nonclinical information with most recent toxicology data.
1.
Update the biomarkers to be analyzed and rationales.
2.
Clarify the objective and endpoint for the Gastric Emptying Breath Test (GEBT).
3.
Clarify that the bloating severity scale is not part of the American Neurogastroenterology and 
4.
Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary (ANMS GCSI-DD), 
but will be collected in the Daily Symptom Diary.
Clarify the criteria for use of rescue medication for nausea and vomiting.
5.
Update the subject eligibility criteria.
6.
Update the list of Excluded Medications.
7.
Clarify the storage information for the study drug.
8.
Clarify timing of GEBT relative to dosing of study drug.
9.
Update the safety section with guidance to investigators for management of extrapyramidal 
10.
symptoms and central nervous system (CNS)/neuropsychiatric adverse events.
Remove use of paper serious adverse event (SAE) reporting for Japan.
11.
Clarify the primary efficacy analysis.
12.
Update and clarify the Schedule of Study Procedures.
13.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use



(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GGIDG
䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢺䢢䢯䢢䣃䢢䣏䣷䣮䣶䣫䣥䣧䣰䣶䣧䣴䢮䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢮䢢䣒䣣䣴䣣䣮䣮䣧䣮䢯䣉䣴䣱䣷䣲䢮䢢䣒䣪䣣䣵䣧䢢䢴䣤䢢䣕䣶䣷䣦䣻
䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣇䣨䣨䣫䣥䣣䣥䣻䢢䣣䣰䣦䢢䣕䣣䣨䣧䣶䣻䢢䣱䣨䢢䣖䣹䣫䣥䣧䢯䣆䣣䣫䣮䣻䢢䣑䣴䣣䣮䢢䣃䣦䣯䣫䣰䣫䣵䣶䣴䣣䣶䣫䣱䣰䢢䣱䣨䢢䣣䢢䣒䣧䣴䣫䣲䣪䣧䣴䣣䣮䣮䣻䢢䣃䣥䣶䣫䣰䣩䢢䣆䣱䣲䣣䣯䣫䣰䣧
䣔䣧䣥䣧䣲䣶䣱䣴䢢䣆䢴䢱䣆䢵䢢䣃䣰䣶䣣䣩䣱䣰䣫䣵䣶䢮䢢䣖䣃䣍䢯䢻䢲䢸䢢䣨䣱䣴䢢䣶䣪䣧䢢䣖䣴䣧䣣䣶䣯䣧䣰䣶䢢䣱䣨䢢䣃䣦䣷䣮䣶䢢䣕䣷䣤䣬䣧䣥䣶䣵䢢䣙䣫䣶䣪䢢䣕䣻䣯䣲䣶䣱䣯䣣䣶䣫䣥䢢䣋䣦䣫䣱䣲䣣䣶䣪䣫䣥䢢䣱䣴
䣆䣫䣣䣤䣧䣶䣫䣥䢢䣉䣣䣵䣶䣴䣱䣲䣣䣴䣧䣵䣫䣵
&OLQLFDO6FLHQFH$SSURYDO
-XO87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO
-XO87&
%LRVWDWLVWLFV$SSURYDO
-XO87&
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e Te
ate 
te
ble T
HH:mm ‘U
H:mm
Ter
ble
87&
87&


-XO
XO

SAP_001.pdf: 


Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b 
Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally 
Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects 
with Symptomatic Idiopathic or Diabetic Gastroparesis
NCT Number: NCT03544229
SAP Approve Date: 02 August 2021
Certain information within this Statistical Analysis Plan has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information 
or company confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.


1.0
TELINE
STATISTICAL ANALYSIS PLAN
STUDY NUMBER: TAK-906-2002
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study
to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting 
Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects with
Symptomatic Idiopathic or Diabetic Gastroparesis
PHASE 2b
Version: Final
Date: 02 August 2021
Prepared by:
Based on:
Protocol Version: Amendment 08
Protocol Date: 13 July 2020
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
d, Parall
Paral
ministra
inistr
he Trea
he Trea
etetic Ga
ic G
2b
on: Fina
on: Fin
 02 Aug
02 Au
Protoco
Proto
Pro
Pr
For Non-Commerci
perty


TAK-906-2002
Page 2 of 44
Statistical Analysis Plan
02 August 2021
1.1
Approval Signatures
Electronic signatures can be found on the last page of this document. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 3 of 44
Statistical Analysis Plan
02 August 2021
2.0
TABLE OF CONTENTS
1.0
TELINE ..........................................................................................................................1
1.1
Approval Signatures ..................................................................................................2
2.0
TABLE OF CONTENTS.................................................................................................3
List of In-Text Tables............................................................................................................4
List of In-Text Figures...........................................................................................................4
3.0
LIST OF ABBREVIATIONS..........................................................................................5
4.0
OBJECTIVES .................................................................................................................7
4.1
Primary Objectives ....................................................................................................7
4.2
Secondary Objectives.................................................................................................7
4.3
Additional Objectives ................................................................................................7
4.4
Study Design .............................................................................................................7
5.0
ANALYSIS ENDPOINTS...............................................................................................9
5.1
Primary Endpoint.......................................................................................................9
5.2
Secondary Endpoints .................................................................................................9
5.3
Safety and Tolerability Endpoints ............................................................................10
5.4
Additional Endpoints ...............................................................................................10
6.0
DETERMINATION OF SAMPLE SIZE.......................................................................11
7.0
METHODS OF ANALYSIS AND PRESENTATION...................................................11
7.1
General Principles....................................................................................................11
7.1.1
Definition of Study Day, Baseline and Study Visit Windows...........................13
7.1.2
Grouping of Centers ........................................................................................14
7.2
Analysis Sets ...........................................................................................................15
7.3
Disposition of Subjects ............................................................................................16
7.4
Demographic and Other Baseline Characteristics.....................................................16
7.5
Medical History and Concurrent Medical Conditions...............................................17
7.6
Medication History and Concomitant Medications...................................................17
7.7
Study Drug Exposure and Compliance.....................................................................18
7.8
Efficacy Analysis.....................................................................................................19
7.8.1
Endpoints Derivation based on ANMS GCSI-DD Daily Scores .......................21
7.8.2
Primary Efficacy Endpoint...............................................................................22
7.8.3
Secondary Efficacy Endpoints .........................................................................24
7.8.4
Additional Efficacy Endpoints.........................................................................26
7.8.5
Missing Data ...................................................................................................28
7.9
Pharmacokinetic/Pharmacodynamic Analysis ..........................................................28
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 4 of 44
Statistical Analysis Plan
02 August 2021
7.9.1
Pharmacokinetic Analysis................................................................................28
7.9.2
Pharmacodynamic Analysis.............................................................................28
7.10
Other Outcomes.......................................................................................................28
7.11
Safety Analysis........................................................................................................29
7.11.1
Adverse Events................................................................................................29
7.11.2
Clinical Laboratory Evaluations.......................................................................31
7.11.3
Vital Signs and Weight ....................................................................................32
7.11.4
12-Lead ECGs.................................................................................................33
7.11.5
Other Observations Related to Safety...............................................................34
7.12
Interim Analysis ......................................................................................................34
7.13
Multiplicity Adjustments .........................................................................................34
7.14
Changes in the Statistical Analysis Plan...................................................................34
8.0
REFERENCES..............................................................................................................36
LIST OF IN-TEXT TABLES
Table 7.a 
Visit Windows ...................................................................................................14
Table 7.b 
Primary, Secondary and Additional Efficacy Endpoints .....................................19
Table 7.c 
Categories of Abnormal Vital Signs Values .......................................................33
Table 7.d 
Categories of Abnormal ECG Values.................................................................34
LIST OF IN-TEXT FIGURES
Figure 4.a 
Schematic of Study Design ..................................................................................9
LIST OF APPENDICES
Appendix A
Numeric Conversions of PRO data.....................................................................38
Appendix B
Criteria for Markedly Abnormal Values for Lab Parameters...............................39
Appendix C
Criteria for Markedly Abnormal Values for Vital Signs......................................40
Appendix D
Criteria for Markedly Abnormal Values for the 12-Lead ECG Parameters..........41
Appendix E
Details for Pattern Mixture.................................................................................42
Appendix F
Convention for Missing dates for Adverse Events/Concomitant 
Medication/Procedures.......................................................................................43
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 5 of 44
Statistical Analysis Plan
02 August 2021
3.0
LIST OF ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
ANMS GCSI-DD
American Neurogastroenterology and Motility Society Gastroparesis Cardinal 
Symptom Index-Daily Diary 
ANCOVA
analysis of covariance
ANOVA
analysis of variance
AST
aspartate aminotransferase
BID
twice daily
BLQ
below the limit of quantification
BMI
body mass index
BUN
blood urea nitrogen
CCK
Cholecystokinin
CGI-I
Clinical Global Impression Scale–Global Improvement Scale
CGI-S
Clinical Global Impression Scale–Severity of Illness Scale
CI
confidence interval
Ctrough
observed concentration at the end of a dosing interval
CPAP
Clinical Pharmacology Analysis Plan
CRP
C-reactive protein
CSSR
clinician symptom severity rating
DA
dopamine 
DG
diabetic gastroparesis
ECG
electrocardiogram
eCRF
electronic case report form
eGFR
estimated glomerular filtration rate
ePRO
electronic patient reported outcomes
EPS
extrapyramidal symptoms
FAS
full analysis set
GE
gastric emptying
GEBT
gastric emptying breath test
GGT
γ-glutamyl transferase
GI
Gastrointestinal
GIP
glucose-dependent insulinotropic polypeptide 
GP
Gastroparesis
HbA1c
glycosylated hemoglobin
IA
Interim analysis
ICF
Informed Consent Form
ICH
International Conference on Harmonisation
IDMC
Independent Data Monitoring Committee
IG
idiopathic gastroparesis
IVRS
Interactive Voice Response System
LDH
lactate dehydrogenase
LLN
lower limit of normal
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 6 of 44
Statistical Analysis Plan
02 August 2021
LOCF
last observation carried forward
LS
least squares
MAR
missing at random
MAV
markedly abnormal value
MCS
Mental Component Summary
MedDRA
Medical Dictionary for Regulatory Activities
MI
Multiple Imputation
MMRM
mixed model for repeated measures
MNAR
missing not at random
OC
observed case
OTE
Overall Treatment Effect
PAGI-QoL
Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life Index
PAGI-SYM
Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index
PCS
Physical Component Summary
PD
pharmacodynamics
PGI-I
Patient Global Impression of Improvement
PGI-S
Patient Global Impression of Severity
PGx
pharmacogenomics
PK
pharmacokinetics
PO
oral administration or orally
PRO
patient-reported outcome
PT
preferred term
PTE
pretreatment events
PYY
Peptide YY
QOL
quality-of-life
QTcF
QT interval with Fridericia correction method
RBC
red blood cell
SAE
serious adverse event
SAP
statistical analysis plan
SD
standard deviation
SDB
standard database
SE
Standard error
SF12
Short Form-12 Health Survey
SOC
system organ class
TEAE
treatment-emergent adverse event
TLGs
tables, listings, and graphs
ULN
upper limit of normal
WBC
white blood cell
WHODrug
World Health Organization Drug Dictionary
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 7 of 44
Statistical Analysis Plan
02 August 2021
4.0
OBJECTIVES
4.1
Primary Objectives
To assess the efficacy of treatment with various dose levels of TAK-906 in adult subjects with 
gastroparesis compared with placebo during the 12 weeks of treatment.
4.2
Secondary Objectives
To evaluate the safety and tolerability of TAK-906 doses compared with placebo during the 12 
weeks of treatment.
4.3
Additional Objectives

To evaluate the PK of TAK-906 in subjects with gastroparesis. 

To evaluate the effect of TAK-906 on quality of life compared with placebo.

To evaluate the potential relationship between changes in C-reactive protein (CRP), glucose-
dependent insulinotropic peptide (GIP), and peptide tyrosine tyrosine (PYY) and clinical and 
motility responses to TAK-906.

To evaluate the effect of TAK-906 on Gastric Emptying Breath Test (GEBT).
4.4
Study Design
This is a global multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 
2b study to evaluate the efficacy and safety of BID PO capsule administration of a peripherally 
acting DA receptor D2/D3 antagonist, TAK-906, in adult male and female subjects aged 18 to 85 
years, inclusive, with symptomatic IG or DG. Gastroparesis is a disorder of the stomach 
characterized by delayed gastric emptying, in the absence of mechanical obstruction.
The study is designed to characterize the dose-response relationship to support dose selection for 
evaluation of subjects to be enrolled in the planned phase 3 studies. 
There was a substantial protocol amendment after the COVID-19 pandemic (Protocol 
Amendment 8, 13 July 2020), where 
1) the 5 mg arm dropped 
2) modifications were made in data collection to alleviate site burden and based on agency 
recommendations. 
Subjects will attend the study site for a screening/consent visit (Visit 1, Day -35), when their 
consent will be obtained, and general eligibility to participate in the study will be reviewed. After 
signing the informed consent form, subjects will have a blood sample taken to assess their 
laboratory values. Subjects will discontinue all excluded medications and return to the site 3 to 
17 days later to perform a 4-hour C-Spirulina GEBT (Visit 2, if required). 
In Protocol Amendment 8, subjects who have confirmed of delayed gastric emptying confirmed 
by an accepted diagnostic test method (ie, scintigraphy, GEBT, or wireless motility capsule) that 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 8 of 44
Statistical Analysis Plan
02 August 2021
is documented in the subject’s medical records prior to screening, are not required to undergo the 
Visit 2 GEBT, and may proceed directly to Visit 3.
Subjects who are not taking any medications at the screening visit that require washout may 
attend the clinic for Visit 2 earlier than 2 weeks and only after laboratory results have been 
reviewed by the investigator. An 8-hour fast is required before the GEBT. Subjects will then 
return within 7 days after the GEBT visit to confirm their eligibility based on the gastric 
emptying criteria (Visit 3, Day -14). 
Once eligibility is confirmed by these criteria at this visit, subjects will be instructed on the use 
of an electronic patient reported outcomes tool (ePRO) for collecting the daily symptoms of 
gastroparesis, daily dosing and meal time recordings, and capture of rescue medication use. The 
instrument used to capture symptom data will be the ANMS GCSI-DD along with a bloating 
severity scale. Subjects will record their symptoms once daily (in the evening) and will return to 
the clinic approximately 2 weeks later to assess their gastroparesis symptom eligibility based on 
the ANMS GCSI-DD (Visit 4, randomization). Subjects need to be compliant with completing 
the Daily Symptom Diary, defined as ≥80% diary completions, during the 2-week symptom 
assessment period. 
Medication should be taken 1 dose in the morning approximately 1 hour before the first meal of 
the day and another dose in the evening approximately 1 hour before the main last meal of the 
day, at a regular dose interval. 
Prior to Protocol Amendment 8, Subjects was randomized 1:1:1:1 into 1 of 4 treatment groups: 
TAK-906 maleate (TAK906M abbreviated as TAK-906) 5, 25, and 50 mg capsule BID or 
matching placebo BID, stratified by IG and DG (minimum 30 subjects per indication per arm). 
In Protocol Amendment 8, the randomization into 5 mg arm for TAK-906 was discontinued 
while the randomization into the rest of the treatment groups remains unchanged, ie, subjects will 
be randomized 1:1:1 into TAK-906 25 mg and 50 mg capsule BID or placebo BID. 
Subjects who withdraw prematurely will be seen by the physician for an early termination visit 
as soon as possible and will continue completing the Daily Symptom Diary until this termination 
visit using the ePRO device. They will then be contacted for a follow-up safety call to check if 
any adverse events occurred during this follow-up period.
A schematic of the study design is included as Figure 4.a. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 9 of 44
Statistical Analysis Plan
02 August 2021
Figure 4.a
Schematic of Study Design
Screening Period
Double-Blind Treatment Period
Safety Follow-
up Period
TAK-906 5 mg (discontinued randomization 
at protocol amendment 8)
TAK-906 25 mg
TAK-906 50 mg
Placebo
Visit 1 Visit 2
Visit 3 Randomization
Visit 4
Week 12
Visit 7
Follow-up Call
5.0
ANALYSIS ENDPOINTS
5.1
Primary Endpoint 

Change from baseline to Week 12 of the Treatment Period in the American 
Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily 
Diary (ANMS GCSI-DD) composite score (nausea, early satiety, upper abdominal pain, and 
postprandial fullness). 
5.2
Secondary Endpoints

Proportion of subjects with at least 50% reduction from Baseline in ANMS GCSI-DD 
composite score at Week 12.

Change from baseline to Week 12 of the Treatment Period in the ANMS GCSI-DD nausea 
symptom score.

Change from baseline to Week 12 of the Treatment Period in the ANMS GCSI-DD early 
satiety symptom score. 

Change from baseline to Week 12 of the Treatment Period in the ANMS GCSI-DD 
postprandial fullness symptom score. 

Change from baseline to Week 12 of the Treatment Period in the ANMS GCSI-DD upper 
abdominal pain symptom score. 

Change from baseline to Week 12 of the Treatment Period in the ANMS GCSI-DD recorded 
vomiting frequency.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 10 of 44
Statistical Analysis Plan
02 August 2021

Change from baseline to Week 12 of the Treatment Period in the ANMS GCSI-DD overall 
severity of gastroparesis symptoms score.

Change from baseline to Week 12 of the Treatment Period in the bloating severity scale 
score.

Change from baseline to Week 12 of the Treatment Period in the ANMS GCSI-DD total 
score (nausea, early satiety, upper abdominal pain, postprandial fullness, bloating, and 
vomiting).

Proportion of symptomatic weeks (weeks with average composite symptom score assessed as 
>mild [ANMS GCSI-DD Score ≥2]) during 12 weeks of treatment.

Change from baseline to Week 12 of the Treatment Period in the Patient Assessment of 
Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) total score. 
5.3
Safety and Tolerability Endpoints
Safety and tolerability will be evaluated using the following general assessments:

Treatment-emergent AEs.

Vital signs.

12-lead ECGs. 

Clinical laboratory parameters (hematology, clinical chemistry, and urinalysis).
5.4
Additional Endpoints

Percentage of symptomatic days (days with symptoms assessed as >mild [ANMS GCSI-DD 
Score ≥2]) using the ANMS GCSI-DD during 12 weeks of treatment.

Proportion of patients with ≥20% reduction in ANMS GCSI-DD composite score from 
Baseline in the last 6 consecutive weeks of the study.

Change from baseline to Week 12 of the treatment period in the ANMS GCSI-DD core 
symptom score (nausea, early satiety, upper abdominal pain, postprandial fullness, and 
vomiting).

Change from baseline to Week 12 of the Treatment Period in Clinician Symptom Severity 
Rating form.

Change from baseline to Week 12 of the Treatment Period in Patient Assessment of Upper 
Gastrointestinal Disorders Quality-of-Life Index (PAGI-QOL) total score. 

Differences at Week 12 in Overall Treatment Effect (OTE) Scales. 

Change from baseline to Week 12 in Clinical Global Impression Scale–Severity of Illness 
Scale (CGI-S).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 11 of 44
Statistical Analysis Plan
02 August 2021

Differences at Week 12 in Clinical Global Impression Scale–Global Improvement Scale
(CGI-I).

Change from baseline to Week 12 in Patient Global Impression of Severity (PGI-S) both 
version 1 (Collected daily) and version 2 (collected over the past 7 days). 

Differences at Week 12 in Patient Global Impression of Improvement (PGI-I) and Patient 
Global Impression of Change (PGI-C)

TAK-906 predose (trough) plasma concentration at Week 12.

Change from baseline to Week 12 of the Treatment Period in Short Form-12 (SF12) Health 
Survey subscale scores.

Use of rescue medication during the 12-week Treatment Period.

Assess change in CRP, GIP, and PYY from baseline to Week 12.

Change from baseline to Week 4 and 12 in GEBT time to gastric half emptying (t1/2). 
6.0
DETERMINATION OF SAMPLE SIZE
In order to manage the likelihood of statistical, clinical, and operational success of this study in 
the setting of the COVID-19 pandemic, the sample-size considerations are revisited in Protocol 
Amendment 8. The statistical testing is revised from 2-sided (with a significance level of 5%) to 
1-sided (with a significance level of 5%), the planned sample size is reduced by 10 subjects per 
arm and randomization into the 5 mg dose arm is to be discontinued.
The sample-size rationale for the resultant reduced sample size and updated 1-sided statistical 
testing is as follows: Assuming a SD of 1.25 and a true difference of 0.625 between TAK-906 
active dose and placebo in the change from baseline in the ANMS GCSI-DD composite score, 
and a 15% dropout rate, a total of 205 subjects is sufficient to achieve approximately 80% power 
to detect the treatment effect of 0.625 at a 1-sided 5% significance level. The total of 205 
subjects consists of approximately 25 subjects who have already been randomized to receive 5 
mg capsule BID prior to terminating randomization of subjects into the 5 mg dose arm, and 60 
subjects per treatment groups of placebo, TAK-906 25 mg, and TAK-906 50 mg.
7.0
METHODS OF ANALYSIS AND PRESENTATION
7.1
General Principles 
Categorical data will be summarized as the number and percentage of subjects in each category. 
Percentages will be reported to 1 decimal place.
Continuous data will be summarized using descriptive statistics, including the number of 
subjects, mean, standard deviation (SD), median, minimum, and maximum. The coefficient of 
variation (%CV) and geometric mean will be included in the summary of continuous data where 
indicated. Arithmetic means, geometric means, and medians will be presented to 1 more decimal 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 12 of 44
Statistical Analysis Plan
02 August 2021
place than the recorded data, and SDs will be presented to 2 more decimal places than the 
recorded data, where appropriate. 
All statistical tests will be 1-tailed at α=0.05 level for statistical significance unless otherwise 
stated. Where applicable, 90% confidence intervals (CIs) corresponding to a parameter estimate 
will be presented using the same number of decimal places as the parameter estimate and p-
values will be rounded to 3 decimal places prior to assessment of statistical significance.
The logistic regression models based on maximum likelihood approach will be used to analyze 
binary efficacy endpoint at each visit separately as default. In case quasi-complete separation 
issue exists at a specific visit where the maximum likelihood estimate from the logistic 
regression model becomes questionable, the Firth’s penalized likelihood approach (ie, model 
/FIRTH option for Proc Logistic in SAS) will be used instead for that visit. 
Study-related raw data for enrolled subjects, including derived data, will be presented in data 
listings where indicated. The actual day relative to the first dose will be presented, where 
applicable.
All statistical analyses will be performed using the SAS System Version 9.4 or a later version. 
SF-12 Mental Component Summary (MCS) and Physical Component Summary (PCS) will be 
calculated based on PRO Core® (version 2, 17-Dec-2020) a software from Quality Metric 
(Maruish, 2012).
In case of irregular data entry, the algorithms below will be used to identity the ANMS GCSI-
DD score for analysis. All ANMS GCSI-DD scores will be listed and flagged if the score is 
excluded from analysis. 
1. If a subject has data entry for ANMS GCSI-DD scores entered one day earlier before the 
planned data entry date or at least two days after the planned data entry date, the ANMS 
GCSI-DD scores will not be used for analysis. Only the ANMS GCSI-DD scores entered on 
the same day as planned data entry date or one day after (within one calendar day) will be 
used for analysis. Data points entered after first dose will not be used for deriving baseline.
2. If a subject has two entries for the ANMS GCSI-DD scores for the same day, the data entry 
that will be used for analysis is determined as below:

If both entries are before the evening*, the entry closer to the evening* will be used for 
analysis. 

If one entry is before and one entry is after the evening*, the entry after the evening* will 
be used for analysis because it encompasses longer time interval for the respective day. 

If both entries are after the evening*, the latter entry will be used for analysis as it 
encompasses longer time interval for the respective day (and as long as the entry is within 
one calendar day). 
*as per the study protocol, patients were advised to complete the dairy in the evening at 5.00 p.m
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 13 of 44
Statistical Analysis Plan
02 August 2021
7.1.1
Definition of Study Day, Baseline and Study Visit Windows
A windowing convention will be used to determine the value for analysis variables for a given 
study visit that applies to observed data.
Study Day 1 is defined as the date of the first dose of study drug, as recorded on the electronic 
case report form (eCRF). Other study days are defined relative to Study Day 1. Study days prior 
to the first dose of study drug will be calculated as: [date of interest – date of first dose of study 
drug]. Study days on or after the first dose of study drug will be calculated as: [date of interest –
date of first dose of study drug + 1]. 
For each visit, a window will be defined such that the lower and upper bounds of each window is 
generally the midpoint between 2 consecutive study visits. The visit windows and applicable 
study day ranges are presented below in Table 7.a.
More than 1 result for a study endpoint measurement may be obtained in a visit window. In such 
an event, the result with the date closest to the scheduled visit day will be used. In the event of 
2 observations equidistant to the scheduled visit day, the later of the observations will be used.
In the safety data summary, the treatment period ‘End of Treatment Visit’ values will be defined 
irrespective of falling in a particular window. Hence, the windowed Week 12 value may be 
different than the End of Treatment Visit value.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 14 of 44
Statistical Analysis Plan
02 August 2021
Table 7.a
Visit Windows
Analysis
/Nominal 
Visit Week
Nominal 
Visit Day
ANMS 
GCSI-DD
CSSR, SF12
OTE (b), 
CGI-I, PGI-I
GEBT 
(c)
PAGI-SYM, PAGI-QoL, CGI-
S, PGI-S, ECG, Vital Sign, Lab
Baseline
-1 (a)
≤0
≤1
NA
≤1
≤1 
1
7
1—7
2
14
8—14
3
21
15—21
4
28
22—28
2—56
2—42
5
35
29—35
6
42
36—42
7
49
43—49
8
56
50—56
43—70
9
63
57—63
10
70
64—70
11
77
71—77
12
84
78—84
≥ 2
≥ 2
≥ 57
≥ 71
(a) Nominal Visit Day -1 corresponds to the date(s) of the Baseline visit for each assessment. For some assessments, 
baseline is collected on Study Day 1 before study drug administration. Daily Collected ANMS GCSI-DD Scores 
will be derived into Analysis Week Values. 
(b) Both OTE subject and OTE physician scales.
(c) Collection of GEBT for post baseline assessment was removed in Protocol Amendment 8.
In general, the baseline value for a variable is defined as the last non-missing observation prior to 
the first dose of double-blind study medication (visit date/time ≤first dose date/time), including 
the screening value, if necessary. The baseline value for ANMS GCSI-DD scores is defined in 
Section 7.8.2.
Adverse events that start more than 30 days after the last dose of double-blind study medication 
(start date – last dose date >30) will be listed, but excluded from the summaries and analyses. 
For efficacy and other safety measurements, data that are obtained more than 7 days after the last 
dose of double-blind study medication (visit date – last dose date >7) will be listed, but excluded 
from summaries and analyses.
The data listings will display Analysis Visits or Nominal Visits where applicable.
7.1.2
Grouping of Centers
No adjustment of study centers in the statistical analyses will be made. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 15 of 44
Statistical Analysis Plan
02 August 2021
7.2
Analysis Sets

Safety Analysis Set: The safety analysis set will include all subjects who were randomized 
and received at least 1 dose of double-blind study medication. In safety summaries, subjects 
will be analyzed according to the treatment they received. 
If a subject receives more than 1 treatment, the actual treatment is defined as the one that is 
used most frequently. If two or more treatments are tied in frequency of use, the actual 
treatment will be the one with highest dose level.

Randomized Set: The randomized set will include all subjects who were randomized. In 
summaries based on randomized set, subjects will be analyzed by the treatment to which they 
were randomized.

Full Analysis Set (FAS): The FAS will include all subjects who were randomized, received 
at least 1 dose of study drug, and have a baseline value for assessment of primary endpoint. 
In FAS efficacy summaries, subjects will be analyzed by the treatment to which they were 
randomized.

Per-Protocol Set (PPS): The PPS will include all FAS subjects who had no major protocol 
violations that could significantly impact the clinical outcomes. If more than 5% of the total 
subjects in the FAS have major protocol violations, analyses based on the PPS will be 
performed for the primary efficacy variable only. Subjects with major protocol violations 
will be identified as part of the blinded data review prior to the unblinding of subject’s 
treatment assignment, and will be listed by study center and subject number. The categories 
of major protocol violations include: 
a) informed consent was not obtained
b) Not meeting inclusion/exclusion criteria 

inclusion criteria of 3, 4, 5, 6, 9, 13

exclusion criteria of 6, 12, 13, 14, 18, 23, 30 

exclusion criteria 34 for Protocol Amendment 8 enrolled subjects, exclusion criteria 
36 for subjects enrolled prior to Protocol Amendment 8 
c) Receiving incorrect study medication
d) Low study drug compliance (<80%)
e) Study medication exposure less than 8 weeks

((last dose date – first dose date +1)/7) <8)
f)
Treatment blind broken
g) Use of rescue medications is used 3 days BID per week for more than 2 consecutive 
weeks. If end date of rescue medication is missing, the end date of rescue medication will 
be imputed by last date of rescue medication from the ePRO device. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 16 of 44
Statistical Analysis Plan
02 August 2021
7.3
Disposition of Subjects
Study Information, including date of first subject signing Informed Consent Form (ICF), date of 
first/last study drug, date of last subject’s last visit/contact, date of last subject’s last procedure 
for collection of data for primary endpoint, Medical Dictionary for Drug Regulatory Activities 
(MedDRA) Version, World Health Organization Drug Dictionary (WHODrug) Version, and 
SAS Version, will be tabulated.
Disposition of all screened subjects will be summarized descriptively, including a summary of 
the number of screened subjects, the number of subjects eligible/not eligible for randomization, 
and the primary reason for ineligibility for randomization. The number of screen failures and 
their characteristics will also be summarized. The inclusion and exclusion data will be listed by 
subject. 
Disposition for all randomized subjects will be summarized by treatment group and overall. 
Disposition categories include:

Number of randomized subjects by country and site.

Number of subjects randomized but not dosed, subjects completing or prematurely 
discontinuing study drug along with the primary reason for study drug discontinuation, and 
subjects completing or not completing all study visits along with the primary reason for 
discontinuation of study visits.
Important/Significant protocol deviations will be summarized based on the Randomized Set. 
Reasons for exclusion from the PPS will be summarized based on the FAS. All protocol 
deviations will be listed, separately. COVID-19 related Protocol Deviations will be summarized 
separately. 
The impact due to COVID-19 will be summarized using the number and percentage of subjects 
in each category of impact by treatment group and overall based on all randomized subjects: 

Subjects with at least one alternative contact method used due to COVID-19.

Subject with alternative contact method used due to COVID-19 by study visit.

Subjects with assessments done via alternative contact method by study visit. 
Meanwhile, a listing of all participants who were affected by the COVID-19 related study 
disruption will be provided by including unique subject number identifier, investigational site, 
and a description of how the individual’s participation was altered. 
The analysis sets defined in Section 7.2 will be summarized.
7.4
Demographic and Other Baseline Characteristics
Demographic and baseline characteristics including sex, age, age category (18-64 years, 
65-84 years, 85 years and over), race, height, weight, BMI (<25, 25-<30, >=30), and smoking 
status will be listed and summarized for each treatment group and overall. The demographic and 
baseline characteristics summary will be based on all randomized subjects.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 17 of 44
Statistical Analysis Plan
02 August 2021
Disease history characteristics including disease population (DG, IG), prior diagnosis of GP 
(Yes, No), time since symptom onset (month), confirmation of absence of upper GI obstruction 
though imaging (Yes, No), prior diagnostic test(s) for GP (Scintigraphy, GEBT, Wireless 
Motility Capsule, Other), and test results (Delayed Gastric Emptying, Normal Gastric Emptying) 
will be listed and summarized for each treatment group and overall. The disease history 
summary will be based on randomized set.
Baseline values for efficacy parameters (ANMS GCSI-DD, PAGI-SYM, and Clinician Symptom 
Severity Rating, PGI-S, CGI-S, PAGI-QoL, MCS SF-12, PCS SF-12, and GEBT t1/2) will also 
be presented for each treatment group, overall TAK-906 treated group based on the FAS. 
All individual demographic and baseline data will be listed by treatment, and subject number.
7.5
Medical History and Concurrent Medical Conditions
Medical history refers to significant conditions/diseases that resolved at or before Screening 
(time of informed consent). Concurrent medical conditions are those significant ongoing 
conditions/diseases present at Screening (time of informed consent).
Medical history and concurrent medical conditions will be coded using Medical Dictionary for 
Regulatory Activities (MedDRA) latest version and will be summarized by treatment group and 
overall using System Organ Class (SOC) and MedDRA preferred term. The table will include 
number and percentages of subjects, and will be sorted in alphabetical order by SOC. Within an 
SOC, PTs are sorted in decreasing frequency based on the total number of subjects. A subject 
will only be counted once within a particular class even if he/she has multiple 
conditions/symptoms. Summaries will be based on all randomized subjects.
All medical history and concurrent medical condition data will be listed by treatment, study 
center and subject number.
7.6
Medication History and Concomitant Medications
The medication history and concomitant medications are defined as follows:

Medication history refers to the medication that the study subjects stopped taking at or within 
90 days prior to time of first dose.

Concomitant medication is defined as medication that the study subjects continued taking or 
took from time of first dose through end of study:
–
Concomitant medication that started prior to and was ongoing at first dose date (ie, start 
date < first dose date, and stop date ≥ first dose date).
–
Concomitant medication that started after first dose (ie, start date ≥first dose date).
–
Concomitant medication taken during the study (ie, start date and stop dates are between 
first and last dose date).
–
Concomitant medication that started post last dose (ie, start date >last dose date).
If start date and stop date are missing, medication will be assumed to occur both prior and 
concomitantly.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 18 of 44
Statistical Analysis Plan
02 August 2021
Medication history and concomitant medications will be coded using the latest version of the 
World Health Organization (WHO) Drug Dictionary and summarized by giving the number and 
percentage of subjects by preferred term within each therapeutic class, with therapeutic class 
sorted in alphabetical order and preferred term sorted in decreasing frequency based on the total 
number of subjects. The number of subjects with medications in each selected therapeutic class 
will also be presented. If a subject report taking 2 drugs belonging to the same class, he/she will 
only be counted once within that class. Summaries of medication history and concomitant 
medication will be based on all randomized subjects.
In addition, number and percentage of subjects who took antinausea/antivomiting rescue 
medication will be summarized. 
All prior and concomitant medications will be listed by treatment, study center and subject 
number. Rescue medications will also be listed by treatment, study center, and subject number. 
Rescue medications from ePRO device and EDC will be listed, separately. 
7.7
Study Drug Exposure and Compliance
The summary of study drug exposure and compliance will be based on the safety analysis set.
Duration of exposure to double-blind study medication is defined as (date of last dose – date of 
first dose +1). Treatment duration will be summarized by duration category in weeks (<1 week, 
≥1 to <4 weeks, ≥4 to <8 weeks, ≥8 to <12 weeks, ≥12 weeks) and the number of subjects in 
each duration category by treatment group. Treatment duration (weeks) will also be summarized 
as a continuous variable using descriptive statistics.
For subjects who returned all dispensed bottles, the following equation will be used to calculate 
the percent of study drug compliance: 
(number of capsules dispensed – number of capsules returned)/[(date of last dose – date of first 
dose +1)×2]×100%. 
For subjects who did not return all bottles that were dispensed, the dosing data from ePRO 
device will be used to impute the number of capsules taken for calculating the percent of study 
drug compliance during the period of time for which the bottle(s) was not returned: 
[sum of (number of capsules dispensed – number of capsules returned, at the corresponding visit 
from IRT) for the visits where dispensed bottles were returned + sum of number of capsules 
taken from ePRO device for the visits where dispensed bottles were not returned]/ [(date of last 
dose – date of first dose +1)×2]×100%.
If the missing dispensed bottle is not the last bottle, count the number of capsules taken from the 
dispense date to the day before next dispense date in ePRO device.
If the missing dispensed bottle is the last bottle, count the number of capsules taken from the last 
dispense date to date of last capsule taken in ePRO device.
For each treatment group, study medication compliance will be summarized by compliance 
category (<80%, 80%-100%, >100%) and the number of subjects in each compliance category. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 19 of 44
Statistical Analysis Plan
02 August 2021
Study medication compliance will also be summarized as a continuous variable using descriptive 
statistics for each treatment group.
All study drug administration and accountability data will be listed by treatment, study center, 
and subject number. The following variables will be listed: subject identifier, first and last dose 
dates, medication identification number, date dispensed and returned, number of capsules 
dispensed and returned, and percent compliance. Study drug data collected from ePRO will be 
listed. 
7.8
Efficacy Analysis
The analyses and summaries for efficacy will be based on the FAS. 
The primary, secondary, and additional efficacy endpoints for this study are presented in 
Table 7.b. All derived endpoints (indicated by ‘D’) in this table will be accompanied by a listing 
of intermediate data for supporting the derivation including but not limited to weekly scores and 
subscale calculations, severity scores, and missing data imputations. 
The composite score, total score, and core symptom score will be graphed. 
Table 7.b
Primary, Secondary and Additional Efficacy Endpoints
Endpoint (1)
Parameter
Description
Variable 
Type (2)
Primary
ANMS GCSI-DD_COMP 
Composite score (nausea, early satiety, 
postprandial fullness, upper abdominal pain). 
c/ D
Secondary
ANMS GCSI-DD_TOT 
Total score (nausea, early satiety, postprandial 
fullness, upper abdominal pain, bloating, and 
vomiting). 
c/ D
ANMS GCSI-DD_CS
Core symptom score (nausea, early satiety, upper 
abdominal pain, postprandial fullness, and 
vomiting). 
c/ D
Secondary
ANMS GCSI-DD_NA
Nausea symptom score 
c
Secondary
ANMS GCSI-DD_ES
Early satiety symptom score
c
Secondary
ANMS GCSI-DD_PF
Postprandial fullness symptom score
c
Secondary
ANMS GCSI-DD_UAP
Upper abdominal pain symptom score
c
Secondary
ANMS GCSI-DD_VM
Vomiting symptom frequency score
c
Secondary
ANMS GCSI-DD_GL
Overall severity of GP symptom
c
Secondary
ANMS GCSI-DD_RESP1
ANMS GCSI-DD response defined as ≥50% 
decrease from baseline in ANMS GCSI-DD 
composite score at week 12
b/ D
Secondary
ANMS GCSI-DD_WK
Proportion of symptomatic weeks (weeks with 
average composite symptom score assessed as 
worse than mild [weekly ANMS GCSI-
DD_COMP≥2]) during 12 weeks of treatment. 
c/ D
ANMS GCSI-DD_RESP2
ANMS GCSI-DD response defined as ≥20% 
b/ D
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 20 of 44
Statistical Analysis Plan
02 August 2021
Table 7.b
Primary, Secondary and Additional Efficacy Endpoints
Endpoint (1)
Parameter
Description
Variable 
Type (2)
decrease from baseline in ANMS GCSI-DD 
composite score in the last 6 consecutive weeks of 
the study. 
ANMS GCSI-DD_DAY
Percentage of symptomatic days (days with 
symptoms assessed as worse than mild [daily 
ANMS GCSI-DD_COMP≥2]) during 12 weeks of 
treatment. 
c/ D
Secondary
BLOATING
Bloating severity scale score
c
Secondary
PAGI-SYM_TOT
Mean of PAGI-SYM subscale scores
c
PAGI-SYM_NAVM
Mean of Nausea/vomiting subscale score (nausea, 
retching, vomiting)
c/ D
PAGI-SYM_PFES
Mean of Postprandial fullness/early satiety
subscale score (stomach fullness, not able to finish 
a normal-sized meal, feeling excessively full after 
meals, loss of appetite)
c/ D
PAGI-SYM_BL
Mean of Bloating subscale score (bloating, 
stomach or belly visibly larger)
c/ D
PAGI-SYM_UAP
Mean of Upper abdominal pain subscale score 
(upper abdominal pain, upper abdominal 
discomfort)
c/ D
PAGI-SYM_LAP
Mean of lower abdominal pain subscale score 
(lower abdominal pain, lower abdominal 
discomfort)
c/ D
PAGI-SYM_HBRE
Mean of Heartburn/regurgitation subscale score 
(heartburn during the day, heartburn when lying 
down, feeling of discomfort inside your chest 
during the day, feeling of discomfort inside your 
chest at night, regurgitation or reflux during the 
day, regurgitation or reflux when lying down, 
bitter, acid or sour taste in your mouth)
c/ D
CSSR_TOT
Clinician symptom scale rating total score
c/ D
PAGI-QoL_TOT
Mean of PAGI-QoL subscale scores
c/ D
SF-12
SF-12 subscale scores (physical functioning, role-
physical, bodily pain, general health, vitality, 
social functioning, role emotional, and mental 
health) 
c/ D
MCS SF-12
Mental Component Summary SF-12
c/P
PCS SF-12
Physical Component Summary SF-12 
c/P
GEBT t1/2
GEBT time to gastric half emptying
c/ D
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 21 of 44
Statistical Analysis Plan
02 August 2021
Table 7.b
Primary, Secondary and Additional Efficacy Endpoints
Endpoint (1)
Parameter
Description
Variable 
Type (2)
OTE_S
Overall treatment effect (OTE) scale rated by 
subject
o
OTE_C
Overall treatment effect (OTE) scale rated by 
clinician
o
CGI-I
Clinician Global Impression of improvement
o
CGI-S
Clinician Global Impression of severity
o
PGI-S (3)
PGI severity
o
PGI-C (4)
PGI change
o
PGI-I (4)
PGI improvement
o
(1) Primary and Secondary Endpoints are identified. The rest are additional Endpoints. 
(2) b = binary; c = continuous, o = ordinal / D =derived, P=PRO Core software used
(3) PGI-S has two versions (PGI-S Version 1 prior to Protocol Amendment 08: recall period is the same day when 
the form was filled out; PGI-S Version 2 under Protocol Amendment 08: recall period over the past 7 days). 
(4) PGI-I was replaced with PGI-C (PGI-Improvement: collected daily prior to Protocol Amendment 08; PGI-
Change: collected under Protocol Amendment 08).
(5) CGI-I, CGI-S, CSSR_TOT and OTE_C will be summarized when responded by qualified personnel on or after 
they were trained. Otherwise, data will be available in the listings only. 
7.8.1
Endpoints Derivation based on ANMS GCSI-DD Daily Scores
The ANMS GCSI-DD individual symptom scores are as follows:

The scores for nausea, early satiety, postprandial fullness, and upper abdominal pain range 
from 0 to 4. 

The open-ended vomiting frequency assesses the number of vomiting episodes during the 
day. 

The patient global rating of the overall severity of GP symptom ranges from 0 to 4. 
The ANMS GCSI-DD daily composite and total scores are calculated as follows:

The daily composite score is calculated by summing the scores on the 4 symptom items 
(nausea, early satiety, postprandial fullness, and upper abdominal pain) and then dividing by 
4, that is the number of items within the composite score. Thus, the maximum daily 
composite score could be (4 symptoms × maximum score 4 divided by 4) = 16/4 = 4. The 
ANMS GCSI-DD daily composite score can range from 0 to 4 with higher scores reflecting 
greater symptom severity. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 22 of 44
Statistical Analysis Plan
02 August 2021

The daily total score is calculated by summing the scores on each of the 5 symptom items in 
ANMS GCSI-DD (nausea, early satiety, postprandial fullness, upper abdominal pain, and 
vomiting) plus the bloating severity item and then dividing by 6. When calculating the total 
score, the vomiting frequency will be scored from 0 to 4 (where 0 = no vomiting and 4 = four 
or more episodes of vomiting), similar to the scoring of the other individual symptom items. 
The maximum total symptom score could be (6 symptoms × maximum score 4 divided by 6) 
= 24/6 = 4. The ANMS GCSI-DD daily total score can range from 0 to 4 with higher scores 
reflecting greater symptom severity.

The daily core symptom score is calculated by summing the scores on each of the 5 
symptom items in ANMS GCSI-DD (nausea, early satiety, postprandial fullness, upper 
abdominal pain, and vomiting) and then dividing by 5. When calculating the core symptom 
score, the vomiting frequency will be scored from 0 to 4 (where 0 = no vomiting and 4 = four 
or more episodes of vomiting), similar to the scoring of the other individual symptom items. 
The maximum core symptom score could be (5 symptoms × maximum score 4 divided by 
5) = 20/5 = 4. The ANMS GCSI-DD daily core symptom score can range from 0 to 4 with 
higher scores reflecting greater symptom severity.
The ANMS GCSI-DD weekly scores for individual items, composite, total, and core symptom 
will be derived from the daily scores calculated based on electronic diaries completed by the 
patients. These scores for baseline and each week will be calculated as follows:

Baseline value: the baseline value is the average of daily scores from the most recent 
7 consecutive days (Day -7 to Day -1) before the first dose date of the baseline visit.

The score for each postbaseline week is the average of the 7 daily scores within the targeted 
week relative to the first dose date. For example, Week 1 score will be the average of the 
7 daily scores from Day 1 to Day 7; Week 2 score will be the average of the 7 daily scores 
from Day 8 to Day 14; and so on for duration of the study.

General rules for dealing with missing individual items or daily scores are described in 
Section 7.8.5.
7.8.2
Primary Efficacy Endpoint
The primary efficacy endpoint is the change from baseline to Week 12 of the Treatment Period 
in the weekly ANMS GCSI-DD composite score.
7.8.2.1
Analysis of Primary Efficacy Endpoint
The change from baseline in weekly ANMS GCSI-DD composite score will be analyzed using a 
mixed-effects model for repeated measures (MMRM) with treatment, week, subject disease 
population (DG/IG), treatment-by-week interaction as fixed effects, baseline and baseline score-
by-week interaction as covariates, with an unstructured variance covariance matrix. The 
estimates of the least squares mean (LSM) difference between TAK-906 dose groups and 
placebo at each week and their 90% CIs will be reported. In particular, the LSM differences 
between TAK-906 dose groups and placebo at Week 12 will be used to evaluate the treatment 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 23 of 44
Statistical Analysis Plan
02 August 2021
effects. The restricted maximum likelihood (ie, REML) method will be used to estimate the 
covariance parameters and Kenward-Roger approximation will be used to estimate the 
denominator degrees of freedom for the tests of fixed effects resulting from the model. 
If the model does not converge, other variance covariance matrix structures will be considered in 
the following order: 
1. Fit MMRM model with unstructured covariance using Singular statement in Proc Mixed 
(eg, singular=1e-11).
2. Kiernan, Tao, and Gibbs from SAS institute (2012) pointed out that non-convergence may 
happen when the default convergence criteria in SAS are too tight (eg, parameter estimates 
have a small magnitude and the default relative convergence criteria cannot be satisfied) and 
setting one’s own criteria can help to obtain convergence. 
3. Fit MMRM model with unstructured covariance using PARMS statement in Proc Mixed 
(initial values will be obtained based on Fisher scoring algorithm).
4. Kiernan, Tao, and Gibbs (2012) pointed out that the default starting values in SAS might not 
work for a particular dataset and using the PARMS statement to specify a different set of 
starting values can help to obtain convergence. The Fisher scoring algorithm (via the 
SCORING option of the PROC MIXED statement) will be used to obtain the initial values of 
covariance parameters. 
5. Use the no-diagonal factor analytic structure (via the TYPE=FA0(T) option of the 
REPEATED statement, where T is the total number of time points). 
6. Lu and Mehrotra (2010) pointed out that no-diagonal factor analytic structure effectively 
performs the Cholesky decomposition of the covariance matrix and is numerically more 
stable.
7. Use the following alternative covariance structures sequentially (from generous to 
parsimonious):
Toeplitz, Variance Components, Autoregressive (1), and Compound Symmetry.
The same variance covariance matrix structure will be used for the corresponding sensitivity 
analysis. 
The following sensitivity analyses will be conducted for the primary efficacy endpoint:
To deal with subjects who received rescue therapy during the treatment period:
1. A sensitivity analysis will be done by considering ANMS GCSI-DD scores reported on and 
after start of rescue medication through 48 hours after the end date of rescue medication as 
missing at random (MAR). The rescue medication is assumed not to have any effect on the
ANMS GCSI-DD scores 48 hours after the end date of rescue medication.
2. A sensitivity analysis will be done by imputing ANMS GCSI-DD scores reported on and 
after start of rescue medication through 48 hours after the end date of rescue medication by 
considering the Nausea symptom level as the worst score (ie, 4). Because the protocol 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 24 of 44
Statistical Analysis Plan
02 August 2021
specified use of antinausea/antivomiting rescue medication is permitted for moderate nausea 
and/or vomiting CTCAE Grade 2 (for nausea, oral intake decreased without significant 
weight loss, dehydration or malnutrition; for vomiting; outpatient IV hydration required) the 
rescue medication is assumed to primarily affect Nausea or Vomiting symptoms and not to 
have any effect on the these symptoms 48 hours after the end date of rescue medication. 
The timing of 48 hours for the two sensitivity analysis above was determined by 5 times the half-
life of rescue medications allowed in the study. 
To deal with subjects who have missing values:
1. As a sensitivity analysis to the MAR assumption in the primary analysis described above, a 
pattern mixture model (PMM) with the control-based imputation will be applied to handle 
missing values. The strategy for implementing control-based pattern imputation using 
regression-based multiple imputation (MI) for monotone missingness (Ratitch 2011 and Li 
2019) can be summarized in 4 steps of the imputation process as follows. Details are in 
Appendix E Details for Pattern Mixture.
If more than 5% of total subjects in the FAS are excluded, the primary analysis will also be 
performed based on the PPS. 
Subgroup Analyses
For the primary efficacy endpoint, subgroup analyses by:

Subject disease population (DG, IG) (the MMRM for subgroup analysis will not include 
disease population as a fixed effect),

Age (≤65, >65),

Sex (female, male),

Baseline composite score (≤median, >median),

Geographical Region (North America, Europe, Asia), 
will be performed. The treatment groups will be compared within each subgroup. 
7.8.3
Secondary Efficacy Endpoints
Change from baseline in weekly ANMS GCSI-DD total score, ANMS GCSI-DD individual 
symptom scores (nausea, early satiety, upper abdominal pain, and postprandial fullness), 
recorded vomiting frequency, overall severity of gastroparesis symptoms score, and bloating 
severity scale score, will be analyzed using similar method (MMRM) for primary efficacy 
endpoint. 
The recorded vomiting frequency greater or equal to 60 is deemed as clinically implausible, and 
will be set to missing for analysis. The derivation for total ANMS GCSI-DD score will be based 
on this vomiting frequency (setting clinically implausible number as missing) capped at 4 (User 
Manuel for the ANMS GCSI-DD). 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 25 of 44
Statistical Analysis Plan
02 August 2021
The estimates of the least squares mean (LSM) difference between TAK-906 dose groups and 
placebo at each week and their 90% CIs will be reported. In particular, the LSM differences 
between TAK-906 dose groups and placebo at Week 12 will be used to evaluate the treatment 
effects in each endpoint, respectively.
The proportion of subjects with at least 50% reduction from Baseline in the weekly ANMS 
GCSI-DD composite score will be estimated by logistic regression adjusting for baseline score, 
subject disease population, and treatment by week. The missing values will be handled in 3 ways 
by last observation carried forward (LOCF), observed case (OC) and non-responder imputation 
(NRI).

For LOCF imputation, the last non-missing post-baseline values would be carried forward to 
impute the weekly ANMS GCSI-DD composite score. 

For the OC analysis, only includes subjects who have non-missing ANMS GCSI-DD 
composite score, there will not be any imputation.

For NRI imputation, subject with missing ANMS GCSI-DD composite score would be 
handled as non-responder.
Percentage of symptomatic weeks (weeks with average composite symptom score assessed as 
>mild [ANMS GCSI-DD weekly composite score ≥2]) during 12 weeks of treatment will be 
analyzed using ANOVA with treatment, subject disease population as fixed factors. If the 
weekly ANMS GCSI-DD composite score is missing, that week is considered a symptomatic 
week. 
Change from baseline in PAGI-SYM total and subscale scores will be analyzed using similar 
method as the primary efficacy endpoint. The estimates of the least squares mean (LSM) 
difference between TAK-906 dose groups and placebo at each week and their 90% CIs will be 
reported. In particular, the LSM differences between TAK-906 dose groups and placebo at Week 
12 will be used to evaluate the treatment effects in each endpoint, respectively.
The PAGI-SYM contains 20 items grouped into 6 subscale scores. A 6-point Likert response 
scale, ranging from 0 (none) to 5 (very severe), is used for rating the severity of each symptom. 
Normality assumption will be assessed for the analysis of weekly ANMS GCSI-DD composite 
scores, total score, and core symptom scores. If a significant departure from the normality 
assumption is detected, a generalized estimating equations (GEE) approach will be applied. 
The GEE analysis model will be similar to the MMRM for the analysis of primary efficacy 
endpoint (with treatment, week, subject disease population (DG/IG), treatment-by-week 
interaction as fixed effects, baseline and baseline score-by-week interaction as covariates, with 
an unstructured working covariance matrix as default). If GEE model with unstructured working
covariance matrix fails to converge, use alternative working covariance structures sequentially:
Autoregressive (1), then Compound Symmetry. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 26 of 44
Statistical Analysis Plan
02 August 2021
7.8.4
Additional Efficacy Endpoints
The proportion of subjects with ≥20% reduction in ANMS GCSI-DD composite score from 
baseline in the last 6 consecutive weeks of the study will be estimated by logistic regression 
model adjusting for baseline score, subject disease population, and treatment. The missing value 
will be handled in 3 ways by (1) last observation carried forward (LOCF), (2) observed case 
(OC) and (3) non-responder imputation (NRI).
For the observed case analysis, only includes subjects who have the length of treatment period 
>= 6 weeks. 

If a subject consistently met ≥20% reduction in ANMS GCSI-DD weekly composite score 
from baseline for the last 6 consecutive weeks, the subject will be a responder. 

If a subject does not consistently meet the ≥20% reduction in ANMS GCSI-DD weekly 
composite score from baseline for the last 6 consecutive weeks, the subject will be a non-
responder. 
For the LOCF imputation, all subjects would be included. 

The last non-missing post-baseline ANMS GCSI-DD weekly composite score prior to the 
missing weeks will be carried forward to impute the missing values. 

Based on the imputed data, if a subject met ≥20% reduction in ANMS GCSI-DD weekly 
composite score from baseline for last 6 consecutive weeks, the subject will be a responder. 
Otherwise, the subject will be a non-responder.
For the non-responder imputation, all subjects would be included. The responder and non-
responder will be derived as follows:

The subject will be considered as non-responder if, subject 
–
Participated in study less than 6 weeks or
–
Had missing values for ANMS GCSI-DD composite weekly score in the last 6 
consecutive weeks of the study or 
–
Didn’t meet the ≥20% reduction in ANMS GCSI-DD weekly score for the last 6 
consecutive weeks of the study.

If a subject consistently met ≥20% reduction in ANMS GCSI-DD weekly composite score 
from baseline for last 6 consecutive weeks, the subject would be a responder.
Percentage of symptomatic days (days with symptoms assessed as >mild [ANMS GCSI-DD 
composite score ≥2]) using the ANMS GCSI-DD during 12 weeks of treatment will be analyzed 
using ANOVA with treatment, subject disease population as fixed factors. The day with missing 
daily composite score will be considered symptomatic day.
Change from baseline in CSSR total score (CSSR total score will be an average of all the items, 
in which each item ranges from 0 (none) to 5 (very severe)) and SF-12 subscale (based on norm-
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 27 of 44
Statistical Analysis Plan
02 August 2021
based scores) scores will be analyzed using ANCOVA with treatment and subject disease 
population as fixed factors, and baseline score as covariate. 
As a supplementary analysis, the CSSR based on nominal visit will be analyzed using ANCOVA 
with treatment and subject disease population as fixed factors, and baseline score as covariate.
Change from baseline in SF-12 PCS and MCS will be analyzed using ANCOVA with treatment 
and subject disease population as fixed factors, and baseline score as covariate. SF-12 derived 
sub-scales, and sub-sales that are norm-based scores will all be listed.
Change from baseline in weekly ANMS GCSI-DD core symptom score, weekly PAGI-QoL 
total, and weekly subscale scores, and weekly GEBT t1/2 will be analyzed using similar method 
as the primary efficacy endpoint. The estimates of the least squares mean (LSM) difference 
between TAK-906 dose groups and placebo at each week and their 90% CIs will be reported. In 
particular, the LSM differences between TAK-906 dose groups and placebo at Week 12 will be 
used to evaluate the treatment effects in each endpoint, respectively.
OTE-C and OTE-S will be summarized for the TAK-906 dose groups and placebo by the landing 
question and its subsequent question. 
CGI-I, CGI-S, PGI-I, and PGI-C scores will be tabulated (count and percentage) by visit for 
TAK-906 dose groups and placebo. 
As a supplemental analysis, the CGI-S scores based on the nominal visit will be tabulated (count 
and percentage) by visit for TAK-906 dose groups and placebo. 
PGI-S will be summarized based on which versions of the PGI-S subjects answered: PGI-S 
(version 1), PGI-S (version 2), and PGI-S (mixed versions 1 and 2). The PGI-S tables will have 
total, and subgroups by Disease Type at Randomization. All data will be listed. 
For the clinician-based rating scores (CGI-I, CGI-S, CSSR_TOT and OTE_C), the analysis will 
only include rating scores that were evaluated by qualified and trained PI/SI/Staff per 
MedAvante training requirements as shown in table below. All datapoints will be listed. 
Qualified/ Trained?
Evaluator Category
Evaluated by 
trained and 
qualified 
PI/SI/Staff
PI/SI trained (or IM trained) and qualified
1
Y
Staff trained and qualified
2
Y
PI/SI - not qualified or NOT trained
3
N
Staff qualified but not trained
4
N
Staff not qualified and not trained
5
N
*Raters that aren’t principle investigator or sub-investigator would be considered staff.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 28 of 44
Statistical Analysis Plan
02 August 2021
7.8.5
Missing Data
For some reasons, subjects may not complete the full task as requested, or subjects used irregular 
procedure and/or questionable effort. In such cases, the data may be considered missing, 
unreliable and/or invalid. 
The general rule when individual items are missing from a multiple-item assessment is as 
follows: 

Composite, core symptom score, or total ANMS GCSI-DD score will be calculated as (sum 
of non-missing item scores) / (number of non-missing items). 

If more than 20% of the items are missing, the composite/total score/core symptoms score 
will be set to missing. For example, if there is one item missing for a daily average, then the 
denominator will be the number of non-missing items (eg, for total score, if one of the items 
are missing, then divide by 5 rather than 6).

If 3 or less days of diary data are available for the baseline or a postbaseline week, that 
weekly score will be considered missing (ie, each week would need at least 4 of the 7 days).
Missing date imputation for medication and adverse events is detailed in Appendix F Convention 
for Missing dates for Adverse Events/Concomitant Medication/Procedures. These imputation 
rules will be derived to create flags, but in the listings display actual collected. 
7.9
Pharmacokinetic/Pharmacodynamic Analysis
7.9.1
Pharmacokinetic Analysis
No formal noncompartmental PK analyses will be performed on concentration-time data. 
Individual concentration-time data will be included in summary table and listings. Additional 
analyses may be conducted if deemed necessary for the interpretation of the data. 
A more detailed description of these analyses will be provided in a separate analysis plan. 
For summary analysis, any assay result below the lower limit of quantification (BLQ) will be 
considered as zero. 
If dose-response or exposure-response modeling is warranted, it will be documented in a separate 
SAP. 
7.9.2
Pharmacodynamic Analysis
Not applicable.
7.10
Other Outcomes
The pharmacogenomic data will not be included in the CSR.
For biomarker data, tables and listings will be prepared. Summary statistics will be done for C-
reactive protein (CRP), Glucose-dependent insulinotropic polypeptide (GIP), and Peptide YY 
(PYY) by treatment group for overall for the actual values and change from baseline values. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 29 of 44
Statistical Analysis Plan
02 August 2021
7.11
Safety Analysis
All safety summaries will be based on the safety analysis set. Safety summaries will include 
descriptive statistics for values, changes, and incidence of events for each TAK-906 dose level 
and total TAK-906 combined (regardless of TAK-906 dosing level) and placebo.
7.11.1
Adverse Events
All adverse events will be coded using MedDRA latest version. All adverse events will be 
included in the data listings but only treatment emergent adverse events will be included in the 
summary tables.
A treatment-emergent adverse event (TEAE) will be defined as an AE or serious adverse event 
(SAE) that started or worsened after first study drug administration and within 30 days of last 
dose of study drug (AE onset date – date of last dose ≤30). AEs with missing onset dates will be 
summarized with TEAEs regardless of severity and relationship to study medication. 
If AE start date is missing, it will be considered TEAE unless AE end date is prior to 
randomization date. 
If a part of the AE start date or AE end date is missing, parts of randomization date will be 
assumed to derive the TEAE flag. For example, if only month is missing for ae start date, then 
randomization month will be used to derive TEAE flag. 
The following summaries will be presented:

Overview of TEAEs during the study - number and percentage of subjects, number of events.

TEAEs by SOC and PT - number and percentage of subjects.

TEAEs by PT - number and percentage of subjects.

Intensity of TEAEs by SOC and PT - number and percentage of subjects.

Relationship of TEAEs by SOC and PT - number and percentage of subjects.

Drug-related TEAEs by SOC and PT - number and percentage of subjects.

TEAEs Related to Study Medication by SOC and PT - number and percentage of subjects.

TEAEs leading to study discontinuation by SOC and PT - number and percentage of 
subjects.

Serious treatment-emergent AEs by SOC and PT - number and percentage of subjects, 
number of events.

Treatment-emergent Adverse Events of Special Interest by SOC and PT - number and 
percentage of subjects, number of events.

Most Frequent (>=5%) Treatment-emergent Non-serious AEs by SOC and PT - number and 
percentage of subjects, number of events.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 30 of 44
Statistical Analysis Plan
02 August 2021

Most Frequent (>=5%) Treatment-emergent AEs by SOC and PT - number and percentage of 
subjects, number of events.

Pretreatment Events by SOC and PT - number and percentage of subjects.
SOCs will be sorted in descending order of total number of subjects with the SOC among all the 
treatment groups. Within an SOC, adverse events will be sorted in descending order of total 
number of subjects with the preferred term among all the treatment groups.
In the high-level adverse event summary tables, TEAEs will be summarized regardless of 
intensity and relationship to study drug. Within each subject, multiple reports of events that map 
to a common MedDRA term will be counted only once.
At the adverse event level, the summary tables will present the number of subjects reporting each 
of these MedDRA events, ie, the number of subjects reporting 1 or more events that map to the 
given MedDRA term.
At the SOC level, the summary tables will present the number of subjects reporting 1 or more 
events that map to the given SOC. That is, the number of subjects reported at the SOC level will 
be less than or equal to the sum of the subject counts across all adverse events within that SOC.
In selected summaries (see above), adverse events will be summarized by the number of events 
reported in addition to the number and percentage of subjects with events.
For the summary of TEAEs by SOC, preferred term and maximum intensity, if a subject 
experiences more than 1 episode of a particular coded adverse event, the subject will be counted 
only once by the maximum intensity of the episode (preferred term). Similarly, if a subject has 
more than 1 adverse event within an SOC, the subject will be counted only once by the 
maximum intensity in that SOC. 
TEAEs classified in the eCRF as possibly or probably related to the study medication will also 
be summarized by preferred term and SOC. If a subject experiences more than 1 episode of a 
particular coded adverse event, the subject will be counted only once by the most related report 
for the preferred term. Similarly, if a subject has more than 1 adverse event within an SOC, the 
subject will be counted only once by the most related report in that SOC. Adverse events with 
missing relationship will be classified as related to study drug.
All adverse events will be listed by treatment, study center, subject number and onset date of the 
adverse event. The listing will contain: subject identifier, age, sex, body weight, race, adverse 
event (preferred term and reported term), SOC, onset date, end date or whether the event was 
ongoing, duration, frequency, intensity (mild, moderate or severe), action taken concerning study 
drug, causality to study drug, the outcome, whether the adverse event was an SAE and whether 
the event was an adverse event of special interest (AESI).
Special listings for TEAEs leading to study discontinuation, SAEs, deaths, related AEs, and AE 
of special interest will also be presented. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 31 of 44
Statistical Analysis Plan
02 August 2021
7.11.2
Clinical Laboratory Evaluations
For each laboratory parameter, the following will be displayed for each scheduled time point
(each visit and end of treatment) as applicable.

Summary statistics (n, mean, SD, median, minimum, and maximum) by treatment group and 
overall for the actual values and change from Baseline values.

Shift tables for the change from Baseline to each post-baseline time point will be presented. 
For these tables, each subject will be categorized as low, normal, or high for the baseline 
value, and low, normal, or high for each post-baseline time point, according to the central 
laboratory reference ranges. The number of subjects in each of the combinations of shifts will 
be presented.

Markedly abnormal values (MAVs), as defined in Appendix B, will be summarized by 
treatment group and overall. The number and percentage of subjects with MAV values 
observed post-baseline in each of the applicable laboratory parameters will be presented.

In addition to the MAV summary, for the following laboratory parameters, the number and 
percentages of subjects with the worst post-baseline values that fall in each of the listed 
categories will be summarized by treatment group:
–
Prolactin:

>ULN;

>2.5 × ULN;

>5 × ULN;

>10 × ULN.
–
Glucose:

<2.2 mmol/L;

<1.7 mmol/L;

>13.9 mmol/L;

>27.8 mmol/L.
Liver Test Parameters
–
ALT:

>3 × ULN;

>3 – ≤5 × ULN;

>5 – ≤8 × ULN;

>8 – ≤20 × ULN;
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 32 of 44
Statistical Analysis Plan
02 August 2021

>20.0 × ULN.
–
AST:

>3 × ULN;

>3 – ≤5 × ULN;

>5 – ≤8 × ULN;

>8 – ≤20 × ULN;

>20 × ULN.
–
ALT or AST:

ALT >3 × ULN or AST >3 × ULN;

(ALT >3 × ULN and ALT ≤5 × ULN) or (AST >3 × ULN and AST ≤5 × ULN);

(ALT >5 × ULN and ALT ≤8 × ULN) or (AST >5 × ULN and AST ≤8 × ULN);

(ALT >8 × ULN and ALT ≤20 × ULN) or (AST >8 × ULN and AST ≤20 × ULN);

ALT >20 × ULN or AST >20 × ULN.
–
ALT/AST and Total Bilirubin:

ALT >3 × ULN AND TBILI >2 × ULN;

AST >3 × ULN AND TBILI >2 × ULN;

(ALT >3 × ULN or AST >3 × ULN) AND TBILI >2 × ULN.
A listing of all laboratory data will be provided. Laboratory data outside of the normal reference 
range will be flagged on the listing along with values meeting MAV criteria. 
Summaries and listings of laboratory data will be presented in System International (SI) unit.
7.11.3
Vital Signs and Weight
Vital signs and weight at scheduled visits and their changes from Baseline will be summarized 
for each treatment group and overall using descriptive statistics by visit and end of treatment. 
The number and percentage of subjects with at least one post-baseline abnormal vital sign value 
that falls in the each of the category defined in Table 7.c will be tabulated for each variable 
across all visits. 
Bot plots will be provided for vial sign parameters for each treatment group by visit and end of 
treatment visit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 33 of 44
Statistical Analysis Plan
02 August 2021
Table 7.c
Categories of Abnormal Vital Signs Values
Parameter
Low Abnormal
High Abnormal
Pulse rate (HR)
<50 bpm
>120 bpm
Decrease from baseline >20 bpm
Increase from baseline >20 bpm
<50 bpm AND decrease from baseline >20 
bpm
>120 bpm AND increase from baseline >20 
bpm
SBP
<90 mmHg
>160 mmHg
>20 mmHg decrease from baseline
>20 mmHg increase from baseline
<90 mmHg AND >20 mmHg decrease from 
baseline
>160 mmHg AND >20 mmHg increase from 
baseline
DBP
<60 mmHg
>90 mmHg
>10 mmHg decrease from baseline
>10 mmHg increase from baseline
<60 mmHg AND >10 mmHg decrease from 
baseline
>90 mmHg AND >10 mmHg increase from 
baseline
Body Temperature
< 35.0 oC
>38.3 oC
A listing of all vital signs and weight data will be provided. Values meeting the MAV criteria 
will be flagged. The criteria for identification of vital signs MAVs are given in Appendix C.
7.11.4
12-Lead ECGs
ECG variables at scheduled visits and their changes from Baseline will be summarized for each 
treatment group and overall using descriptive statistics by study visit and end of treatment. A 
shift table for the investigator’s ECG interpretation will provide the number of subjects in each 
of the appropriate categories (Normal, Abnormal but not clinically significant, or Abnormal and 
clinically significant) at the scheduled visit relative to the Baseline status. The number and
percentage of subjects with at least one post-baseline abnormal ECG value that falls in each of 
the category defined in Table 7.d will be tabulated for each variable across all visits. 
Box plots will be provided for ECG parameters for each treatment group by visit and end of 
treatment visit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 34 of 44
Statistical Analysis Plan
02 August 2021
Table 7.d
Categories of Abnormal ECG Values
Parameter
Low Abnormal
High Abnormal
Heart rate (HR)
<50 bpm
>120 bpm
Decrease from baseline >20 bpm
Increase from baseline >20 bpm
<50 bpm AND decrease from baseline 
>20 bpm
>120 bpm AND increase from baseline >20 
bpm
PR
<120 milliseconds
>200 milliseconds
>200 milliseconds AND increase from 
baseline >25%
QRS
<60 milliseconds
>120 milliseconds
-
>120 milliseconds AND increase from 
baseline >25%
QTcF
-
>450 and ≤480 milliseconds
-
>480 and ≤500 milliseconds
-
>500 milliseconds
-
Change from baseline of >30 and ≤60 
milliseconds
-
Change from baseline of >60 milliseconds
-
>450 milliseconds AND >30 milliseconds 
change from baseline
A listing of all ECG data will be provided. Values meeting the MAV criteria will be flagged. The 
criteria for identification of ECG MAVs are given in Appendix D.
7.11.5
Other Observations Related to Safety
For female subjects, pregnancy test results will be listed by treatment, study center and subject 
number.
7.12
Interim Analysis
Based on Protocol Amendment 8, interim analysis has been canceled. 
7.13
Multiplicity Adjustments
There are no multiplicity adjustment proposed for this study. 
7.14
Changes in the Statistical Analysis Plan 
Version 
Description
Changes
Rationale
1
Original Document 
based on Protocol 
Amendment 6, 8 
August 2019
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 35 of 44
Statistical Analysis Plan
02 August 2021
Version 
Description
Changes
Rationale
2
Based on Protocol 
Amendment 8, 
13 July 2020 
Interim Analysis was removed. 
2-sided analysis was modified to 1-
sided analysis at alpha 0.05. 
Data Collection was modified in 
Protocol Amendment 8, analysis will 
still be conducted for subjects who 
entered in a previous version of the
protocol. Ex) The data collection 
GEBT has changed in Protocol 
Amendment 8. 
PGI-S Scores version 1was replace 
with version 2. 
PGI-I Scores was changed to PGI-C 
Scores. 
Added an assessment on COVID-19 
impacted subjects. 
Due to modifications in Protocol
Amendment 8, the following were 
implemented.
Per-Protocol Definition Clarified. 
To narrow down the factors 
important to objective of study.
Clarified how to handle AE date 
missing in deriving TEAE flag.
There was no clarification on missing 
dates in the previous SAP.
ANOVA and Cochran-Mantel-
Haenszel for baseline variables are 
removed. 
Descriptive statistics are sufficient 
for baseline variables.
AUC analysis removed.
To simplify analysis.
Sensitivity Analysis modified.
To provide robust analysis amongst 
subjects with rescue medication.
Changes from the 
Protocol Version 8.0 
For both continuous and categorical 
analysis, center will not be used as a 
fixed factor. The mixed models will 
have all the factors from the protocol 
except the center variable.
Insufficient number of subjects 
enrolled in a site may lead to small 
sample size in a strata. It is assumed 
that center to center variability in 
subjects are similar since following 
one protocol.
Safety Analysis set updated to be at 
least 1 dose of study drug
To evaluate safety in all subjects that 
were exposed to any amount of study 
drug.
3
Updated drug compliance 
calculation.
Updated drug compliance calculation 
to address the missing bottles. 
Set the recorded vomiting frequency 
that is clinically Implausible as 
missing.
Recorded vomiting frequency above 
60 per day is considered clinically 
implausible and will be set to 
missing, and summarized as recorded 
vomiting frequency.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 36 of 44
Statistical Analysis Plan
02 August 2021
Version 
Description
Changes
Rationale
Summary tables added for impact 
due to COVID-19, CGI-I, CGI-S, 
PGI-I and PGI-C. 
Summary analysis are added to help 
interpret data in addition to by-
subject listing.
PK summary table is added. 
Biomarker summary table is added. 
Summary analysis are added to help 
interpret data in addition to by-
subject listing.
Clarifications added for
50% reduction from baseline in the 
weekly ANMS GCSI-DD 
>=20% reduction in last 6 
consecutive weeks, 
Pattern Mixture Sensitivity Analysis
Clarifications added to help
implementation.
Safety Analysis Set definition 
updated to handle if subject received 
more than one treatment
To have conservative approach for 
safety analysis when subject received 
more than one treatment.
Removed ‘at least 1 valid 
postbaseline value’ in the definition 
for FAS.
Address FDA’s comments. 
Sensitivity analysis 1 and 2 modified 
to incorporate the timing of when the 
rescue medication was used. 
Address FDA’s comments.
Clarifications added for handling 
irregular data 
[1] Analyses only include data 
evaluated by trained and qualified 
evaluators.
[2] Clarified to how to handle 
duplicate data entry, data entered not 
on the same day as planned.
[1] Exclude data evaluated by non-
trained and non-qualified evaluators 
to avoid misleading information.
[2] Use algorithms to derive robust 
dataset for analysis.
SF-12 MCS and PCS derivations will 
be based on PRO Core® software. 
Use commercial software to derive 
SF-12 MCS and PCS since the 
algorithm to the norm-based scoring 
is proprietary. 
8.0
REFERENCES
1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b 
Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a 
Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of 
Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis, Millennium 
Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company 
Limited, Protocol No. TAK-906-2002, Amendment 08, dated 13 July, 2020.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 37 of 44
Statistical Analysis Plan
02 August 2021
2. Revicki DA, Camilleri M, Kuo B, et al. Evaluating symptom outcomes in gastroparesis 
clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-
Daily Diary (GCSI-DD). Neurogastroenterol Motil 2012;24:456-463.
3. Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of 
the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in 
patients with upper gastrointestinal disorders. Qual Life Res 2004;13:1737-1749.
4. Szarka L, Camilleri M, Vella A, et al. A Stable Isotope Breath Test With a Standard Meal for 
Abnormal Gastric Emptying of Solids in the Clinic and in Research. Clinical 
Gastroenterology and Hepatology 2008;6:635–643
5. Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not affect 
the type I error rate. Statistics in Medicine. 2003; 22: 3571-3581.
6. Kiernan K, Tao J, Gibbs P. Tips and strategies for mixed modeling with SAS/Stat 
procedures. SAS global forum 2012.
7. Lu, K, Mehrotra, DV. Specification of covariance structure in longitudinal data analysis for 
randomized clinical trials. Statistics in Medicine. 2010; 29: 474–488.
8. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12 Physical and Mental 
Health Summary Scales. Boston, MA. The Health Institute, New England Medical Center, 
Second Edition, 1995. 
9. Bohdana Ratitch, Michael O’Kelly. Implementation of Pattern-Mixture Models using 
Standard SAS/STAT Procedures. Available at link:
https://www.pharmasug.org/proceedings/2011/SP/PharmaSUG-2011-SP04.pdf. (accessed 
10August2020)Maruish, M. E. (Ed.). (2012). User’s manual for the SF-12v2 Health Survey 
(3rd ed.). Lincoln, RI: QualityMetric Incorporated.
10. Lingling Li. SAS® V9.4 MNAR statement for multiple imputations for missing not at 
random in longitudinal clinical trials. Available at link:
https://www.pharmasug.org/proceedings/2019/ST/PharmaSUG-2019-ST-103.pdf (Accessed 
10August2020).
11. Parkman, Henry, et al. User Manuel for the ANMS GCSI-DD (2018) Available at link: 
https://www.fda.gov/media/125038/download (Accessed 29July2021)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 38 of 44
Statistical Analysis Plan
02 August 2021
Appendix A
Numeric Conversions of PRO data
Parameter
Numeric Conversions
Composite Score 
Total Symptom Score
Core Symptom Score
For nausea, early satiety, postprandial fullness, upper abdominal pain, bloating 
severity and overall gastroparesis severity, the responses will be coded into 
following numeric values: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very 
Severe
The vomiting frequency will be scored from 0 to 4 (where 0 = no vomiting and 4 = 
four or more episodes of vomiting)
PAGI-SYM_TOT
PAGI-SYM_NAVM
PAGI-SYM_PFES
PAGI-SYM_BL
PAGI-SYM_UAP
PAGI-SYM_LAP
PAGI-SYM_HBRE
The PAGI-SYM contains 20 items grouped into 6 subscale scores. A 6-point 
Likert response scale, ranging from 0 (none) to 5 (very severe), is used for rating 
the severity of each symptom.
CSSR_TOT
CSSR total score will be an average of all the items, in which each item ranges 
from 0 (none) to 5 (very severe).
PAGI-QoL
PAGI-QoL Responses will be coded in the numeric values; 0= None of the time, 
1= A Little of the time, 2= Some of the time, 3= A good bit of the time, 4= Most 
of the time, 5= All of the time
30 items of PAGI-QOL cover five domains/subscales: 

Daily Activities

Clothing, Diet and Food Habits

Relationship

Psychological Well-Being 

Distress
5 dimensions: Daily Activities (10 items related to avoiding or having difficulties 
with daily activities), Clothing (2 items, one related to feeling constricted and one 
related to the frustration felt about not being able to dress as wanted), Diet and 
Food Habits (7 items related to restrictions made and induced frustration), 
Relationship (3 items describing the impact of the disease on relationships with 
their partner, relatives, and friends), and Psychological Well-being and Distress (8 
items describing disease impact on feelings or emotional state)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 39 of 44
Statistical Analysis Plan
02 August 2021
Appendix B
Criteria for Markedly Abnormal Values for Lab Parameters
Parameter
Lower Criteria 
Upper Criteria
Prolactin
>5 x ULN
Albumin
<20 g/L
Total protein
<0.8 x LLN
>1.2 x ULN
Creatinine
>1.5 x ULN
Blood urea nitrogen
>1.5 x ULN
Creatine kinase (CPK)
>5 x ULN
>10 × ULN
Potassium
<3.0 mmol/L
>5.5 mmol/L
Sodium
<130 mmol/L
>155 mmol/L
Calcium
<2.0 mmol/L
>2.9 mmol/L
Chloride
<0.8 x LLN
>1.2 x ULN
Magnesium
<0.4 mmol/L
>1.23 mmol/L
Phosphate
<0.6 mmol/L
Total cholesterol
>10.34 mmol/L
Triglycerides
>5.7 mmol/L
High-density lipoprotein cholesterol
<LLN
Low-density lipoprotein cholesterol 
>ULN
Glucose
<2.2 mmol/L
>13.9 mmol/L
Uric Acid
>1.2 x ULN
ALT
>3 x ULN
AST
>3 x ULN
Total Bilirubin
-
>2 x ULN
GGT
-
>2.5 x ULN
Alkaline Phosphatase
-
>2.5 x ULN
Direct bilirubin
-
>1.5 x ULN
HbA1c
-
>1.2 x ULN
Red blood cells
<0.8 x LLN
>1.2 x ULN
White blood cells
<2.0 x 109/L
>100 x 109/L
Neutrophils
<1.0 x 109/L
Lymphocytes
< 0.5 x 109/L
>20 x 109/L
Hemoglobin
<80 g/L
>40 g/L above ULN
Hematocrit
<0.8 x LLN
>1.2 x ULN
Platelets
<75.0 x 109/L
>600 x 109/L
Mean corpuscular hemoglobin
<0.8 x LLN
>1.2 x ULN
PT
>2.5 x ULN
INR
>2.5 x ULN
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 40 of 44
Statistical Analysis Plan
02 August 2021
Appendix C
Criteria for Markedly Abnormal Values for Vital Signs
Parameter
Unit
Lower Criteria 
Upper Criteria
Heart Rate
Bpm
<50 or decrease from 
baseline >20
>120 or increase from 
baseline of >20
Systolic blood pressure
mm Hg
<90 or decrease from 
baseline >20
>160 or increase from 
baseline of >20
Diastolic blood pressure
mm Hg
<60 or decrease from 
baseline of >10
>90 or increase from 
baseline of >10
Body temperature
oC
oF
<35.0 
<95 
>38.3
>100.9
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 41 of 44
Statistical Analysis Plan
02 August 2021
Appendix D
Criteria for Markedly Abnormal Values for the 12-Lead ECG Parameters
Parameter
Lower Criteria
Upper Criteria
Heart rate
<50 bpm or decrease from baseline of 
>20
>120 bpm or increase from baseline of >20
PR
<120 milliseconds
>200 milliseconds
QTcF Interval
>500 milliseconds or 
>30 milliseconds increase from baseline and
>450 milliseconds
QRS
<60 milliseconds
>120 milliseconds
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 42 of 44
Statistical Analysis Plan
02 August 2021
Appendix E
Details for Pattern Mixture
Step 1: use Proc MI’s Monte Carlo Markov Chain (MCMC) statement, to produce monotone 
missing data patterns to impute the outcome variable at consecutive visits in a sequential manner. 

Set the imputation model including the treatment, stratum, and weekly composite scores at 
baseline, and visit 1 through 12 in the VAR statement, where the Minimum and Maximum 
for weekly composite scores at baseline, and visit 1 through 12 are set to zero and four, 
respectively.

Set random seed and use MCMC statement with single chain and impute = monotone to 
create the 100 copies (numbered by _Imputation_) of dataset with monotone missing patterns 
and set MINMAXITER as 10000 to make sure all imputed values within the specified values 
of Minimum and Maximum.
Step 2: Assemble the dataset from step 1, use monotone regression and MNAR statement to 
impute missing weekly composite scores, by _Imputation, where the imputation model is derived 
by data from control group (ie, TRT01PN=1) only. If visit t is complete for all subjects, then 
MNAR statement would start from visit t+1. 

Set the imputation model including the stratum, and weekly composite scores at baseline, and 
visit 1 through 12 in the Var statement with treatment and stratum in Class statement, where 
the Minimum and Maximum for weekly composite scores at baseline, and visit 1 through 12 
are set to zero and four, respectively.

Set random seed and use monotone regression and MNAR statement with MODELOBS= 
(TRT01PN=’1’) specifying that the control group is used to derive the imputation model to 
impute missing weekly composite scores in the order listed in the VAR statement in step 1.
Step 3: Assemble the imputed dataset from step 2 to derive the primary endpoint, analyze the 
primary endpoint using MMRM with same fixed effects and covariates in section 7.8.2.1 and 
with unstructured covariance matrix by _Imputation_ to obtain the lsmeans difference between 
treatments (TAK-906 vs Placebo) at each visit.
Step 4: the results (lsmeans estimates and standard errors) from step 3 will be combined by 
Rubin’s rules using Proc MIANALYZE by visit to estimate treatment differences and associated 
90%CIs at each visit. The 1-sided p-value for testing treatment differences (TAK-906 vs 
Placebo) in primary endpoint at each visit will be based on the t-test with degrees of freedom 
from the MMRM in step 3.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 43 of 44
Statistical Analysis Plan
02 August 2021
Appendix F
Convention for Missing dates for Adverse Events/Concomitant 
Medication/Procedures
Conventions for Missing/Partial Dates for Adverse Event/Concomitant Medication/Procedures
The start date that is completely or partially missing will be imputed as follows:

If month and year are known but day is missing 
–
If month and year are the same as month and year of the 1st dose date, the day of the 1st 
dose date will be used to impute the missing day. 
–
If month and year are prior to the month and year of the 1st dose date, the last day of the 
month will be used to impute the missing day. 
–
If month and year are after the month and year of the 1st dose date, the 1st day of the 
month will be used to impute the missing day. 

If year is known, but both day and month are missing 
–
If the year is same as year of the 1st dose date, the month and day of the 1st dose date 
will be used to impute the missing month and day, respectively. 
–
If the year is prior to the year of the 1st dose date, December 31st of the year will be used 
to impute the missing month and day, respectively. 
–
If the year is after the year of the 1st dose date, January 1st of the year will be used to 
impute the missing month and day, respectively.

If all (day, month, year) are missing, the 1st dose date will be used to impute the missing 
year, month, and day, respectively. 
Imputing missing start date is mandatory. After imputation, all imputed dates are checked against 
the stop dates to ensure that start dates do not occur after stop dates. If an imputed start date 
occurs after the stop date, then change the imputed start date to be the same as the stop date. 
The stop dates that are completely or partially missing will be imputed as follows: 

If the AE is “ongoing”, no imputation is necessary. 

If month and year are known but day is missing, the last day of the month will be used to 
impute the missing day.

If year is known, but both day and month are missing 
–
December 31st of the year will be used to impute the missing month and day, 
respectively. 

If all (day, month, year) are missing, the event will be considered as ongoing. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-906-2002
Page 44 of 44
Statistical Analysis Plan
02 August 2021
Imputing missing stop date is not mandatory if event is considered as ongoing. However if it is to 
be done, the rules are outlined above. If subject dies, then use death date for the stop date. After 
imputation, all imputed dates are checked against start dates to ensure that stop dates do not 
occur before start dates. If an imputed stop date occurs prior to the start date, then change the 
imputed stop date to be the same as the start date.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use



(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GEG
䢳䢸䢯䢳䢯䢻䢯䢵䢢䣕䣶䣣䣶䣫䣵䣶䣫䣥䣣䣮䢢䣃䣰䣣䣮䣻䣵䣫䣵䢢䣒䣮䣣䣰䢢䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢴䢢䢴䢲䢴䢳䢯䢲䢺䢯䢲䢴䣡䢵
%LRVWDWLVWLFV$SSURYDO
$XJ87&
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e Te
ate 
te
ble T
HH:mm ‘U
H:mm
Ter
ble
87&
87